23. Literaturverzeichnis – Magenkarzinom
1. Gemeinsame Publikation des Zentrums für Krebsregisterdaten und der Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V., Krebs in Deutschland für 2019/2020,Robert Koch-Institut, 2023. 14. Ausgabe:, https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/krebs_in_deutschland_node.html
2. Porschen, R., Buck, A., Fischbach, W., Gockel, I., Gorling, U., Grenacher, L., et.al. S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus (Langversion 1.0–September 2015, AWMF-Registernummer: 021/023OL)., Z Gastroenterol, 2015. 53(11): p. 1288-347., https://www.ncbi.nlm.nih.gov/pubmed/26562403
3. Institut, Robert Koch, Krebs in Deutschland 2013/2014,, http://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2017/krebs_in_deutschland_2017.pdf, 11. Auflage 2017, eingesehen am 5.2.2018:.
4. Plummer, M., Franceschi, S., Vignat, J., Forman, D., de Martel, C., Global burden of gastric cancer attributable to Helicobacter pylori, Int J Cancer, 2015. 136(2): p. 487-90., https://www.ncbi.nlm.nih.gov/pubmed/24889903
5. Ford, A. C., Forman, D., Hunt, R. H., Yuan, Y., Moayyedi, P., Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials, BMJ, 2014. 348: p. g3174., https://www.ncbi.nlm.nih.gov/pubmed/24846275
6. Cavaleiro-Pinto, M., Peleteiro, B., Lunet, N., Barros, H., Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis, Cancer Causes Control, 2011. 22(3): p. 375-87., https://www.ncbi.nlm.nih.gov/pubmed/21184266
7. Fischbach, W., Malfertheiner, P., Lynen Jansen, P., Bolten, W., Bornschein, J., Buderus, S., et.al. [S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease], Z Gastroenterol, 2016. 54(4): p. 327-63., https://www.ncbi.nlm.nih.gov/pubmed/27512738
8. de Martel, C., Franceschi, S., Infections and cancer: established associations and new hypotheses, Crit Rev Oncol Hematol, 2009. 70(3): p. 183-94., https://www.ncbi.nlm.nih.gov/pubmed/18805702
9. Sugano, K, Tack, J, Kuipers, EJ, Graham, DY, El-Omar, EM, Miura, S, et.al. Kyoto global consensus report on Helicobacter pylori gastritis., Gut, 2015. 64 (9)(9): p. 1353-67., https://pubmed.ncbi.nlm.nih.gov/26187502/
10. Wang, C., Yuan, Y., Hunt, R. H., The association between Helicobacter pylori infection and early gastric cancer: a meta-analysis, Am J Gastroenterol, 2007. 102(8): p. 1789-98., https://www.ncbi.nlm.nih.gov/pubmed/17521398
11. Derks, S., Bass, A. J., Mutational signatures in Helicobacter pylori-induced gastric cancer: lessons from new sequencing technologies, Gastroenterology, 2014. 147(2): p. 267-9., https://www.ncbi.nlm.nih.gov/pubmed/24973679
12. Shimizu, T., Marusawa, H., Matsumoto, Y., Inuzuka, T., Ikeda, A., Fujii, Y., et.al. Accumulation of somatic mutations in TP53 in gastric epithelium with Helicobacter pylori infection, Gastroenterology, 2014. 147(2): p. 407-17 e3., https://www.ncbi.nlm.nih.gov/pubmed/24786892
13. Stoicov, C., Saffari, R., Cai, X., Hasyagar, C., Houghton, J., Molecular biology of gastric cancer: Helicobacter infection and gastric adenocarcinoma: bacterial and host factors responsible for altered growth signaling, Gene, 2004. 341: p. 1-17., https://www.ncbi.nlm.nih.gov/pubmed/15474284
14. Kodaman, N., Pazos, A., Schneider, B. G., Piazuelo, M. B., Mera, R., Sobota, R. S., et.al. Human and Helicobacter pylori coevolution shapes the risk of gastric disease, Proc Natl Acad Sci U S A, 2014. 111(4): p. 1455-60., https://www.ncbi.nlm.nih.gov/pubmed/24474772
15. Bornschein, J, Leja, M, Kupcinskas, J, Link, A, Weaver, J, Rugge, M, et.al. Molecular diagnostics in gastric cancer., Front Biosci (Landmark Ed), 2014. 19 (2)(2): p. 312-38., https://pubmed.ncbi.nlm.nih.gov/24389187/
16. Ekstrom, A. M., Eriksson, M., Hansson, L. E., Lindgren, A., Signorello, L. B., Nyren, O., et.al. Occupational exposures and risk of gastric cancer in a population-based case-control study, Cancer Res, 1999. 59(23): p. 5932-7., https://www.ncbi.nlm.nih.gov/pubmed/10606238
17. Ekstrom, A. M., Serafini, M., Nyren, O., Hansson, L. E., Ye, W., Wolk, A., Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the intestinal and diffuse types: a population-based case-control study in Sweden, Int J Cancer, 2000. 87(1): p. 133-40., https://www.ncbi.nlm.nih.gov/pubmed/10861464
18. Gonzalez, C. A., Jakszyn, P., Pera, G., Agudo, A., Bingham, S., Palli, D., et.al. Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC), J Natl Cancer Inst, 2006. 98(5): p. 345-54., https://www.ncbi.nlm.nih.gov/pubmed/16507831
19. Gonzalez, C. A., Lopez-Carrillo, L., Helicobacter pylori, nutrition and smoking interactions: their impact in gastric carcinogenesis, Scand J Gastroenterol, 2010. 45(1): p. 6-14., https://www.ncbi.nlm.nih.gov/pubmed/20030576
20. IARC Helicobacter pylori Working Group, Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer, 2014. 8:, https://publications.iarc.fr/Book-And-Report-Series/Iarc-Working-Group-Reports/-Em-Helicobacter-Pylori-Em-Eradication-As-A-Strategy-For-Preventing-Gastric-Cancer-2014
21. Liou, JM, Malfertheiner, P, Lee, YC, Sheu, BS, Sugano, K, Cheng, HC, et.al. Screening and eradication of , Gut, 2020. 69 (12)(12): p. 2093-2112., https://pubmed.ncbi.nlm.nih.gov/33004546/
22. Correa, P., Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention, Cancer Res, 1992. 52(24): p. 6735-40., https://www.ncbi.nlm.nih.gov/pubmed/1458460
23. Ormiston, M. C., Gear, M. W., Codling, B. W., Five year follow-up study of gastritis, J Clin Pathol, 1982. 35(7): p. 757-60., https://www.ncbi.nlm.nih.gov/pubmed/7096598
24. Kapadia, C. R., Gastric atrophy, metaplasia, and dysplasia: a clinical perspective, J Clin Gastroenterol, 2003. 36(5 Suppl): p. S29-36; discussion S61-2., https://www.ncbi.nlm.nih.gov/pubmed/12702963
25. Huang, J. Q., Sridhar, S., Chen, Y., Hunt, R. H., Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer, Gastroenterology, 1998. 114(6): p. 1169-79., https://www.ncbi.nlm.nih.gov/pubmed/9609753
26. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts., Gut, 2001. Sep;49(3): p. 347-53., https://pubmed.ncbi.nlm.nih.gov/11511555/
27. Huang, J. Q., Zheng, G. F., Sumanac, K., Irvine, E. J., Hunt, R. H., Meta-analysis of the relationship between cagA seropositivity and gastric cancer, Gastroenterology, 2003. 125(6): p. 1636-44., https://www.ncbi.nlm.nih.gov/pubmed/14724815
28. Ekstrom, A. M., Hansson, L. E., Signorello, L. B., Lindgren, A., Bergstrom, R., Nyren, O., Decreasing incidence of both major histologic subtypes of gastric adenocarcinoma--a population-based study in Sweden, Br J Cancer, 2000. 83(3): p. 391-6., https://www.ncbi.nlm.nih.gov/pubmed/10917557
29. Herrero, R., Park, J. Y., Forman, D., The fight against gastric cancer - the IARC Working Group report, Best Pract Res Clin Gastroenterol, 2014. 28(6): p. 1107-14., https://www.ncbi.nlm.nih.gov/pubmed/25439075
30. Fock, K. M., Graham, D. Y., Malfertheiner, P., Helicobacter pylori research: historical insights and future directions, Nat Rev Gastroenterol Hepatol, 2013. 10(8): p. 495-500., https://www.ncbi.nlm.nih.gov/pubmed/23752823
31. Li, W. Q., Ma, J. L., Zhang, L., Brown, L. M., Li, J. Y., Shen, L., et.al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups, J Natl Cancer Inst, 2014. 106(7):, https://www.ncbi.nlm.nih.gov/pubmed/24925350
32. Murphy, G., Pfeiffer, R., Camargo, M. C., Rabkin, C. S., Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location, Gastroenterology, 2009. 137(3): p. 824-33., https://www.ncbi.nlm.nih.gov/pubmed/19445939
33. Lagergren, J., Bergstrom, R., Lindgren, A., Nyren, O., Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma, N Engl J Med, 1999. 340(11): p. 825-31., https://www.ncbi.nlm.nih.gov/pubmed/10080844
34. Velanovich, V., Hollingsworth, J., Suresh, P., Ben-Menachem, T., Relationship of gastroesophageal reflux disease with adenocarcinoma of the distal esophagus and cardia, Dig Surg, 2002. 19(5): p. 349-53., https://www.ncbi.nlm.nih.gov/pubmed/12435904
35. Wu, A. H., Tseng, C. C., Bernstein, L., Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma, Cancer, 2003. 98(5): p. 940-8., https://www.ncbi.nlm.nih.gov/pubmed/12942560
36. Chak, A., Faulx, A., Eng, C., Grady, W., Kinnard, M., Ochs-Balcom, H., et.al. Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia, Cancer, 2006. 107(9): p. 2160-6., https://www.ncbi.nlm.nih.gov/pubmed/17019737
37. Correa, P, Haenszel, W, Cuello, C, Zavala, D, Fontham, E, Zarama, G, et.al. Gastric precancerous process in a high risk population: cohort follow-up., Cancer Res, 1990. 50 (15)(15): p. 4737-40., https://pubmed.ncbi.nlm.nih.gov/2369748/
38. Hansson, L. E., Engstrand, L., Nyren, O., Evans, D. J., Jr., Lindgren, A., Bergstrom, R., et.al. Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma, Gastroenterology, 1993. 105(4): p. 1098-103., https://www.ncbi.nlm.nih.gov/pubmed/8405854
39. Thrift, AP, Nguyen, TH, Gastric Cancer Epidemiology., Gastrointest Endosc Clin N Am, 2021. 31 (3)(3): p. 425-439., https://pubmed.ncbi.nlm.nih.gov/34053631/
40. Norwood, DA, Montalvan-Sanchez, E, Dominguez, RL, Morgan, DR, Gastric Cancer: Emerging Trends in Prevention, Diagnosis, and Treatment., Gastroenterol Clin North Am, 2022. 51 (3)(3): p. 501-518., https://pubmed.ncbi.nlm.nih.gov/36153107/
41. Ernst, PB, Gold, BD, The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer., Annu Rev Microbiol, 2000. 54 (): p. 615-40., https://pubmed.ncbi.nlm.nih.gov/11018139/
42. Everhart, JE, Recent developments in the epidemiology of Helicobacter pylori., Gastroenterol Clin North Am, 2000. 29 (3)(3): p. 559-78., https://pubmed.ncbi.nlm.nih.gov/11030073/
43. Abrams, JA, Sharaiha, RZ, Gonsalves, L, Lightdale, CJ, Neugut, AI, Dating the rise of esophageal adenocarcinoma: analysis of Connecticut Tumor Registry data, 1940-2007., Cancer Epidemiol Biomarkers Prev, 2011. 20 (1)(1): p. 183-6., https://pubmed.ncbi.nlm.nih.gov/21127287/
44. Shaheen, N, Ransohoff, DF, Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review., JAMA, 2002. 287 (15)(15): p. 1972-81., https://pubmed.ncbi.nlm.nih.gov/11960540/
45. Barbera, M, Fitzgerald, RC, Cellular origin of Barrett's metaplasia and oesophageal stem cells., Biochem Soc Trans, 2010. 38 (2)(2): p. 370-3., https://pubmed.ncbi.nlm.nih.gov/20298185/
46. Weusten, BLAM, Bisschops, R, Dinis-Ribeiro, M, di Pietro, M, Pech, O, Spaander, MCW, et.al. Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline., Endoscopy, 2023. 55 (12)(12): p. 1124-1146., https://pubmed.ncbi.nlm.nih.gov/37813356/
47. Rubenstein, J. H., Thrift, A. P., Risk factors and populations at risk: selection of patients for screening for Barrett's oesophagus, Best Pract Res Clin Gastroenterol, 2015. 29(1): p. 41-50., http://www.ncbi.nlm.nih.gov/pubmed/25743455, http://www.sciencedirect.com/science/article/pii/S1521691814001887
48. Cook, M. B., Corley, D. A., Murray, L. J., Liao, L. M., Kamangar, F., Ye, W., et.al. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON), PLoS One, 2014. 9(7): p. e103508., https://www.ncbi.nlm.nih.gov/pubmed/25075959
49. Yaghoobi, M., McNabb-Baltar, J., Bijarchi, R., Hunt, R. H., What is the quantitative risk of gastric cancer in the first-degree relatives of patients? A meta-analysis, World J Gastroenterol, 2017. 23(13): p. 2435-2442., https://www.ncbi.nlm.nih.gov/pubmed/28428723
50. Duell, EJ, Travier, N, Lujan-Barroso, L, Boutron-Ruault, MC, Clavel-Chapelon, F, Palli, D, et.al. Menstrual and reproductive factors, exogenous hormone use, and gastric cancer risk in a cohort of women from the European Prospective Investigation Into Cancer and Nutrition., Am J Epidemiol, 2010. 172 (12)(12): p. 1384-93., https://pubmed.ncbi.nlm.nih.gov/21051447/
51. Liu, Z, Zhang, Y, Lagergren, J, Li, S, Li, J, Zhou, Z, et.al. Circulating Sex Hormone Levels and Risk of Gastrointestinal Cancer: Systematic Review and Meta-Analysis of Prospective Studies., Cancer Epidemiol Biomarkers Prev, 2023. 32 (7)(7): p. 936-946., https://pubmed.ncbi.nlm.nih.gov/37104672/
52. Steffen, A., Huerta, J. M., Weiderpass, E., Bueno-de-Mesquita, H. B., May, A. M., Siersema, P. D., et.al. General and abdominal obesity and risk of esophageal and gastric adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition, Int J Cancer, 2015. 137(3): p. 646-57., https://www.ncbi.nlm.nih.gov/pubmed/25598323
53. Loomans-Kropp, HA, Umar, A, Analysis of Body Mass Index in Early and Middle Adulthood and Estimated Risk of Gastrointestinal Cancer., JAMA Netw Open, 2023. 6 (5)(5): p. e2310002., https://pubmed.ncbi.nlm.nih.gov/37163267/
54. Dabo, B, Pelucchi, C, Rota, M, Jain, H, Bertuccio, P, Bonzi, R, et.al. The association between diabetes and gastric cancer: results from the Stomach Cancer Pooling Project Consortium., Eur J Cancer Prev, 2022. 31 (3)(3): p. 260-269., https://pubmed.ncbi.nlm.nih.gov/34183534/
55. Rota, M, Alicandro, G, Pelucchi, C, Bonzi, R, Bertuccio, P, Hu, J, et.al. Education and gastric cancer risk-An individual participant data meta-analysis in the StoP project consortium., Int J Cancer, 2020. 146 (3)(3): p. 671-681., https://pubmed.ncbi.nlm.nih.gov/30919464/
56. Ferro, A, Morais, S, Rota, M, Pelucchi, C, Bertuccio, P, Bonzi, R, et.al. Tobacco smoking and gastric cancer: meta-analyses of published data versus pooled analyses of individual participant data (StoP Project)., Eur J Cancer Prev, 2018. 27 (3)(3): p. 197-204., https://pubmed.ncbi.nlm.nih.gov/29595756/
57. Praud, D, Rota, M, Pelucchi, C, Bertuccio, P, Rosso, T, Galeone, C, et.al. Cigarette smoking and gastric cancer in the Stomach Cancer Pooling (StoP) Project., Eur J Cancer Prev, 2018. 27 (2)(2): p. 124-133., https://pubmed.ncbi.nlm.nih.gov/27560662/
58. The World Cancer Research Fund (WCRF), Analysing research on cancer prevention and survival Revised 2018 2016 Diet, nutrition, physical activity and stomach cancer, 2018.
59. Deng, W, Jin, L, Zhuo, H, Vasiliou, V, Zhang, Y, Alcohol consumption and risk of stomach cancer: A meta-analysis., Chem Biol Interact, 2021. 336 (): p. 109365., https://pubmed.ncbi.nlm.nih.gov/33412155/
60. Wang, PL, Xiao, FT, Gong, BC, Liu, FN, Alcohol drinking and gastric cancer risk: a meta-analysis of observational studies., Oncotarget, 2017. 8 (58)(58): p. 99013-99023., https://pubmed.ncbi.nlm.nih.gov/29228746/
61. He, Z, Zhao, TT, Xu, HM, Wang, ZN, Xu, YY, Song, YX, et.al. Association between alcohol consumption and the risk of gastric cancer: a meta-analysis of prospective cohort studies., Oncotarget, 2017. 8 (48)(48): p. 84459-84472., https://pubmed.ncbi.nlm.nih.gov/29137439/
62. Han, X, Xiao, L, Yu, Y, Chen, Y, Shu, HH, Alcohol consumption and gastric cancer risk: a meta-analysis of prospective cohort studies., Oncotarget, 2017. 8 (47)(47): p. 83237-83245., https://pubmed.ncbi.nlm.nih.gov/29137337/
63. Bagnardi, V, Rota, M, Botteri, E, Tramacere, I, Islami, F, Fedirko, V, et.al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis., Br J Cancer, 2015. 112 (3)(3): p. 580-93., https://pubmed.ncbi.nlm.nih.gov/25422909/
64. Barstad, B, Sørensen, TI, Tjønneland, A, Johansen, D, Becker, U, Andersen, IB, et.al. Intake of wine, beer and spirits and risk of gastric cancer., Eur J Cancer Prev, 2005. 14 (3)(3): p. 239-43., https://pubmed.ncbi.nlm.nih.gov/15901992/
65. Collatuzzo, G, Pelucchi, C, Negri, E, López-Carrillo, L, Tsugane, S, Hidaka, A, et.al. Exploring the interactions between Helicobacter pylori (Hp) infection and other risk factors of gastric cancer: A pooled analysis in the Stomach cancer Pooling (StoP) Project., Int J Cancer, 2021. 149 (6)(6): p. 1228-1238., https://pubmed.ncbi.nlm.nih.gov/33990950/
66. Jin, G, Lv, J, Yang, M, Wang, M, Zhu, M, Wang, T, et.al. Genetic risk, incident gastric cancer, and healthy lifestyle: a meta-analysis of genome-wide association studies and prospective cohort study., Lancet Oncol, 2020. 21 (10)(10): p. 1378-1386., https://pubmed.ncbi.nlm.nih.gov/33002439/
67. Morgagni, P., Gardini, A., Marrelli, D., Vittimberga, G., Marchet, A., de Manzoni, G., et.al. Gastric stump carcinoma after distal subtotal gastrectomy for early gastric cancer: experience of 541 patients with long-term follow-up, Am J Surg, 2015. 209(6): p. 1063-8., https://www.ncbi.nlm.nih.gov/pubmed/25218580
68. Doukas, SG, Doukas, PG, Vageli, DP, Broder, A, Gastric cancer after Bariatric Bypass Surgery. Do they relate? (A Systematic Review)., Obes Surg, 2023. 33 (6)(6): p. 1876-1888., https://pubmed.ncbi.nlm.nih.gov/37041375/
69. Wu, B, Yang, D, Yang, S, Zhang, G, Dietary Salt Intake and Gastric Cancer Risk: A Systematic Review and Meta-Analysis., Front Nutr, 2021. 8 (): p. 801228., https://pubmed.ncbi.nlm.nih.gov/34957192/
70. Fang, X, Wei, J, He, X, An, P, Wang, H, Jiang, L, et.al. Landscape of dietary factors associated with risk of gastric cancer: A systematic review and dose-response meta-analysis of prospective cohort studies., Eur J Cancer, 2015. 51 (18)(18): p. 2820-32., https://pubmed.ncbi.nlm.nih.gov/26589974/
71. Yoo, JY, Cho, HJ, Moon, S, Choi, J, Lee, S, Ahn, C, et.al. Pickled Vegetable and Salted Fish Intake and the Risk of Gastric Cancer: Two Prospective Cohort Studies and a Meta-Analysis., Cancers (Basel), 2020. 12 (4)(4):, https://pubmed.ncbi.nlm.nih.gov/32316595/
72. Kim, SR, Kim, K, Lee, SA, Kwon, SO, Lee, JK, Keum, N, et.al. Effect of Red, Processed, and White Meat Consumption on the Risk of Gastric Cancer: An Overall and Dose⁻Response Meta-Analysis., Nutrients, 2019. 11 (4)(4):, https://pubmed.ncbi.nlm.nih.gov/30979076/
73. Zhao, Z, Yin, Z, Zhao, Q, Red and processed meat consumption and gastric cancer risk: a systematic review and meta-analysis., Oncotarget, 2017. 8 (18)(18): p. 30563-30575., https://pubmed.ncbi.nlm.nih.gov/28430644/
74. Naemi Kermanshahi, M, Safaei, E, Tutunchi, H, Naghshi, S, Mobarak, S, Asadi, M, et.al. Fruit and vegetable intake in relation to gastric cancer risk: A comprehensive and updated systematic review and dose-response meta-analysis of cohort studies., Front Nutr, 2023. 10 (): p. 973171., https://pubmed.ncbi.nlm.nih.gov/36814513/
75. Song, H, Shen, X, Chu, Q, Zheng, X, Coffee consumption is not associated with the risk of gastric cancer: An updated systematic review and meta-analysis of prospective cohort studies., Nutr Res, 2022. 102 (): p. 35-44., https://pubmed.ncbi.nlm.nih.gov/35405601/
76. Xie, Y, Huang, S, He, T, Su, Y, Coffee consumption and risk of gastric cancer: an updated meta-analysis., Asia Pac J Clin Nutr, 2016. 25 (3)(3): p. 578-88., https://pubmed.ncbi.nlm.nih.gov/27440694/
77. Li, L, Gan, Y, Wu, C, Qu, X, Sun, G, Lu, Z, Coffee consumption and the risk of gastric cancer: a meta-analysis of prospective cohort studies., BMC Cancer, 2015. 15 (): p. 733., https://pubmed.ncbi.nlm.nih.gov/26481317/
78. Liu, H, Hua, Y, Zheng, X, Shen, Z, Luo, H, Tao, X, et.al. Effect of coffee consumption on the risk of gastric cancer: a systematic review and meta-analysis of prospective cohort studies., PLoS One, 2015. 10 (5)(5): p. e0128501., https://pubmed.ncbi.nlm.nih.gov/26023935/
79. Zeng, SB, Weng, H, Zhou, M, Duan, XL, Shen, XF, Zeng, XT, Long-Term Coffee Consumption and Risk of Gastric Cancer: A PRISMA-Compliant Dose-Response Meta-Analysis of Prospective Cohort Studies., Medicine (Baltimore), 2015. 94 (38)(38): p. e1640., https://pubmed.ncbi.nlm.nih.gov/26402838/
80. Zhao, LG, Li, ZY, Feng, GS, Ji, XW, Tan, YT, Li, HL, et.al. Tea Drinking and Risk of Cancer Incidence: A Meta-Analysis of Prospective Cohort Studies and Evidence Evaluation., Adv Nutr, 2021. 12 (2)(2): p. 402-412., https://pubmed.ncbi.nlm.nih.gov/33002099/
81. Filippini, T, Malavolti, M, Borrelli, F, Izzo, AA, Fairweather-Tait, SJ, Horneber, M, et.al. Green tea (Camellia sinensis) for the prevention of cancer., Cochrane Database Syst Rev, 2020. 3 (3)(3): p. CD005004., https://pubmed.ncbi.nlm.nih.gov/32118296/
82. Huang, Y, Chen, H, Zhou, L, Li, G, Yi, D, Zhang, Y, et.al. Association between green tea intake and risk of gastric cancer: a systematic review and dose-response meta-analysis of observational studies., Public Health Nutr, 2017. 20 (17)(17): p. 3183-3192., https://pubmed.ncbi.nlm.nih.gov/28980522/
83. Schmiegel, W., Buchberger, B., Follmann, M., Graeven, U., Heinemann, V., Langer, T., et.al. S3-Leitlinie – Kolorektales Karzinom., Z Gastroenterol, 2017. 55(12): p. 1344-1498., https://www.ncbi.nlm.nih.gov/pubmed/29212104
84. Gao, Y., Hu, N., Han, X., Giffen, C., Ding, T., Goldstein, A., et.al. Family history of cancer and risk for esophageal and gastric cancer in Shanxi, China, BMC Cancer, 2009. 9: p. 269., https://www.ncbi.nlm.nih.gov/pubmed/19656375
85. Shin, C. M., Kim, N., Yang, H. J., Cho, S. I., Lee, H. S., Kim, J. S., et.al. Stomach cancer risk in gastric cancer relatives: interaction between Helicobacter pylori infection and family history of gastric cancer for the risk of stomach cancer, J Clin Gastroenterol, 2010. 44(2): p. e34-9., https://www.ncbi.nlm.nih.gov/pubmed/19561529
86. Foschi, R., Lucenteforte, E., Bosetti, C., Bertuccio, P., Tavani, A., La Vecchia, C., et.al. Family history of cancer and stomach cancer risk, Int J Cancer, 2008. 123(6): p. 1429-32., https://www.ncbi.nlm.nih.gov/pubmed/18567000
87. Chen, M. J., Wu, D. C., Ko, Y. C., Chiou, Y. Y., Personal history and family history as a predictor of gastric cardiac adenocarcinoma risk: a case-control study in Taiwan, Am J Gastroenterol, 2004. 99(7): p. 1250-7., https://www.ncbi.nlm.nih.gov/pubmed/15233662
88. Kondo, T., Toyoshima, H., Tsuzuki, Y., Hori, Y., Yatsuya, H., Tamakoshi, K., et.al. Aggregation of stomach cancer history in parents and offspring in comparison with other sites, Int J Epidemiol, 2003. 32(4): p. 579-83., https://www.ncbi.nlm.nih.gov/pubmed/12913033
89. Munoz, N., Plummer, M., Vivas, J., Moreno, V., De Sanjose, S., Lopez, G., et.al. A case-control study of gastric cancer in Venezuela, Int J Cancer, 2001. 93(3): p. 417-23., https://www.ncbi.nlm.nih.gov/pubmed/11433408
90. Brenner, H., Arndt, V., Sturmer, T., Stegmaier, C., Ziegler, H., Dhom, G., Individual and joint contribution of family history and Helicobacter pylori infection to the risk of gastric carcinoma, Cancer, 2000. 88(2): p. 274-9., https://www.ncbi.nlm.nih.gov/pubmed/10640957
91. Garcia-Gonzalez, M. A., Lanas, A., Quintero, E., Nicolas, D., Parra-Blanco, A., Strunk, M., et.al. Gastric cancer susceptibility is not linked to pro-and anti-inflammatory cytokine gene polymorphisms in whites: a Nationwide Multicenter Study in Spain, Am J Gastroenterol, 2007. 102(9): p. 1878-92., https://www.ncbi.nlm.nih.gov/pubmed/17640324
92. Yatsuya, H., Toyoshima, H., Tamakoshi, A., Kikuchi, S., Tamakoshi, K., Kondo, T., et.al. Individual and joint impact of family history and Helicobacter pylori infection on the risk of stomach cancer: a nested case-control study, Br J Cancer, 2004. 91(5): p. 929-34., https://www.ncbi.nlm.nih.gov/pubmed/15280918
93. Choi, IJ, Kim, CG, Lee, JY, Kim, YI, Kook, MC, Park, B, et.al. Family History of Gastric Cancer and , N Engl J Med, 2020. 382 (5)(5): p. 427-436., https://pubmed.ncbi.nlm.nih.gov/31995688/
94. Rustgi, SD, Ching, CK, Kastrinos, F, Inherited Predisposition to Gastric Cancer., Gastrointest Endosc Clin N Am, 2021. 31 (3)(3): p. 467-487., https://pubmed.ncbi.nlm.nih.gov/34053634/
95. Blair, VR, McLeod, M, Carneiro, F, Coit, DG, D'Addario, JL, van Dieren, JM, et.al. Hereditary diffuse gastric cancer: updated clinical practice guidelines., Lancet Oncol, 2020. 21 (8)(8): p. e386-e397., https://pubmed.ncbi.nlm.nih.gov/32758476/
96. Oliveira, C., Pinheiro, H., Figueiredo, J., Seruca, R., Carneiro, F., Familial gastric cancer: genetic susceptibility, pathology, and implications for management, Lancet Oncol, 2015. 16(2): p. e60-70., https://www.ncbi.nlm.nih.gov/pubmed/25638682
97. Colvin, H., Yamamoto, K., Wada, N., Mori, M., Hereditary Gastric Cancer Syndromes, Surg Oncol Clin N Am, 2015. 24(4): p. 765-77., https://www.ncbi.nlm.nih.gov/pubmed/26363540
98. Pinheiro, H., Oliveira, C., Seruca, R., Carneiro, F., Hereditary diffuse gastric cancer - pathophysiology and clinical management, Best Pract Res Clin Gastroenterol, 2014. 28(6): p. 1055-68., https://www.ncbi.nlm.nih.gov/pubmed/25439071
99. Worthley, D. L., Phillips, K. D., Wayte, N., Schrader, K. A., Healey, S., Kaurah, P., et.al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome, Gut, 2012. 61(5): p. 774-9., https://www.ncbi.nlm.nih.gov/pubmed/21813476
100. Majewski, I. J., Kluijt, I., Cats, A., Scerri, T. S., de Jong, D., Kluin, R. J., et.al. An alpha-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer, J Pathol, 2013. 229(4): p. 621-9., https://www.ncbi.nlm.nih.gov/pubmed/23208944
101. Donner, I., Kiviluoto, T., Ristimaki, A., Aaltonen, L. A., Vahteristo, P., Exome sequencing reveals three novel candidate predisposition genes for diffuse gastric cancer, Fam Cancer, 2015. 14(2): p. 241-6., https://www.ncbi.nlm.nih.gov/pubmed/25576241
102. Li, J., Woods, S. L., Healey, S., Beesley, J., Chen, X., Lee, J. S., et.al. Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant, Am J Hum Genet, 2016. 98(5): p. 830-842., https://www.ncbi.nlm.nih.gov/pubmed/27087319
103. Zaffaroni, G, Mannucci, A, Koskenvuo, L, de Lacy, B, Maffioli, A, Bisseling, T, et.al. Updated European guidelines for clinical management of familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), gastric adenocarcinoma, proximal polyposis of the stomach (GAPPS) and other rare adenomatous polyposis syndromes: a joint EHTG-ESCP revision., Br J Surg, 2024. 111 (5)(5):, https://pubmed.ncbi.nlm.nih.gov/38722804/
104. Carneiro, F, Familial and hereditary gastric cancer, an overview., Best Pract Res Clin Gastroenterol, 2022. 58-59 (): p. 101800., https://pubmed.ncbi.nlm.nih.gov/35988963/
105. Zeng, C, Bastarache, LA, Tao, R, Venner, E, Hebbring, S, Andujar, JD, et.al. Association of Pathogenic Variants in Hereditary Cancer Genes With Multiple Diseases., JAMA Oncol, 2022. 8 (6)(6): p. 835-844., https://pubmed.ncbi.nlm.nih.gov/35446370/
106. Latchford, A. R., Neale, K., Phillips, R. K., Clark, S. K., Juvenile polyposis syndrome: a study of genotype, phenotype, and long-term outcome, Dis Colon Rectum, 2012. 55(10): p. 1038-43., https://www.ncbi.nlm.nih.gov/pubmed/22965402
107. Masciari, S., Dewanwala, A., Stoffel, E. M., Lauwers, G. Y., Zheng, H., Achatz, M. I., et.al. Gastric cancer in individuals with Li-Fraumeni syndrome, Genet Med, 2011. 13(7): p. 651-7., https://www.ncbi.nlm.nih.gov/pubmed/21552135
108. Giardiello, F. M., Brensinger, J. D., Tersmette, A. C., Goodman, S. N., Petersen, G. M., Booker, S. V., et.al. Very high risk of cancer in familial Peutz-Jeghers syndrome, Gastroenterology, 2000. 119(6): p. 1447-53., https://www.ncbi.nlm.nih.gov/pubmed/11113065
109. Streff, H., Profato, J., Ye, Y., Nebgen, D., Peterson, S. K., Singletary, C., et.al. Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers, Oncologist, 2016. 21(7): p. 869-74., https://www.ncbi.nlm.nih.gov/pubmed/27306910
110. van der Post, R. S., Vogelaar, I. P., Carneiro, F., Guilford, P., Huntsman, D., Hoogerbrugge, N., et.al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers, J Med Genet, 2015. 52(6): p. 361-74., https://www.ncbi.nlm.nih.gov/pubmed/25979631
111. van der Post, RS, Oliveira, C, Guilford, P, Carneiro, F, Hereditary gastric cancer: what's new? Update 2013-2018., Fam Cancer, 2019. 18 (3)(3): p. 363-367., https://pubmed.ncbi.nlm.nih.gov/30989426/
112. Hüneburg, R, Aretz, S, Büttner, R, Daum, S, Engel, C, Fechner, G, et.al. [Current recommendations for surveillance, risk reduction and therapy in Lynch syndrome patients]., Z Gastroenterol, 2019. 57 (11)(11): p. 1309-1320., https://pubmed.ncbi.nlm.nih.gov/31739377/
113. Stjepanovic, N, Moreira, L, Carneiro, F, Balaguer, F, Cervantes, A, Balmaña, J, et.al. Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†., Ann Oncol, 2019. 30 (10)(10): p. 1558-1571., https://pubmed.ncbi.nlm.nih.gov/31378807/
114. Schmiegel W, Pox, C et al., S3-Leitlinie Kolorektales Karzinom v2.1Leitlinienprogramm Onkologie, 2019.
115. Corso, G., Marrelli, D., Pascale, V., Vindigni, C., Roviello, F., Frequency of CDH1 germline mutations in gastric carcinoma coming from high- and low-risk areas: metanalysis and systematic review of the literature, BMC Cancer, 2012. 12: p. 8., https://www.ncbi.nlm.nih.gov/pubmed/22225527
116. Network, Cancer Genome Atlas Research, Comprehensive molecular characterization of gastric adenocarcinoma., Nature, 2014. 513(7517): p. 202-9., https://pubmed.ncbi.nlm.nih.gov/25079317/
117. Lee, K, Krempely, K, Roberts, ME, Anderson, MJ, Carneiro, F, Chao, E, et.al. Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants., Hum Mutat, 2018. 39 (11)(11): p. 1553-1568., https://pubmed.ncbi.nlm.nih.gov/30311375/
118. Hansford, S., Kaurah, P., Li-Chang, H., Woo, M., Senz, J., Pinheiro, H., et.al. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond, JAMA Oncol, 2015. 1(1): p. 23-32., https://www.ncbi.nlm.nih.gov/pubmed/26182300
119. Asif, B, Sarvestani, AL, Gamble, LA, Samaranayake, SG, Famiglietti, AL, Fasaye, GA, et.al. Cancer surveillance as an alternative to prophylactic total gastrectomy in hereditary diffuse gastric cancer: a prospective cohort study., Lancet Oncol, 2023. 24 (4)(4): p. 383-391., https://pubmed.ncbi.nlm.nih.gov/36990610/
120. Lee, CYC, Olivier, A, Honing, J, Lydon, AM, Richardson, S, O'Donovan, M, et.al. Endoscopic surveillance with systematic random biopsy for the early diagnosis of hereditary diffuse gastric cancer: a prospective 16-year longitudinal cohort study., Lancet Oncol, 2023. 24 (1)(1): p. 107-116., https://pubmed.ncbi.nlm.nih.gov/36509094/
121. Corso, G., Figueiredo, J., Biffi, R., Trentin, C., Bonanni, B., Feroce, I., et.al. E-cadherin germline mutation carriers: clinical management and genetic implications, Cancer Metastasis Rev, 2014. 33(4): p. 1081-94., https://www.ncbi.nlm.nih.gov/pubmed/25332147
122. Coudert, M, Drouet, Y, Delhomelle, H, Svrcek, M, Benusiglio, PR, Coulet, F, et.al. First estimates of diffuse gastric cancer risks for carriers of , J Med Genet, 2022. 59 (12)(12): p. 1189-1195., https://pubmed.ncbi.nlm.nih.gov/36038258/
123. Petrovchich, I., Ford, J. M., Genetic predisposition to gastric cancer, Semin Oncol, 2016. 43(5): p. 554-559., https://www.ncbi.nlm.nih.gov/pubmed/27899187
124. Seevaratnam, R., Coburn, N., Cardoso, R., Dixon, M., Bocicariu, A., Helyer, L., A systematic review of the indications for genetic testing and prophylactic gastrectomy among patients with hereditary diffuse gastric cancer, Gastric Cancer, 2012. 15 Suppl 1: p. S153-63., https://www.ncbi.nlm.nih.gov/pubmed/22160243
125. Huntsman, D. G., Carneiro, F., Lewis, F. R., MacLeod, P. M., Hayashi, A., Monaghan, K. G., et.al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations, N Engl J Med, 2001. 344(25): p. 1904-9., https://www.ncbi.nlm.nih.gov/pubmed/11419427
126. Lewis, F. R., Mellinger, J. D., Hayashi, A., Lorelli, D., Monaghan, K. G., Carneiro, F., et.al. Prophylactic total gastrectomy for familial gastric cancer, Surgery, 2001. 130(4): p. 612-7; discussion 617-9., https://www.ncbi.nlm.nih.gov/pubmed/11602891
127. Rogers, W. M., Dobo, E., Norton, J. A., Van Dam, J., Jeffrey, R. B., Huntsman, D. G., et.al. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications, Am J Surg Pathol, 2008. 32(6): p. 799-809., https://www.ncbi.nlm.nih.gov/pubmed/18391748
128. Koornstra, J. J., Mourits, M. J., Sijmons, R. H., Leliveld, A. M., Hollema, H., Kleibeuker, J. H., Management of extracolonic tumours in patients with Lynch syndrome, Lancet Oncol, 2009. 10(4): p. 400-8., https://www.ncbi.nlm.nih.gov/pubmed/19341971
129. Barrow, E., Robinson, L., Alduaij, W., Shenton, A., Clancy, T., Lalloo, F., et.al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations, Clin Genet, 2009. 75(2): p. 141-9., https://www.ncbi.nlm.nih.gov/pubmed/19215248
130. Capelle, L. G., Van Grieken, N. C., Lingsma, H. F., Steyerberg, E. W., Klokman, W. J., Bruno, M. J., et.al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands, Gastroenterology, 2010. 138(2): p. 487-92., https://www.ncbi.nlm.nih.gov/pubmed/19900449
131. Vasen, H. F., Stormorken, A., Menko, F. H., Nagengast, F. M., Kleibeuker, J. H., Griffioen, G., et.al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families, J Clin Oncol, 2001. 19(20): p. 4074-80., https://www.ncbi.nlm.nih.gov/pubmed/11600610
132. Lee, S. E., Kang, S. Y., Cho, J., Lee, B., Chang, D. K., Woo, H., et.al. Pyloric gland adenoma in Lynch syndrome, Am J Surg Pathol, 2014. 38(6): p. 784-92., https://www.ncbi.nlm.nih.gov/pubmed/24518125
133. Park, Y. J., Shin, K. H., Park, J. G., Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea, Clin Cancer Res, 2000. 6(8): p. 2994-8., https://www.ncbi.nlm.nih.gov/pubmed/10955776
134. Gylling, A., Abdel-Rahman, W. M., Juhola, M., Nuorva, K., Hautala, E., Jarvinen, H. J., et.al. Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study, Gut, 2007. 56(7): p. 926-33., https://www.ncbi.nlm.nih.gov/pubmed/17267619
135. Goecke, T., Schulmann, K., Engel, C., Holinski-Feder, E., Pagenstecher, C., Schackert, H. K., et.al. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium, J Clin Oncol, 2006. 24(26): p. 4285-92., https://www.ncbi.nlm.nih.gov/pubmed/16908935
136. Geary, J., Sasieni, P., Houlston, R., Izatt, L., Eeles, R., Payne, S. J., et.al. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC), Fam Cancer, 2008. 7(2): p. 163-72., https://www.ncbi.nlm.nih.gov/pubmed/17939062
137. Vasen, H. F., Moslein, G., Alonso, A., Bernstein, I., Bertario, L., Blanco, I., et.al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer), J Med Genet, 2007. 44(6): p. 353-62., https://www.ncbi.nlm.nih.gov/pubmed/17327285
138. Renkonen-Sinisalo, L., Sipponen, P., Aarnio, M., Julkunen, R., Aaltonen, L. A., Sarna, S., et.al. No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer, Scand J Gastroenterol, 2002. 37(5): p. 574-7., https://www.ncbi.nlm.nih.gov/pubmed/12059060
139. Schulmann, K., Brasch, F. E., Kunstmann, E., Engel, C., Pagenstecher, C., Vogelsang, H., et.al. HNPCC-associated small bowel cancer: clinical and molecular characteristics, Gastroenterology, 2005. 128(3): p. 590-9., https://www.ncbi.nlm.nih.gov/pubmed/15765394
140. Aktualisierte S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Z Gastroenterol, 2022. 61 (5)(5): p. 544 - 606., https://pubmed.ncbi.nlm.nih.gov/37146633/
141. Malfertheiner, P., Megraud, F., O'Morain, C. A., Atherton, J., Axon, A. T., Bazzoli, F., et.al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report, Gut, 2012. 61(5): p. 646-64., https://www.ncbi.nlm.nih.gov/pubmed/22491499
142. Fuccio, L., Zagari, R. M., Eusebi, L. H., Laterza, L., Cennamo, V., Ceroni, L., et.al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?, Ann Intern Med, 2009. 151(2): p. 121-8., https://www.ncbi.nlm.nih.gov/pubmed/19620164
143. Kosunen, T. U., Pukkala, E., Sarna, S., Seppala, K., Aromaa, A., Knekt, P., et.al. Gastric cancers in Finnish patients after cure of Helicobacter pylori infection: A cohort study, Int J Cancer, 2011. 128(2): p. 433-9., https://www.ncbi.nlm.nih.gov/pubmed/20309944
144. Ogura, K., Hirata, Y., Yanai, A., Shibata, W., Ohmae, T., Mitsuno, Y., et.al. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer, J Clin Gastroenterol, 2008. 42(3): p. 279-83., https://www.ncbi.nlm.nih.gov/pubmed/18223496
145. Wong, B. C., Lam, S. K., Wong, W. M., Chen, J. S., Zheng, T. T., Feng, R. E., et.al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial, JAMA, 2004. 291(2): p. 187-94., https://www.ncbi.nlm.nih.gov/pubmed/14722144
146. Shiotani, A., Uedo, N., Iishi, H., Yoshiyuki, Y., Ishii, M., Manabe, N., et.al. Predictive factors for metachronous gastric cancer in high-risk patients after successful Helicobacter pylori eradication, Digestion, 2008. 78(2-3): p. 113-9., https://www.ncbi.nlm.nih.gov/pubmed/19023205
147. Maehata, Y., Nakamura, S., Fujisawa, K., Esaki, M., Moriyama, T., Asano, K., et.al. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer, Gastrointest Endosc, 2012. 75(1): p. 39-46., https://www.ncbi.nlm.nih.gov/pubmed/22018552
148. Fukase, K., Kato, M., Kikuchi, S., Inoue, K., Uemura, N., Okamoto, S., et.al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial, Lancet, 2008. 372(9636): p. 392-7., https://www.ncbi.nlm.nih.gov/pubmed/18675689
149. Kwon, Y. H., Heo, J., Lee, H. S., Cho, C. M., Jeon, S. W., Failure of Helicobacter pylori eradication and age are independent risk factors for recurrent neoplasia after endoscopic resection of early gastric cancer in 283 patients, Aliment Pharmacol Ther, 2014. 39(6): p. 609-18., https://www.ncbi.nlm.nih.gov/pubmed/24461252
150. Seo, J. Y., Lee, D. H., Cho, Y., Lee, D. H., Oh, H. S., Jo, H. J., et.al. Eradication of Helicobacter pylori reduces metachronous gastric cancer after endoscopic resection of early gastric cancer, Hepatogastroenterology, 2013. 60(124): p. 776-80., https://www.ncbi.nlm.nih.gov/pubmed/23165228
151. Toyokawa, T., Suwaki, K., Miyake, Y., Nakatsu, M., Ando, M., Eradication of Helicobacter pylori infection improved gastric mucosal atrophy and prevented progression of intestinal metaplasia, especially in the elderly population: a long-term prospective cohort study, J Gastroenterol Hepatol, 2010. 25(3): p. 544-7., https://www.ncbi.nlm.nih.gov/pubmed/19817964
152. Kodama, M., Murakami, K., Okimoto, T., Abe, T., Nakagawa, Y., Mizukami, K., et.al. Helicobacter pylori eradication improves gastric atrophy and intestinal metaplasia in long-term observation, Digestion, 2012. 85(2): p. 126-30., https://www.ncbi.nlm.nih.gov/pubmed/22269293
153. Lee, Y. C., Chiang, T. H., Chou, C. K., Tu, Y. K., Liao, W. C., Wu, M. S., et.al. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis, Gastroenterology, 2016. 150(5): p. 1113-1124 e5., https://www.ncbi.nlm.nih.gov/pubmed/26836587
154. Pan, K. F., Zhang, L., Gerhard, M., Ma, J. L., Liu, W. D., Ulm, K., et.al. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication, Gut, 2016. 65(1): p. 9-18., https://www.ncbi.nlm.nih.gov/pubmed/25986943
155. S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease., Z Gastroenterol, 2017. 55 (2)(2): p. 167-206., https://pubmed.ncbi.nlm.nih.gov/27919112/
156. Cho, S. J., Choi, I. J., Kook, M. C., Yoon, H., Park, S., Kim, C. G., et.al. Randomised clinical trial: the effects of Helicobacter pylori eradication on glandular atrophy and intestinal metaplasia after subtotal gastrectomy for gastric cancer, Aliment Pharmacol Ther, 2013. 38(5): p. 477-89., https://www.ncbi.nlm.nih.gov/pubmed/23822578
157. Wu, C. Y., Kuo, K. N., Wu, M. S., Chen, Y. J., Wang, C. B., Lin, J. T., Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease, Gastroenterology, 2009. 137(5): p. 1641-8 e1-2., https://www.ncbi.nlm.nih.gov/pubmed/19664631
158. Yang, H. B., Sheu, B. S., Wang, S. T., Cheng, H. C., Chang, W. L., Chen, W. Y., H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole, Am J Gastroenterol, 2009. 104(7): p. 1642-9., https://www.ncbi.nlm.nih.gov/pubmed/19436275
159. Rokkas, T., Sechopoulos, P., Pistiolas, D., Margantinis, G., Koukoulis, G., Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis, Eur J Gastroenterol Hepatol, 2010. 22(9): p. 1128-33., https://www.ncbi.nlm.nih.gov/pubmed/20410824
160. [Not Available]., Z Gastroenterol, 2019. 57 (3)(3): p. 295., https://pubmed.ncbi.nlm.nih.gov/30861552/
161. Shichijo, S., Hirata, Y., Niikura, R., Hayakawa, Y., Yamada, A., Ushiku, T., et.al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication, Gastrointest Endosc, 2016. 84(4): p. 618-24., https://www.ncbi.nlm.nih.gov/pubmed/26995689
162. Huang, Y. K., Yu, J. C., Kang, W. M., Ma, Z. Q., Ye, X., Tian, S. B., et.al. Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis, PLoS One, 2015. 10(11): p. e0142080., https://www.ncbi.nlm.nih.gov/pubmed/26556485
163. Terasawa, T., Nishida, H., Kato, K., Miyashiro, I., Yoshikawa, T., Takaku, R., et.al. Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis, PLoS One, 2014. 9(10): p. e109783., https://www.ncbi.nlm.nih.gov/pubmed/25314140
164. di Mario, F., Cavallaro, L. G., Non-invasive tests in gastric diseases, Dig Liver Dis, 2008. 40(7): p. 523-30., https://www.ncbi.nlm.nih.gov/pubmed/18439884
165. Cao, Q., Ran, Z. H., Xiao, S. D., Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies, J Dig Dis, 2007. 8(1): p. 15-22., https://www.ncbi.nlm.nih.gov/pubmed/17261130
166. Kikuchi, S., Kato, M., Katsuyama, T., Tominaga, S., Asaka, M., Design and planned analyses of an ongoing randomized trial assessing the preventive effect of Helicobacter pylori eradication on occurrence of new gastric carcinomas after endoscopic resection, Helicobacter, 2006. 11(3): p. 147-51., https://www.ncbi.nlm.nih.gov/pubmed/16684261
167. Leja, M., Kupcinskas, L., Funka, K., Sudraba, A., Jonaitis, L., Ivanauskas, A., et.al. The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology, Dig Dis Sci, 2009. 54(11): p. 2377-84., https://www.ncbi.nlm.nih.gov/pubmed/19731026
168. Kitahara, F., Kobayashi, K., Sato, T., Kojima, Y., Araki, T., Fujino, M. A., Accuracy of screening for gastric cancer using serum pepsinogen concentrations, Gut, 1999. 44(5): p. 693-7., https://www.ncbi.nlm.nih.gov/pubmed/10205207
169. Watabe, H., Mitsushima, T., Yamaji, Y., Okamoto, M., Wada, R., Kokubo, T., et.al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study, Gut, 2005. 54(6): p. 764-8., https://www.ncbi.nlm.nih.gov/pubmed/15888780
170. Oishi, Y., Kiyohara, Y., Kubo, M., Tanaka, K., Tanizaki, Y., Ninomiya, T., et.al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study, Am J Epidemiol, 2006. 163(7): p. 629-37., https://www.ncbi.nlm.nih.gov/pubmed/16443800
171. Ikeda, F., Shikata, K., Hata, J., Fukuhara, M., Hirakawa, Y., Ohara, T., et.al. Combination of Helicobacter pylori Antibody and Serum Pepsinogen as a Good Predictive Tool of Gastric Cancer Incidence: 20-Year Prospective Data From the Hisayama Study, J Epidemiol, 2016. 26(12): p. 629-636., https://www.ncbi.nlm.nih.gov/pubmed/27265836
172. Miki, K., Gastric cancer screening using the serum pepsinogen test method, Gastric Cancer, 2006. 9(4): p. 245-53., https://www.ncbi.nlm.nih.gov/pubmed/17235625
173. Yoshihara, M., Hiyama, T., Yoshida, S., Ito, M., Tanaka, S., Watanabe, Y., et.al. Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: a case-control study, Scand J Gastroenterol, 2007. 42(6): p. 760-4., https://www.ncbi.nlm.nih.gov/pubmed/17505999
174. Yanaoka, K., Oka, M., Mukoubayashi, C., Yoshimura, N., Enomoto, S., Iguchi, M., et.al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males, Cancer Epidemiol Biomarkers Prev, 2008. 17(4): p. 838-45., https://www.ncbi.nlm.nih.gov/pubmed/18398025
175. Zhang, X., Xue, L., Xing, L., Wang, J., Cui, J., Mi, J., et.al. Low serum pepsinogen I and pepsinogen I/II ratio and Helicobacter pylori infection are associated with increased risk of gastric cancer: 14-year follow up result in a rural Chinese community, Int J Cancer, 2012. 130(7): p. 1614-9., https://www.ncbi.nlm.nih.gov/pubmed/21547904
176. Lomba-Viana, R., Dinis-Ribeiro, M., Fonseca, F., Vieira, A. S., Bento, M. J., Lomba-Viana, H., Serum pepsinogen test for early detection of gastric cancer in a European country, Eur J Gastroenterol Hepatol, 2012. 24(1): p. 37-41., https://www.ncbi.nlm.nih.gov/pubmed/21989121
177. Yeh, J. M., Hur, C., Ward, Z., Schrag, D., Goldie, S. J., Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis, Gut, 2016. 65(4): p. 563-74., https://www.ncbi.nlm.nih.gov/pubmed/25779597
178. Selgrad, M, Bornschein, J, Kandulski, A, Weigt, J, Roessner, A, Wex, T, et.al. Combined Gastric and Colorectal Cancer Screening-A New Strategy., Int J Mol Sci, 2018. 19 (12)(12):, https://pubmed.ncbi.nlm.nih.gov/30513960/
179. Dinis-Ribeiro, M., Areia, M., de Vries, A. C., Marcos-Pinto, R., Monteiro-Soares, M., O'Connor, A., et.al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED), Endoscopy, 2012. 44(1): p. 74-94., https://www.ncbi.nlm.nih.gov/pubmed/22198778
180. de Vries, A. C., Haringsma, J., Kuipers, E. J., The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection, Helicobacter, 2007. 12(1): p. 1-15., https://www.ncbi.nlm.nih.gov/pubmed/17241295
181. de Vries, A. C., van Grieken, N. C., Looman, C. W., Casparie, M. K., de Vries, E., Meijer, G. A., et.al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands, Gastroenterology, 2008. 134(4): p. 945-52., https://www.ncbi.nlm.nih.gov/pubmed/18395075
182. Rugge, M., Genta, R. M., Group, Olga, Staging gastritis: an international proposal, Gastroenterology, 2005. 129(5): p. 1807-8., https://www.ncbi.nlm.nih.gov/pubmed/16285989
183. Rugge, M., Meggio, A., Pennelli, G., Piscioli, F., Giacomelli, L., De Pretis, G., et.al. Gastritis staging in clinical practice: the OLGA staging system, Gut, 2007. 56(5): p. 631-6., https://www.ncbi.nlm.nih.gov/pubmed/17142647
184. Capelle, L. G., de Vries, A. C., Haringsma, J., Ter Borg, F., de Vries, R. A., Bruno, M. J., et.al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis, Gastrointest Endosc, 2010. 71(7): p. 1150-8., https://www.ncbi.nlm.nih.gov/pubmed/20381801
185. Isajevs, S., Liepniece-Karele, I., Janciauskas, D., Moisejevs, G., Putnins, V., Funka, K., et.al. Gastritis staging: interobserver agreement by applying OLGA and OLGIM systems, Virchows Arch, 2014. 464(4): p. 403-7., https://www.ncbi.nlm.nih.gov/pubmed/24477629
186. Leja, M., Funka, K., Janciauskas, D., Putnins, V., Ruskule, A., Kikuste, I., et.al. Interobserver variation in assessment of gastric premalignant lesions: higher agreement for intestinal metaplasia than for atrophy, Eur J Gastroenterol Hepatol, 2013. 25(6): p. 694-9., https://www.ncbi.nlm.nih.gov/pubmed/23337173
187. Marcos-Pinto, R., Carneiro, F., Dinis-Ribeiro, M., Wen, X., Lopes, C., Figueiredo, C., et.al. First-degree relatives of patients with early-onset gastric carcinoma show even at young ages a high prevalence of advanced OLGA/OLGIM stages and dysplasia, Aliment Pharmacol Ther, 2012. 35(12): p. 1451-9., https://www.ncbi.nlm.nih.gov/pubmed/22548492
188. Rugge, M., de Boni, M., Pennelli, G., de Bona, M., Giacomelli, L., Fassan, M., et.al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study, Aliment Pharmacol Ther, 2010. 31(10): p. 1104-11., https://www.ncbi.nlm.nih.gov/pubmed/20180784
189. Li, D., Bautista, M. C., Jiang, S. F., Daryani, P., Brackett, M., Armstrong, M. A., et.al. Risks and Predictors of Gastric Adenocarcinoma in Patients with Gastric Intestinal Metaplasia and Dysplasia: A Population-Based Study, Am J Gastroenterol, 2016. 111(8): p. 1104-13., https://www.ncbi.nlm.nih.gov/pubmed/27185078
190. Song, H., Ekheden, I. G., Zheng, Z., Ericsson, J., Nyren, O., Ye, W., Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population, BMJ, 2015. 351: p. h3867., https://www.ncbi.nlm.nih.gov/pubmed/26215280
191. den Hoed, C. M., Holster, I. L., Capelle, L. G., de Vries, A. C., den Hartog, B., Ter Borg, F., et.al. Follow-up of premalignant lesions in patients at risk for progression to gastric cancer, Endoscopy, 2013. 45(4): p. 249-56., https://www.ncbi.nlm.nih.gov/pubmed/23533073
192. Take, S., Mizuno, M., Ishiki, K., Yoshida, T., Ohara, N., Yokota, K., et.al. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori, J Gastroenterol, 2011. 46(3): p. 318-24., https://www.ncbi.nlm.nih.gov/pubmed/21103997
193. Rokkas, T., Pistiolas, D., Sechopoulos, P., Robotis, I., Margantinis, G., The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis, Helicobacter, 2007. 12 Suppl 2: p. 32-8., https://www.ncbi.nlm.nih.gov/pubmed/17991174
194. Yoshida, T., Kato, J., Inoue, I., Yoshimura, N., Deguchi, H., Mukoubayashi, C., et.al. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer, Int J Cancer, 2014. 134(6): p. 1445-57., https://www.ncbi.nlm.nih.gov/pubmed/24009139
195. O'Connor, A., McNamara, D., O'Morain, C. A., Surveillance of gastric intestinal metaplasia for the prevention of gastric cancer, Cochrane Database Syst Rev, 2013. p. CD009322., https://www.ncbi.nlm.nih.gov/pubmed/24062262
196. de Vries, A. C., Haringsma, J., de Vries, R. A., Ter Borg, F., van Grieken, N. C., Meijer, G. A., et.al. Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions, Helicobacter, 2010. 15(4): p. 259-64., https://www.ncbi.nlm.nih.gov/pubmed/20633186
197. Areia, M., Dinis-Ribeiro, M., Rocha Goncalves, F., Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions, Helicobacter, 2014. 19(6): p. 425-36., https://www.ncbi.nlm.nih.gov/pubmed/25164596
198. Hassan, C., Zullo, A., Di Giulio, E., Annibale, B., Lahner, E., De Francesco, V., et.al. Cost-effectiveness of endoscopic surveillance for gastric intestinal metaplasia, Helicobacter, 2010. 15(3): p. 221-6., https://www.ncbi.nlm.nih.gov/pubmed/20557364
199. Pimentel-Nunes, P., Libanio, D., Marcos-Pinto, R., Areia, M., Leja, M., Esposito, G., et.al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019, Endoscopy, 2019. 51(4): p. 365-388., https://pubmed.ncbi.nlm.nih.gov/30841008/
200. den Hoed, C. M., van Eijck, B. C., Capelle, L. G., van Dekken, H., Biermann, K., Siersema, P. D., et.al. The prevalence of premalignant gastric lesions in asymptomatic patients: predicting the future incidence of gastric cancer, Eur J Cancer, 2011. 47(8): p. 1211-8., https://www.ncbi.nlm.nih.gov/pubmed/21239166
201. Hooi, JKY, Lai, WY, Ng, WK, Suen, MMY, Underwood, FE, Tanyingoh, D, et.al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis., Gastroenterology, 2017. 153 (2)(2): p. 420-429., https://pubmed.ncbi.nlm.nih.gov/28456631/
202. Franck, C, Hoffmann, A, Link, A, Schulz, C, Wuttig, K, Becker, E, et.al. Prevalence of Helicobacter pylori infection among blood donors in Saxony-Anhalt, Germany - a region at intermediate risk for gastric cancer., Z Gastroenterol, 2017. 55 (7)(7): p. 653-656., https://pubmed.ncbi.nlm.nih.gov/28437803/
203. Macke, L., HelicoPTER – lokale Prävalenz, Therapieerfolg und Antibiotikaresistenz der Helicobacter pylori-Infektion in Deutschland, Z Gastroenterol, 2022. 60(04): p. e258 - e259.
204. Lansdorp-Vogelaar, I., Sharp, L., Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention, Best Pract Res Clin Gastroenterol, 2013. 27(6): p. 933-47., https://www.ncbi.nlm.nih.gov/pubmed/24182612
205. Chen, Q, Liang, X, Long, X, Yu, L, Liu, W, Lu, H, Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases., Helicobacter, 2019. 24 (2)(2): p. e12563., https://pubmed.ncbi.nlm.nih.gov/30672082/
206. Lansdorp-Vogelaar, I, Meester, RGS, Laszkowska, M, Escudero, FA, Ward, ZJ, Yeh, JM, Cost-effectiveness of prevention and early detection of gastric cancer in Western countries., Best Pract Res Clin Gastroenterol, 2021. 50-51 (): p. 101735., https://pubmed.ncbi.nlm.nih.gov/33975689/
207. Choi, JM, Kim, SG, Choi, J, Park, JY, Oh, S, Yang, HJ, et.al. Effects of Helicobacter pylori eradication for metachronous gastric cancer prevention: a randomized controlled trial., Gastrointest Endosc, 2018. 88 (3)(3): p. 475-485.e2., https://pubmed.ncbi.nlm.nih.gov/29800546/
208. Choi, Y, Kim, N, Yoon, H, Shin, CM, Park, YS, Lee, DH, et.al. The Incidence and Risk Factors for Metachronous Gastric Cancer in the Remnant Stomach after Gastric Cancer Surgery., Gut Liver, 2022. 16 (3)(3): p. 366-374., https://pubmed.ncbi.nlm.nih.gov/34462394/
209. Choi, IJ, Kook, MC, Kim, YI, Cho, SJ, Lee, JY, Kim, CG, et.al. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer., N Engl J Med, 2018. 378 (12)(12): p. 1085-1095., https://pubmed.ncbi.nlm.nih.gov/29562147/
210. Malfertheiner, P, Megraud, F, Rokkas, T, Gisbert, JP, Liou, JM, Schulz, C, et.al. Management of , Gut, 2022. ():, https://pubmed.ncbi.nlm.nih.gov/35944925/
211. Tersmette, A. C., Offerhaus, G. J., Tersmette, K. W., Giardiello, F. M., Moore, G. W., Tytgat, G. N., et.al. Meta-analysis of the risk of gastric stump cancer: detection of high risk patient subsets for stomach cancer after remote partial gastrectomy for benign conditions, Cancer Res, 1990. 50(20): p. 6486-9., https://www.ncbi.nlm.nih.gov/pubmed/2145061
212. Tersmette, A. C., Giardiello, F. M., Tytgat, G. N., Offerhaus, G. J., Carcinogenesis after remote peptic ulcer surgery: the long-term prognosis of partial gastrectomy, Scand J Gastroenterol Suppl, 1995. 212: p. 96-9., https://www.ncbi.nlm.nih.gov/pubmed/8578237
213. Neugut, A. I., Hayek, M., Howe, G., Epidemiology of gastric cancer, Semin Oncol, 1996. 23(3): p. 281-91., https://www.ncbi.nlm.nih.gov/pubmed/8658212
214. Stalnikowicz, R., Benbassat, J., Risk of gastric cancer after gastric surgery for benign disorders, Arch Intern Med, 1990. 150(10): p. 2022-6., https://www.ncbi.nlm.nih.gov/pubmed/2222087
215. Sinning, C., Schaefer, N., Standop, J., Hirner, A., Wolff, M., Gastric stump carcinoma - epidemiology and current concepts in pathogenesis and treatment, Eur J Surg Oncol, 2007. 33(2): p. 133-9., https://www.ncbi.nlm.nih.gov/pubmed/17071041
216. Vannella, L, Lahner, E, Osborn, J, Annibale, B, Systematic review: gastric cancer incidence in pernicious anaemia., Aliment Pharmacol Ther, 2013. 37 (4)(4): p. 375-82., https://pubmed.ncbi.nlm.nih.gov/23216458/
217. Rugge, M, Genta, RM, Malfertheiner, P, Graham, DY, Atrophic autoimmune gastritis: 'a muddled or misguided core concept compromises our overall comprehension of the problem'., Gut, 2023. 73 (1)(1): p. 207-208., https://pubmed.ncbi.nlm.nih.gov/36868846/
218. Rugge, M, Genta, RM, Malfertheiner, P, Dinis-Ribeiro, M, El-Serag, H, Graham, DY, et.al. RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates., Gut, 2024. 73 (3)(3): p. 407-441., https://pubmed.ncbi.nlm.nih.gov/38383142/
219. Chen, C, Yang, Y, Li, P, Hu, H, Incidence of Gastric Neoplasms Arising from Autoimmune Metaplastic Atrophic Gastritis: A Systematic Review and Case Reports., J Clin Med, 2023. 12 (3)(3):, https://pubmed.ncbi.nlm.nih.gov/36769710/
220. Goldenring, J, No , Gut, 2023. 72 (1)(1): p. 1-2., https://pubmed.ncbi.nlm.nih.gov/35896359/
221. Morson, BC, Sobin, LH, Grundmann, E, Johansen, A, Nagayo, T, Serck-Hanssen, A, Precancerous conditions and epithelial dysplasia in the stomach., J Clin Pathol, 1980. 33 (8)(8): p. 711-21., https://pubmed.ncbi.nlm.nih.gov/7430384/
222. Pimentel-Nunes, P, Libânio, D, Marcos-Pinto, R, Areia, M, Leja, M, Esposito, G, et.al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019., Endoscopy, 2019. 51 (4)(4): p. 365-388., https://pubmed.ncbi.nlm.nih.gov/30841008/
223. Esposito, G, Dilaghi, E, Cazzato, M, Pilozzi, E, Conti, L, Carabotti, M, et.al. Endoscopic surveillance at 3 years after diagnosis, according to European guidelines, seems safe in patients with atrophic gastritis in a low-risk region., Dig Liver Dis, 2021. 53 (4)(4): p. 467-473., https://pubmed.ncbi.nlm.nih.gov/33199230/
224. Mahmud, N, Stashek, K, Katona, BW, Tondon, R, Shroff, SG, Roses, R, et.al. The incidence of neoplasia in patients with autoimmune metaplastic atrophic gastritis: a renewed call for surveillance., Ann Gastroenterol, 2019. 32 (1)(1): p. 67-72., https://pubmed.ncbi.nlm.nih.gov/30598594/
225. Zagari, RM, Rabitti, S, Greenwood, DC, Eusebi, LH, Vestito, A, Bazzoli, F, Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis., Aliment Pharmacol Ther, 2017. 46 (7)(7): p. 657-667., https://pubmed.ncbi.nlm.nih.gov/28782119/
226. Leja, M, Kupcinskas, L, Funka, K, Sudraba, A, Jonaitis, L, Ivanauskas, A, et.al. Value of gastrin-17 in detecting antral atrophy., Adv Med Sci, 2011. 56 (2)(2): p. 145-50., https://pubmed.ncbi.nlm.nih.gov/22037174/
227. Robles, C, Rudzite, D, Polaka, I, Sjomina, O, Tzivian, L, Kikuste, I, et.al. Assessment of Serum Pepsinogens with and without Co-Testing with Gastrin-17 in Gastric Cancer Risk Assessment-Results from the GISTAR Pilot Study., Diagnostics (Basel), 2022. 12 (7)(7):, https://pubmed.ncbi.nlm.nih.gov/35885649/
228. Wada, Y, Nakajima, S, Mori, N, Takemura, S, Chatani, R, Ohara, M, et.al. Evaluation of screening tests for autoimmune gastritis in histopathologically confirmed Japanese patients, and re-evaluation of histopathological classification., BMC Gastroenterol, 2022. 22 (1)(1): p. 179., https://pubmed.ncbi.nlm.nih.gov/35410175/
229. Song, M, Latorre, G, Ivanovic-Zuvic, D, Camargo, MC, Rabkin, CS, Autoimmune Diseases and Gastric Cancer Risk: A Systematic Review and Meta-Analysis., Cancer Res Treat, 2019. 51 (3)(3): p. 841-850., https://pubmed.ncbi.nlm.nih.gov/31048663/
230. Rugge, M, Big Data on Gastric Dysplasia Support Gastric Cancer Prevention., Clin Gastroenterol Hepatol, 2022. 20 (6)(6): p. 1226-1228., https://pubmed.ncbi.nlm.nih.gov/35123082/
231. Rugge, M, Genta, RM, Graham, DY, Di Mario, F, Vaz Coelho, LG, Kim, N, et.al. Chronicles of a cancer foretold: 35 years of gastric cancer risk assessment., Gut, 2016. 65 (5)(5): p. 721-5., https://pubmed.ncbi.nlm.nih.gov/26927528/
232. Tran-Duy, A., Spaetgens, B., Hoes, A. W., de Wit, N. J., Stehouwer, C. D., Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis, Clin Gastroenterol Hepatol, 2016. 14(12): p. 1706-1719 e5., https://www.ncbi.nlm.nih.gov/pubmed/27211501
233. Lamberts, R., Creutzfeldt, W., Stockmann, F., Jacubaschke, U., Maas, S., Brunner, G., Long-term omeprazole treatment in man: effects on gastric endocrine cell populations, Digestion, 1988. 39(2): p. 126-35., https://www.ncbi.nlm.nih.gov/pubmed/3410169
234. Klinkenberg-Knol, E. C., Festen, H. P., Jansen, J. B., Lamers, C. B., Nelis, F., Snel, P., et.al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety, Ann Intern Med, 1994. 121(3): p. 161-7., https://www.ncbi.nlm.nih.gov/pubmed/8017742
235. Havu, N., Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion, Digestion, 1986. 35 Suppl 1: p. 42-55., https://www.ncbi.nlm.nih.gov/pubmed/3792671
236. Laine, L., Ahnen, D., McClain, C., Solcia, E., Walsh, J. H., Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors, Aliment Pharmacol Ther, 2000. 14(6): p. 651-68., https://www.ncbi.nlm.nih.gov/pubmed/10848649
237. Gillen, D., McColl, K. E., Problems associated with the clinical use of proton pump inhibitors, Pharmacol Toxicol, 2001. 89(6): p. 281-6., https://www.ncbi.nlm.nih.gov/pubmed/11903952
238. Waldum, H. L., Gustafsson, B., Fossmark, R., Qvigstad, G., Antiulcer drugs and gastric cancer, Dig Dis Sci, 2005. 50 Suppl 1: p. S39-44., https://www.ncbi.nlm.nih.gov/pubmed/16184420
239. Kuipers, E. J., Lundell, L., Klinkenberg-Knol, E. C., Havu, N., Festen, H. P., Liedman, B., et.al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication, N Engl J Med, 1996. 334(16): p. 1018-22., https://www.ncbi.nlm.nih.gov/pubmed/8598839
240. Ye, W., Nyren, O., Risk of cancers of the oesophagus and stomach by histology or subsite in patients hospitalised for pernicious anaemia, Gut, 2003. 52(7): p. 938-41., https://www.ncbi.nlm.nih.gov/pubmed/12801947
241. Bateman, D. N., Colin-Jones, D., Hartz, S., Langman, M., Logan, R. F., Mant, J., et.al. Mortality study of 18 000 patients treated with omeprazole, Gut, 2003. 52(7): p. 942-6., https://www.ncbi.nlm.nih.gov/pubmed/12801948
242. Garcia Rodriguez, L. A., Lagergren, J., Lindblad, M., Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK, Gut, 2006. 55(11): p. 1538-44., https://www.ncbi.nlm.nih.gov/pubmed/16785284
243. Poulsen, A. H., Christensen, S., McLaughlin, J. K., Thomsen, R. W., Sorensen, H. T., Olsen, J. H., et.al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study, Br J Cancer, 2009. 100(9): p. 1503-7., https://www.ncbi.nlm.nih.gov/pubmed/19352380
244. Attwood, S. E., Ell, C., Galmiche, J. P., Fiocca, R., Hatlebakk, J. G., Hasselgren, B., et.al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies, Aliment Pharmacol Ther, 2015. 41(11): p. 1162-74., https://www.ncbi.nlm.nih.gov/pubmed/25858519
245. Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., et.al. Helicobacter pylori infection and the development of gastric cancer, N Engl J Med, 2001. 345(11): p. 784-9., https://www.ncbi.nlm.nih.gov/pubmed/11556297
246. Maret-Ouda, J., El-Serag, H. B., Lagergren, J., Opportunities for Preventing Esophageal Adenocarcinoma, Cancer Prev Res (Phila), 2016. 9(11): p. 828-834., https://www.ncbi.nlm.nih.gov/pubmed/27623934
247. Song, H., Zhu, J., Lu, D., Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions, Cochrane Database Syst Rev, 2014. p. CD010623., https://www.ncbi.nlm.nih.gov/pubmed/25464111
248. Cheung, K. S., Chan, E. W., Wong, A. Y. S., Chen, L., Wong, I. C. K., Leung, W. K., Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study, Gut, 2018. 67(1): p. 28-35., https://www.ncbi.nlm.nih.gov/pubmed/29089382
249. Guo, H, Zhang, R, Zhang, P, Chen, Z, Hua, Y, Huang, X, et.al. Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis., Front Pharmacol, 2023. 14 (): p. 1129948., https://pubmed.ncbi.nlm.nih.gov/37007006/
250. Peng, TR, Wu, TW, Li, CH, Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review and meta-analysis., Int J Clin Oncol, 2023. 28 (1)(1): p. 99-109., https://pubmed.ncbi.nlm.nih.gov/36224477/
251. Gao, H, Li, L, Geng, K, Teng, C, Chen, Y, Chu, F, et.al. Use of proton pump inhibitors for the risk of gastric cancer., Medicine (Baltimore), 2022. 101 (49)(49): p. e32228., https://pubmed.ncbi.nlm.nih.gov/36626449/
252. Poly, TN, Lin, MC, Syed-Abdul, S, Huang, CW, Yang, HC, Li, YJ, Proton Pump Inhibitor Use and Risk of Gastric Cancer: Current Evidence from Epidemiological Studies and Critical Appraisal., Cancers (Basel), 2022. 14 (13)(13):, https://pubmed.ncbi.nlm.nih.gov/35804824/
253. Liu, K, Wang, YH, Wang, J, Chen, B, Luo, N, Gong, J, Meta-analysis of proton pump inhibitor use and the risk of developing gastric cancer or colorectal cancer., Anticancer Drugs, 2023. 34 (9)(9): p. 971-978., https://pubmed.ncbi.nlm.nih.gov/37578746/
254. Piovani, D, Tsantes, AG, Schünemann, HJ, Bonovas, S, Meta-analysis: Use of proton pump inhibitors and risk of gastric cancer in patients requiring gastric acid suppression., Aliment Pharmacol Ther, 2023. 57 (6)(6): p. 653-665., https://pubmed.ncbi.nlm.nih.gov/36585832/
255. Zhang, L. J., Wang, S. Y., Huo, X. H., Zhu, Z. L., Chu, J. K., Ma, J. C., et.al. Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions, World J Gastroenterol, 2009. 15(22): p. 2731-8., https://www.ncbi.nlm.nih.gov/pubmed/19522023
256. Yamac, D., Ayyildiz, T., Coskun, U., Akyurek, N., Dursun, A., Seckin, S., et.al. Cyclooxygenase-2 expression and its association with angiogenesis, Helicobacter pylori, and clinicopathologic characteristics of gastric carcinoma, Pathol Res Pract, 2008. 204(8): p. 527-36., https://www.ncbi.nlm.nih.gov/pubmed/18462890
257. Epplein, M., Nomura, A. M., Wilkens, L. R., Henderson, B. E., Kolonel, L. N., Nonsteroidal antiinflammatory drugs and risk of gastric adenocarcinoma: the multiethnic cohort study, Am J Epidemiol, 2009. 170(4): p. 507-14., https://www.ncbi.nlm.nih.gov/pubmed/19584132
258. Yang, H. B., Cheng, H. C., Sheu, B. S., Hung, K. H., Liou, M. F., Wu, J. J., Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication, Aliment Pharmacol Ther, 2007. 25(4): p. 455-61., https://www.ncbi.nlm.nih.gov/pubmed/17270001
259. Cuzick, J., Otto, F., Baron, J. A., Brown, P. H., Burn, J., Greenwald, P., et.al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement, Lancet Oncol, 2009. 10(5): p. 501-7., https://www.ncbi.nlm.nih.gov/pubmed/19410194
260. Das, D., Chilton, A. P., Jankowski, J. A., Chemoprevention of oesophageal cancer and the AspECT trial, Recent Results Cancer Res, 2009. 181: p. 161-9., https://www.ncbi.nlm.nih.gov/pubmed/19213566
261. Feng, G. S., Ma, J. L., Wong, B. C., Zhang, L., Liu, W. D., Pan, K. F., et.al. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention, World J Gastroenterol, 2008. 14(28): p. 4535-9., https://www.ncbi.nlm.nih.gov/pubmed/18680235
262. Murata, H., Kawano, S., Tsuji, S., Tsuji, M., Sawaoka, H., Kimura, Y., et.al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma, Am J Gastroenterol, 1999. 94(2): p. 451-5., https://www.ncbi.nlm.nih.gov/pubmed/10022645
263. Joo, Y. E., Oh, W. T., Rew, J. S., Park, C. S., Choi, S. K., Kim, S. J., Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis, Digestion, 2002. 66(4): p. 222-9., https://www.ncbi.nlm.nih.gov/pubmed/12592098
264. Nardone, G., Rocco, A., Malfertheiner, P., Review article: helicobacter pylori and molecular events in precancerous gastric lesions, Aliment Pharmacol Ther, 2004. 20(3): p. 261-70., https://www.ncbi.nlm.nih.gov/pubmed/15274662
265. Seo, SI, Park, CH, Kim, TJ, Bang, CS, Kim, JY, Lee, KJ, et.al. Aspirin, metformin, and statin use on the risk of gastric cancer: A nationwide population-based cohort study in Korea with systematic review and meta-analysis., Cancer Med, 2022. 11 (4)(4): p. 1217-1231., https://pubmed.ncbi.nlm.nih.gov/34970858/
266. Wang, L, Zhang, R, Yu, L, Xiao, J, Zhou, X, Li, X, et.al. Aspirin Use and Common Cancer Risk: A Meta-Analysis of Cohort Studies and Randomized Controlled Trials., Front Oncol, 2021. 11 (): p. 690219., https://pubmed.ncbi.nlm.nih.gov/34277434/
267. Niikura, R, Hirata, Y, Hayakawa, Y, Kawahara, T, Yamada, A, Koike, K, Effect of aspirin use on gastric cancer incidence and survival: A systematic review and meta-analysis., JGH Open, 2020. 4 (2)(2): p. 117-125., https://pubmed.ncbi.nlm.nih.gov/32280753/
268. Kwon, S, Ma, W, Drew, DA, Klempner, SJ, Leonardo, BM, Flynn, JJ, et.al. Association Between Aspirin Use and Gastric Adenocarcinoma: A Prospective Cohort Study., Cancer Prev Res (Phila), 2022. 15 (4)(4): p. 265-272., https://pubmed.ncbi.nlm.nih.gov/34980677/
269. García Rodríguez, LA, Soriano-Gabarró, M, Vora, P, Cea Soriano, L, Low-dose aspirin and risk of gastric and oesophageal cancer: A population-based study in the United Kingdom using The Health Improvement Network., Int J Cancer, 2020. 147 (9)(9): p. 2394-2404., https://pubmed.ncbi.nlm.nih.gov/32329063/
270. Leung, W. K., Ng, E. K., Chan, F. K., Chan, W. Y., Chan, K. F., Auyeung, A. C., et.al. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial, Clin Cancer Res, 2006. 12(15): p. 4766-72., https://www.ncbi.nlm.nih.gov/pubmed/16899628
271. Brusselaers, N, Lagergren, J, Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden., BMJ Open, 2018. 8 (7)(7): p. e021869., https://pubmed.ncbi.nlm.nih.gov/29982219/
272. Win, TT, Aye, SN, Lau Chui Fern, J, Ong Fei, C, Aspirin and Reducing Risk of Gastric Cancer: Systematic Review and Meta-Analysis of the Observational Studies., J Gastrointestin Liver Dis, 2020. 29 (2)(2): p. 191-198., https://pubmed.ncbi.nlm.nih.gov/32530986/
273. Bosetti, C, Santucci, C, Gallus, S, Martinetti, M, La Vecchia, C, Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019., Ann Oncol, 2020. 31 (5)(5): p. 558-568., https://pubmed.ncbi.nlm.nih.gov/32272209/
274. Cheung, KS, Chan, EW, Wong, AYS, Chen, L, Seto, WK, Wong, ICK, et.al. Aspirin and Risk of Gastric Cancer After Helicobacter pylori Eradication: A Territory-Wide Study., J Natl Cancer Inst, 2018. 110 (7)(7): p. 743-749., https://pubmed.ncbi.nlm.nih.gov/29361002/
275. Li, B, Cheung, KS, Wong, IY, Leung, WK, Law, S, Nonaspirin nonsteroidal anti-inflammatory drugs and gastric cancer risk after Helicobacter pylori eradication: A territory-wide study., Cancer, 2021. 127 (11)(11): p. 1805-1815., https://pubmed.ncbi.nlm.nih.gov/33471380/
276. Kim, JE, Kim, TJ, Lee, H, Lee, YC, Chung, HH, Min, YW, et.al. Aspirin Use Is Not Associated with the Risk of Metachronous Gastric Cancer in Patients without , J Clin Med, 2021. 11 (1)(1):, https://pubmed.ncbi.nlm.nih.gov/35011936/
277. Jankowski, JAZ, de Caestecker, J, Love, SB, Reilly, G, Watson, P, Sanders, S, et.al. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial., Lancet, 2018. 392 (10145)(10145): p. 400-408., https://pubmed.ncbi.nlm.nih.gov/30057104/
278. Su, CH, Islam, MM, Jia, G, Wu, CC, Statins and the Risk of Gastric Cancer: A Systematic Review and Meta-Analysis., J Clin Med, 2022. 11 (23)(23):, https://pubmed.ncbi.nlm.nih.gov/36498753/
279. Kim, DS, Kim, HJ, Ahn, HS, Statins and the risk of gastric, colorectal, and esophageal cancer incidence and mortality: a cohort study based on data from the Korean national health insurance claims database., J Cancer Res Clin Oncol, 2022. 148 (10)(10): p. 2855-2865., https://pubmed.ncbi.nlm.nih.gov/35660949/
280. Chung, H, Kim, HJ, Jung, HC, Lee, SK, Kim, SG, Statins and metachronous recurrence after endoscopic resection of early gastric cancer: a nationwide Korean cohort study., Gastric Cancer, 2020. 23 (4)(4): p. 659-666., https://pubmed.ncbi.nlm.nih.gov/31980964/
281. Spence, AD, Busby, J, Hughes, CM, Johnston, BT, Coleman, HG, Cardwell, CR, Statin use and survival in patients with gastric cancer in two independent population-based cohorts., Pharmacoepidemiol Drug Saf, 2019. 28 (4)(4): p. 460-470., https://pubmed.ncbi.nlm.nih.gov/30456916/
282. Vakil, N., Moayyedi, P., Fennerty, M. B., Talley, N. J., Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis, Gastroenterology, 2006. 131(2): p. 390-401; quiz 659-60., http://www.ncbi.nlm.nih.gov/pubmed/16890592
283. Lee, S. W., Chang, C. S., Yeh, H. J., Lien, H. C., Lee, T. Y., Peng, Y. C., The Diagnostic Value of Alarm Features for Identifying Types and Stages of Upper Gastrointestinal Malignancies, Gastroenterology Res, 2017. 10(2): p. 120-125., http://www.ncbi.nlm.nih.gov/pubmed/28496533
284. Smyth, E. C., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., Arnold, D., et.al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2016. 27(suppl 5): p. v38-v49., http://www.ncbi.nlm.nih.gov/pubmed/27664260
285. Weise, F, Vieth, M, Reinhold, D, Haybaeck, J, Goni, E, Lippert, H, et.al. Gastric cancer in autoimmune gastritis: A case-control study from the German centers of the staR project on gastric cancer research., United European Gastroenterol J, 2020. 8 (2)(2): p. 175-184., https://pubmed.ncbi.nlm.nih.gov/32213076/
286. Dekker, W., Tytgat, G. N., Diagnostic accuracy of fiberendoscopy in the detection of upper intestinal malignancy. A follow-up analysis, Gastroenterology, 1977. 73(4 Pt 1): p. 710-4., http://www.ncbi.nlm.nih.gov/pubmed/892375
287. Behrens, A., Labenz, J., Schuler, A., Schroder, W., Runzi, M., Steinmann, R. U., et.al. [How safe is sedation in gastrointestinal endoscopy? A multicentre analysis of 388,404 endoscopies and analysis of data from prospective registries of complications managed by members of the Working Group of Leading Hospital Gastroenterologists (ALGK)], Z Gastroenterol, 2013. 51(5): p. 432-6., http://www.ncbi.nlm.nih.gov/pubmed/23681895
288. Riphaus, A., Wehrmann, T., Hausmann, J., Weber, B., von Delius, S., Jung, M., et.al. Update S3-guideline: "sedation for gastrointestinal endoscopy" 2014 (AWMF-register-no. 021/014), Z Gastroenterol, 2016. 54(1): p. 58-95., http://www.ncbi.nlm.nih.gov/pubmed/26751118
289. Hu, Y. Y., Lian, Q. W., Lin, Z. H., Zhong, J., Xue, M., Wang, L. J., Diagnostic performance of magnifying narrow-band imaging for early gastric cancer: A meta-analysis, World J Gastroenterol, 2015. 21(25): p. 7884-94., http://www.ncbi.nlm.nih.gov/pubmed/26167089
290. Zhang, Q., Wang, F., Chen, Z. Y., Wang, Z., Zhi, F. C., Liu, S. D., et.al. Comparison of the diagnostic efficacy of white light endoscopy and magnifying endoscopy with narrow band imaging for early gastric cancer: a meta-analysis, Gastric Cancer, 2016. 19(2): p. 543-52., http://www.ncbi.nlm.nih.gov/pubmed/25920526
291. Ang, T. L., Pittayanon, R., Lau, J. Y., Rerknimitr, R., Ho, S. H., Singh, R., et.al. A multicenter randomized comparison between high-definition white light endoscopy and narrow band imaging for detection of gastric lesions, Eur J Gastroenterol Hepatol, 2015. 27(12): p. 1473-8., http://www.ncbi.nlm.nih.gov/pubmed/26426836
292. Dutta, A. K., Sajith, K. G., Pulimood, A. B., Chacko, A., Narrow band imaging versus white light gastroscopy in detecting potentially premalignant gastric lesions: a randomized prospective crossover study, Indian J Gastroenterol, 2013. 32(1): p. 37-42., http://www.ncbi.nlm.nih.gov/pubmed/22983839
293. So, J., Rajnakova, A., Chan, Y. H., Tay, A., Shah, N., Salto-Tellez, M., et.al. Endoscopic tri-modal imaging improves detection of gastric intestinal metaplasia among a high-risk patient population in Singapore, Dig Dis Sci, 2013. 58(12): p. 3566-75., https://www.ncbi.nlm.nih.gov/pubmed/23996468
294. Denzer, U., Beilenhoff, U., Eickhoff, A., Faiss, S., Huttl, P., In der Smitten, S., et.al. [S2k guideline: quality requirements for gastrointestinal endoscopy, AWMF registry no. 021-022], Z Gastroenterol, 2015. 53(12): p. E1-227., https://www.ncbi.nlm.nih.gov/pubmed/26783975
295. Asge Technology, Committee, Song, L. M., Adler, D. G., Conway, J. D., Diehl, D. L., Farraye, F. A., et.al. Narrow band imaging and multiband imaging, Gastrointest Endosc, 2008. 67(4): p. 581-9., http://www.ncbi.nlm.nih.gov/pubmed/18374021
296. Committee, Asge Technology, Kwon, R. S., Adler, D. G., Chand, B., Conway, J. D., Diehl, D. L., et.al. High-resolution and high-magnification endoscopes, Gastrointest Endosc, 2009. 69(3 Pt 1): p. 399-407., http://www.ncbi.nlm.nih.gov/pubmed/19231483
297. Zhao, Z., Yin, Z., Wang, S., Wang, J., Bai, B., Qiu, Z., et.al. Meta-analysis: The diagnostic efficacy of chromoendoscopy for early gastric cancer and premalignant gastric lesions, J Gastroenterol Hepatol, 2016. 31(9): p. 1539-45., http://www.ncbi.nlm.nih.gov/pubmed/26860924
298. Hosokawa, O., Watanabe, K., Hatorri, M., Douden, K., Hayashi, H., Kaizaki, Y., Detection of gastric cancer by repeat endoscopy within a short time after negative examination, Endoscopy, 2001. 33(4): p. 301-5., https://www.ncbi.nlm.nih.gov/pubmed/11315889
299. Okanobu, H., Hata, J., Haruma, K., Hara, M., Nakamura, K., Tanaka, S., et.al. Giant gastric folds: differential diagnosis at US, Radiology, 2003. 226(3): p. 686-90., https://www.ncbi.nlm.nih.gov/pubmed/12601220
300. Cherqui, D., Soubrane, O., Laparoscopic Liver Resection: An Ongoing Revolution, Ann Surg, 2017. 265(5): p. 864-865., https://www.ingentaconnect.com/content/wk/sla/2017/00000265/00000005/art00019
301. Chevret, S., Trinchet, J. C., Mathieu, D., Rached, A. A., Beaugrand, M., Chastang, C., A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire, J Hepatol, 1999. 31(1): p. 133-41., https://www.journal-of-hepatology.eu/article/S0168-8278(99)80173-1/fulltext
302. Chiu, C. C., Lee, K. T., Wang, J. J., Sun, D. P., Lee, H. H., Shi, H. Y., Health-Related Quality of Life before and after Surgical Resection of Hepatocellular Carcinoma: A Prospective Study, Asian Pac J Cancer Prev, 2018. 19(1): p. 65-72., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844638/pdf/APJCP-19-65.pdf
303. Pimenta-Melo, AR, Monteiro-Soares, M, Libânio, D, Dinis-Ribeiro, M, Missing rate for gastric cancer during upper gastrointestinal endoscopy: a systematic review and meta-analysis., Eur J Gastroenterol Hepatol, 2016. 28 (9)(9): p. 1041-9., https://pubmed.ncbi.nlm.nih.gov/27148773/
304. Kamran, U, Abbasi, A, Umar, N, Tahir, I, Brookes, MJ, Rutter, M, et.al. Umbrella systematic review of potential quality indicators for the detection of dysplasia and cancer at upper gastrointestinal endoscopy., Endosc Int Open, 2023. 11 (9)(9): p. E835-E848., https://pubmed.ncbi.nlm.nih.gov/37719799/
305. Kaye, P, Lindsay, D, Madhusudan, S, Vohra, R, Catton, J, Platt, C, et.al. Upper GI biopsies for adenocarcinoma - how many biopsies should endoscopists take?, Histopathology, 2019. 74 (6)(6): p. 959-963., https://pubmed.ncbi.nlm.nih.gov/30592780/
306. Tominaga, N, Gotoda, T, Hara, M, Hale, MD, Tsuchiya, T, Matsubayashi, J, et.al. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer., Gastric Cancer, 2016. 19 (2)(2): p. 553-560., https://pubmed.ncbi.nlm.nih.gov/25987463/
307. Ahn, S, Ahn, S, Van Vrancken, M, Lee, M, Ha, SY, Lee, H, et.al. Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens., Oncotarget, 2015. 6 (35)(35): p. 38372-80., https://pubmed.ncbi.nlm.nih.gov/26460823/
308. Chotipanich, C., Kunawudhi, A., Promteangtrong, C., Tungsuppawattanakit, P., Sricharunrat, T., Wongsa, P., Diagnosis of Hepatocellular Carcinoma Using C11 Choline PET/CT: Comparison with F18 FDG, ContrastEnhanced MRI and MDCT, Asian Pac J Cancer Prev, 2016. 17(7): p. 3569-73., https://www.ncbi.nlm.nih.gov/pubmed/27510010
309. Pouw, RE, Barret, M, Biermann, K, Bisschops, R, Czakó, L, Gecse, KB, et.al. Endoscopic tissue sampling - Part 1: Upper gastrointestinal and hepatopancreatobiliary tracts. European Society of Gastrointestinal Endoscopy (ESGE) Guideline., Endoscopy, 2021. 53(11): p. 1174-1188., https://pubmed.ncbi.nlm.nih.gov/34535035/
310. Nishitani, M, Yoshida, N, Tsuji, S, Masunaga, T, Hirai, H, Miyajima, S, et.al. Optimal number of endoscopic biopsies for diagnosis of early gastric cancer., Endosc Int Open, 2019. 7 (12)(12): p. E1683-E1690., https://pubmed.ncbi.nlm.nih.gov/31803818/
311. Ortigão, R, Figueirôa, G, Frazzoni, L, Pimentel-Nunes, P, Hassan, C, Dinis-Ribeiro, M, et.al. Risk factors for gastric metachronous lesions after endoscopic or surgical resection: a systematic review and meta-analysis., Endoscopy, 2022. 54 (9)(9): p. 892-901., https://pubmed.ncbi.nlm.nih.gov/35104897/
312. Zhao, B, Zhang, J, Mei, D, Luo, R, Lu, H, Xu, H, et.al. Does Helicobacter pylori Eradication Reduce the Incidence of Metachronous Gastric Cancer After Curative Endoscopic Resection of Early Gastric Cancer: A Systematic Review and Meta-Analysis., J Clin Gastroenterol, 2020. 54 (3)(3): p. 235-241., https://pubmed.ncbi.nlm.nih.gov/30829904/
313. Lin, Y, Kawai, S, Sasakabe, T, Nagata, C, Naito, M, Tanaka, K, et.al. Effects of Helicobacter pylori eradication on gastric cancer incidence in the Japanese population: a systematic evidence review., Jpn J Clin Oncol, 2021. 51 (7)(7): p. 1158-1170., https://pubmed.ncbi.nlm.nih.gov/33893508/
314. Yue, H, Shan, L, Bin, L, The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysis., Gastric Cancer, 2018. 21 (4)(4): p. 579-587., https://pubmed.ncbi.nlm.nih.gov/29460004/
315. WHO Classification of Tumours Editorial Board, Digestive System Tumours, 2019. Volume 1:, https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Digestive-System-Tumours-2019
316. Akbari, M, Kardeh, B, Tabrizi, R, Ahmadizar, F, Lankarani, KB, Incidence Rate of Gastric Cancer Adenocarcinoma in Patients With Gastric Dysplasia: A Systematic Review and Meta-Analysis., J Clin Gastroenterol, 2019. 53 (10)(10): p. 703-710., https://pubmed.ncbi.nlm.nih.gov/31415022/
317. Vennalaganti, P., Kanakadandi, V., Goldblum, J. R., Mathur, S. C., Patil, D. T., Offerhaus, G. J., et.al. Discordance Among Pathologists in the United States and Europe in Diagnosis of Low-Grade Dysplasia for Patients With Barrett's Esophagus, Gastroenterology, 2017. 152(3): p. 564-570 e4., https://www.ncbi.nlm.nih.gov/pubmed/27818167
318. Langner, C, [Precursors of gastric cancer : Dysplasia and adenoma]., Pathologe, 2017. 38 (2)(2): p. 67-74., https://pubmed.ncbi.nlm.nih.gov/28229187/
319. Lim, H, Jung, HY, Park, YS, Na, HK, Ahn, JY, Choi, JY, et.al. Discrepancy between endoscopic forceps biopsy and endoscopic resection in gastric epithelial neoplasia., Surg Endosc, 2014. 28 (4)(4): p. 1256-62., https://pubmed.ncbi.nlm.nih.gov/24310738/
320. Pimentel-Nunes, P., Mourao, F., Veloso, N., Afonso, L. P., Jacome, M., Moreira-Dias, L., et.al. Long-term follow-up after endoscopic resection of gastric superficial neoplastic lesions in Portugal, Endoscopy, 2014. 46(11): p. 933-40., https://www.ncbi.nlm.nih.gov/pubmed/25019970
321. Zhao, G, Xue, M, Hu, Y, Lai, S, Chen, S, Wang, L, How Commonly Is the Diagnosis of Gastric Low Grade Dysplasia Upgraded following Endoscopic Resection? A Meta-Analysis., PLoS One, 2015. 10 (7)(7): p. e0132699., https://pubmed.ncbi.nlm.nih.gov/26182344/
322. Kim, JL, Kim, SG, Lee, A, Choi, J, Chung, H, Cho, SJ, Long-term natural history after endoscopic resection for gastric dysplasia., Surg Endosc, 2021. 35 (9)(9): p. 5247-5255., https://pubmed.ncbi.nlm.nih.gov/32989550/
323. Jeon, H. K., Ryu, H. Y., Cho, M. Y., Kim, H. S., Kim, J. W., Park, H. J., et.al. A randomized trial to determine the diagnostic accuracy of conventional vs. jumbo forceps biopsy of gastric epithelial neoplasias before endoscopic submucosal dissection; open-label study, Gastric Cancer, 2014. 17(4): p. 661-8., https://www.ncbi.nlm.nih.gov/pubmed/24337434
324. Li, Z., Zuo, X. L., Yu, T., Gu, X. M., Zhou, C. J., Li, C. Q., et.al. Confocal laser endomicroscopy for in vivo detection of gastric intestinal metaplasia: a randomized controlled trial, Endoscopy, 2014. 46(4): p. 282-90., https://www.ncbi.nlm.nih.gov/pubmed/24473908
325. Tongtawee, T., Dechsukhum, C., Leeanansaksiri, W., Kaewpitoon, S., Kaewpitoon, N., Loyd, R. A., et.al. Improved Detection of Helicobacter pylori Infection and Premalignant Gastric Mucosa Using "Site Specific Biopsy": a Randomized Control Clinical Trial, Asian Pac J Cancer Prev, 2015. 16(18): p. 8487-90., https://www.ncbi.nlm.nih.gov/pubmed/26745106
326. Evans, E., Harris, O., Dickey, D., Hartley, L., Difficulties in the endoscopic diagnosis of gastric and oesophageal cancer, Aust N Z J Surg, 1985. 55(6): p. 541-4., https://www.ncbi.nlm.nih.gov/pubmed/3868990
327. Yalamarthi, S., Witherspoon, P., McCole, D., Auld, C. D., Missed diagnoses in patients with upper gastrointestinal cancers, Endoscopy, 2004. 36(10): p. 874-9., https://www.ncbi.nlm.nih.gov/pubmed/15452783
328. Voutilainen, M. E., Juhola, M. T., Evaluation of the diagnostic accuracy of gastroscopy to detect gastric tumours: clinicopathological features and prognosis of patients with gastric cancer missed on endoscopy, Eur J Gastroenterol Hepatol, 2005. 17(12): p. 1345-9., https://www.ncbi.nlm.nih.gov/pubmed/16292088
329. Amin, A., Gilmour, H., Graham, L., Paterson-Brown, S., Terrace, J., Crofts, T. J., Gastric adenocarcinoma missed at endoscopy, J R Coll Surg Edinb, 2002. 47(5): p. 681-4., https://www.ncbi.nlm.nih.gov/pubmed/12463707
330. Will, U., Zinsser, E., Raabe, G., Bosseckert, H., [Value of endosonography in diagnosis of diffusely growing stomach carcinomas], Z Gastroenterol, 1998. 36(2): p. 151-7., https://www.ncbi.nlm.nih.gov/pubmed/9544498
331. Fujishima, H., Misawa, T., Chijiwa, Y., Maruoka, A., Akahoshi, K., Nawata, H., Scirrhous carcinoma of the stomach versus hypertrophic gastritis: findings at endoscopic US, Radiology, 1991. 181(1): p. 197-200., https://www.ncbi.nlm.nih.gov/pubmed/1653442
332. Gines, A., Pellise, M., Fernandez-Esparrach, G., Soria, M. T., Mata, A., Membrillo, A., et.al. Endoscopic ultrasonography in patients with large gastric folds at endoscopy and biopsies negative for malignancy: predictors of malignant disease and clinical impact, Am J Gastroenterol, 2006. 101(1): p. 64-9., https://www.ncbi.nlm.nih.gov/pubmed/16405535
333. Songur, Y., Okai, T., Watanabe, H., Motoo, Y., Sawabu, N., Endosonographic evaluation of giant gastric folds, Gastrointest Endosc, 1995. 41(5): p. 468-74., https://www.ncbi.nlm.nih.gov/pubmed/7615225
334. Avunduk, C., Navab, F., Hampf, F., Coughlin, B., Prevalence of Helicobacter pylori infection in patients with large gastric folds: evaluation and follow-up with endoscopic ultrasound before and after antimicrobial therapy, Am J Gastroenterol, 1995. 90(11): p. 1969-73., https://www.ncbi.nlm.nih.gov/pubmed/7485002
335. Caletti, G., Fusaroli, P., Bocus, P., Endoscopic ultrasonography in large gastric folds, Endoscopy, 1998. 30 Suppl 1: p. A72-5., https://www.ncbi.nlm.nih.gov/pubmed/9765090
336. Chung, Y. E., Kim, M. J., Park, Y. N., Choi, J. Y., Pyo, J. Y., Kim, Y. C., et.al. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation, Radiographics, 2009. 29(3): p. 683-700., https://www.ncbi.nlm.nih.gov/pubmed/19448110
337. Lam, E. C., Rego, R. R., Paquin, S. C., Chua, T. S., Raymond, G., Sahai, A. V., In patients referred for investigation because computed tomography suggests thickened gastric folds, endoscopic ultrasound is superfluous if gastroscopy is normal, Am J Gastroenterol, 2007. 102(6): p. 1200-3., https://www.ncbi.nlm.nih.gov/pubmed/17319928
338. Ciuni, R., Biondi, A., Grosso, G., Nunnari, G., Panascia, E., Randisi, L., et.al. Nutritional aspects in patient undergoing liver resection, Updates Surg, 2011. 63(4): p. 249-52., https://link.springer.com/content/pdf/10.1007/s13304-011-0121-4.pdf
339. Wittekind C, Brierley JD, Lee A, van Eycken E (Eds.), TNM - Klassifikation maligner Tumoren, 8. Auflage. korrigierter Nachdruck 2020 mit allen Ergänzungen der UICC aus den Jahren 2017 bis 2019. Hoboken, NJ: John Wiley & Sons, 2020.
340. Wittekind C, (Eds.), TNM Supplement. A Commentary on Uniform Use. 5th Edition, 2019.
341. Jenssen, C., Dietrich, C. F., Burmester, E., [Malignant neoplasias of the gastrointestinal tract--endosonographic staging revisited], Z Gastroenterol, 2011. 49(3): p. 357-68., https://www.ncbi.nlm.nih.gov/pubmed/21391168
342. Jenssen C, Gottschalk U, Maeting, S. Jenssen B., Klassifikation der bösartigen Neubildungen. Die Geheimnisse der Tumorformel – Wegweiser durch ein Labyrinth von Buchstaben und Zahlen, Endo Praxis, 2022. 38(01): p. 25 - 32., http://dx.doi.org/10.1055/a-1644-0630
343. Kotter, E, Pinto Dos Santos, D, [Structured reporting in radiology : German and European radiology societies' point of view]., Radiologe, 2021. 61 (11)(11): p. 979-985., https://pubmed.ncbi.nlm.nih.gov/34661685/
344. Mazzei, MA, Bagnacci, G, Gentili, F, Capitoni, I, Mura, G, Marrelli, D, et.al. Structured and shared CT radiological report of gastric cancer: a consensus proposal by the Italian Research Group for Gastric Cancer (GIRCG) and the Italian Society of Medical and Interventional Radiology (SIRM)., Eur Radiol, 2022. 32 (2)(2): p. 938-949., https://pubmed.ncbi.nlm.nih.gov/34383148/
345. Loch, FN, Beyer, K, Kreis, ME, Kamphues, C, Rayya, W, Schineis, C, et.al. Diagnostic performance of Node Reporting and Data System (Node-RADS) for regional lymph node staging of gastric cancer by CT., Eur Radiol, 2023. ():, https://pubmed.ncbi.nlm.nih.gov/37921924/
346. Bertero, L, Massa, F, Metovic, J, Zanetti, R, Castellano, I, Ricardi, U, et.al. Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why?, Virchows Arch, 2018. 472 (4)(4): p. 519-531., https://pubmed.ncbi.nlm.nih.gov/29209757/
347. Wittekind C, Brierley JD, Lee A, van Eycken E (Eds.), TNM Klassifikation maligner Tumore, 8. Auflage, Wiley-VCH, 2017.
348. Piscaglia, F., Corradi, F., Mancini, M., Giangregorio, F., Tamberi, S., Ugolini, G., et.al. Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer, BMC Cancer, 2007. 7: p. 171., https://www.ncbi.nlm.nih.gov/pubmed/17767722
349. Dietrich, C. F., Kratzer, W., Strobe, D., Danse, E., Fessl, R., Bunk, A., et.al. Assessment of metastatic liver disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT and MRI, World J Gastroenterol, 2006. 12(11): p. 1699-705., https://www.ncbi.nlm.nih.gov/pubmed/16586537
350. Albrecht, T., Blomley, M. J., Burns, P. N., Wilson, S., Harvey, C. J., Leen, E., et.al. Improved detection of hepatic metastases with pulse-inversion US during the liver-specific phase of SHU 508A: multicenter study, Radiology, 2003. 227(2): p. 361-70., https://www.ncbi.nlm.nih.gov/pubmed/12649417
351. Guang, Y., Xie, L., Ding, H., Cai, A., Huang, Y., Diagnosis value of focal liver lesions with SonoVue(R)-enhanced ultrasound compared with contrast-enhanced computed tomography and contrast-enhanced MRI: a meta-analysis, J Cancer Res Clin Oncol, 2011. 137(11): p. 1595-605., https://www.ncbi.nlm.nih.gov/pubmed/21850382
352. Westwood, M., Joore, M., Grutters, J., Redekop, K., Armstrong, N., Lee, K., et.al. Contrast-enhanced ultrasound using SonoVue(R) (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis, Health Technol Assess, 2013. 17(16): p. 1-243., https://www.ncbi.nlm.nih.gov/pubmed/23611316
353. Strobel, D., Seitz, K., Blank, W., Schuler, A., Dietrich, C., von Herbay, A., et.al. Contrast-enhanced ultrasound for the characterization of focal liver lesions--diagnostic accuracy in clinical practice (DEGUM multicenter trial), Ultraschall Med, 2008. 29(5): p. 499-505., https://www.ncbi.nlm.nih.gov/pubmed/19241506
354. Seitz, K., Strobel, D., Bernatik, T., Blank, W., Friedrich-Rust, M., Herbay, Av, et.al. Contrast-Enhanced Ultrasound (CEUS) for the characterization of focal liver lesions - prospective comparison in clinical practice: CEUS vs. CT (DEGUM multicenter trial). Parts of this manuscript were presented at the Ultrasound Dreilandertreffen 2008, Davos, Ultraschall Med, 2009. 30(4): p. 383-9., https://www.ncbi.nlm.nih.gov/pubmed/19688670
355. Dietrich, CF, Nolsøe, CP, Barr, RG, Berzigotti, A, Burns, PN, Cantisani, V, et.al. Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver - Update 2020 - WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS., Ultraschall Med, 2020. 41 (5)(5): p. 562-585., https://pubmed.ncbi.nlm.nih.gov/32707595/
356. Wang, Z., Chen, J. Q., Imaging in assessing hepatic and peritoneal metastases of gastric cancer: a systematic review, BMC Gastroenterol, 2011. 11: p. 19., https://www.ncbi.nlm.nih.gov/pubmed/21385469
357. Schreurs, L. M., Verhoef, C. C., van der Jagt, E. J., van Dam, G. M., Groen, H., Plukker, J. T., Current relevance of cervical ultrasonography in staging cancer of the esophagus and gastroesophageal junction, Eur J Radiol, 2008. 67(1): p. 105-11., https://www.ncbi.nlm.nih.gov/pubmed/17681735
358. Van Overhagen, H., Lameris, J. S., Berger, M. Y., Tilanus, H. W., Van Pel, R., Klooswijk, A. I., et.al. Improved assessment of supraclavicular and abdominal metastases in oesophageal and gastro-oesophageal junction carcinoma with the combination of ultrasound and computed tomography, Br J Radiol, 1993. 66(783): p. 203-8., https://www.ncbi.nlm.nih.gov/pubmed/8472112
359. van Vliet, E. P., van der Lugt, A., Kuipers, E. J., Tilanus, H. W., van der Gaast, A., Hermans, J. J., et.al. Ultrasound, computed tomography, or the combination for the detection of supraclavicular lymph nodes in patients with esophageal or gastric cardia cancer: a comparative study, J Surg Oncol, 2007. 96(3): p. 200-6., https://www.ncbi.nlm.nih.gov/pubmed/17455243
360. Leng, X. F., Zhu, Y., Wang, G. P., Jin, J., Xian, L., Zhang, Y. H., Accuracy of ultrasound for the diagnosis of cervical lymph node metastasis in esophageal cancer: a systematic review and meta-analysis, J Thorac Dis, 2016. 8(8): p. 2146-57., https://www.ncbi.nlm.nih.gov/pubmed/27621871
361. van Vliet, EP, Steyerberg, EW, Eijkemans, MJ, Kuipers, EJ, Siersema, PD, Detection of distant metastases in patients with oesophageal or gastric cardia cancer: a diagnostic decision analysis., Br J Cancer, 2007. 97 (7)(7): p. 868-76., https://pubmed.ncbi.nlm.nih.gov/17848957/
362. van Overhagen, H., Lameris, J. S., Berger, M. Y., van Pel, R., Tilanus, H. W., Klooswijk, A. I., et.al. Assessment of distant metastases with ultrasound-guided fine-needle aspiration biopsy and cytologic study in carcinoma of the esophagus and gastroesophageal junction, Gastrointest Radiol, 1992. 17(4): p. 305-10., https://www.ncbi.nlm.nih.gov/pubmed/1426845
363. van Overhagen, H., Lameris, J. S., Berger, M. Y., van der Voorde, F., Tilanus, H. W., Klooswijk, A. I., et.al. Supraclavicular lymph node metastases in carcinoma of the esophagus and gastroesophageal junction: assessment with CT, US, and US-guided fine-needle aspiration biopsy, Radiology, 1991. 179(1): p. 155-8., https://www.ncbi.nlm.nih.gov/pubmed/2006268
364. Omloo, J. M., van Heijl, M., Smits, N. J., Phoa, S. S., van Berge Henegouwen, M. I., Sloof, G. W., et.al. Additional value of external ultrasonography of the neck after CT and PET scanning in the preoperative assessment of patients with esophageal cancer, Dig Surg, 2009. 26(1): p. 43-9., https://www.ncbi.nlm.nih.gov/pubmed/19155627
365. Wiersema, M. J., Vilmann, P., Giovannini, M., Chang, K. J., Wiersema, L. M., Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment, Gastroenterology, 1997. 112(4): p. 1087-95., https://www.ncbi.nlm.nih.gov/pubmed/9097990
366. Kwee, R. M., Kwee, T. C., Imaging in local staging of gastric cancer: a systematic review, J Clin Oncol, 2007. 25(15): p. 2107-16., https://www.ncbi.nlm.nih.gov/pubmed/17513817
367. Ahn, H. S., Lee, H. J., Yoo, M. W., Kim, S. G., Im, J. P., Kim, S. H., et.al. Diagnostic accuracy of T and N stages with endoscopy, stomach protocol CT, and endoscopic ultrasonography in early gastric cancer, J Surg Oncol, 2009. 99(1): p. 20-7., https://www.ncbi.nlm.nih.gov/pubmed/18937292
368. Bhutani, M. S., Hawes, R. H., Hoffman, B. J., A comparison of the accuracy of echo features during endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration for diagnosis of malignant lymph node invasion, Gastrointest Endosc, 1997. 45(6): p. 474-9., https://www.ncbi.nlm.nih.gov/pubmed/9199903
369. Blackshaw, G., Lewis, W. G., Hopper, A. N., Morgan, M. A., Al-Khyatt, W., Edwards, P., et.al. Prospective comparison of endosonography, computed tomography, and histopathological stage of junctional oesophagogastric cancer, Clin Radiol, 2008. 63(10): p. 1092-8., https://www.ncbi.nlm.nih.gov/pubmed/18774355
370. Catalano, M. F., Sivak, M. V., Jr., Rice, T., Gragg, L. A., Van Dam, J., Endosonographic features predictive of lymph node metastasis, Gastrointest Endosc, 1994. 40(4): p. 442-6., https://www.ncbi.nlm.nih.gov/pubmed/7926534
371. Chen, V. K., Eloubeidi, M. A., Endoscopic ultrasound-guided fine needle aspiration is superior to lymph node echofeatures: a prospective evaluation of mediastinal and peri-intestinal lymphadenopathy, Am J Gastroenterol, 2004. 99(4): p. 628-33., https://www.ncbi.nlm.nih.gov/pubmed/15089893
372. DeWitt, J., LeBlanc, J., McHenry, L., McGreevy, K., Sherman, S., Endoscopic ultrasound-guided fine-needle aspiration of ascites, Clin Gastroenterol Hepatol, 2007. 5(5): p. 609-15., https://www.ncbi.nlm.nih.gov/pubmed/17336593
373. Faige, D. O., EUS in patients with benign and malignant lymphadenopathy, Gastrointest Endosc, 2001. 53(6): p. 593-8., https://www.ncbi.nlm.nih.gov/pubmed/11323584
374. Hassan, H., Vilmann, P., Sharma, V., Impact of EUS-guided FNA on management of gastric carcinoma, Gastrointest Endosc, 2010. 71(3): p. 500-4., https://www.ncbi.nlm.nih.gov/pubmed/20189507
375. Heeren, P. A., van Westreenen, H. L., Geersing, G. J., van Dullemen, H. M., Plukker, J. T., Influence of tumor characteristics on the accuracy of endoscopic ultrasonography in staging cancer of the esophagus and esophagogastric junction, Endoscopy, 2004. 36(11): p. 966-71., https://www.ncbi.nlm.nih.gov/pubmed/15520913
376. Hwang, S. W., Lee, D. H., Lee, S. H., Park, Y. S., Hwang, J. H., Kim, J. W., et.al. Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography, J Gastroenterol Hepatol, 2010. 25(3): p. 512-8., https://www.ncbi.nlm.nih.gov/pubmed/20370729
377. Kim, M. M., Rana, V., Janjan, N. A., Das, P., Phan, A. T., Delclos, M. E., et.al. Clinical benefit of palliative radiation therapy in advanced gastric cancer, Acta Oncol, 2008. 47(3): p. 421-7., https://www.ncbi.nlm.nih.gov/pubmed/17899453
378. Kwee, R. M., Kwee, T. C., Imaging in assessing lymph node status in gastric cancer, Gastric Cancer, 2009. 12(1): p. 6-22., https://www.ncbi.nlm.nih.gov/pubmed/19390927
379. Puli, S. R., Batapati Krishna Reddy, J., Bechtold, M. L., Antillon, M. R., Ibdah, J. A., How good is endoscopic ultrasound for TNM staging of gastric cancers? A meta-analysis and systematic review, World J Gastroenterol, 2008. 14(25): p. 4011-9., https://www.ncbi.nlm.nih.gov/pubmed/18609685
380. Yasuda, I., Tsurumi, H., Omar, S., Iwashita, T., Kojima, Y., Yamada, T., et.al. Endoscopic ultrasound-guided fine-needle aspiration biopsy for lymphadenopathy of unknown origin, Endoscopy, 2006. 38(9): p. 919-24., https://www.ncbi.nlm.nih.gov/pubmed/16981110
381. Agarwal, B., Gogia, S., Eloubeidi, M. A., Correa, A. M., Ho, L., Collins, B. T., Malignant mediastinal lymphadenopathy detected by staging EUS in patients with pancreaticobiliary cancer, Gastrointest Endosc, 2005. 61(7): p. 849-53., https://www.ncbi.nlm.nih.gov/pubmed/15933686
382. Barbour, A. P., Rizk, N. P., Gerdes, H., Bains, M. S., Rusch, V. W., Brennan, M. F., et.al. Endoscopic ultrasound predicts outcomes for patients with adenocarcinoma of the gastroesophageal junction, J Am Coll Surg, 2007. 205(4): p. 593-601., https://www.ncbi.nlm.nih.gov/pubmed/17903735
383. Bentrem, D., Gerdes, H., Tang, L., Brennan, M., Coit, D., Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer, Ann Surg Oncol, 2007. 14(6): p. 1853-9., https://www.ncbi.nlm.nih.gov/pubmed/17357856
384. Chen, C. H., Yang, C. C., Yeh, Y. H., Preoperative staging of gastric cancer by endoscopic ultrasound: the prognostic usefulness of ascites detected by endoscopic ultrasound, J Clin Gastroenterol, 2002. 35(4): p. 321-7., https://www.ncbi.nlm.nih.gov/pubmed/12352295
385. Davies, A. R., Deans, D. A., Penman, I., Plevris, J. N., Fletcher, J., Wall, L., et.al. The multidisciplinary team meeting improves staging accuracy and treatment selection for gastro-esophageal cancer, Dis Esophagus, 2006. 19(6): p. 496-503., https://www.ncbi.nlm.nih.gov/pubmed/17069595
386. Fritscher-Ravens, A., Sriram, P. V., Bobrowski, C., Pforte, A., Topalidis, T., Krause, C., et.al. Mediastinal lymphadenopathy in patients with or without previous malignancy: EUS-FNA-based differential cytodiagnosis in 153 patients, Am J Gastroenterol, 2000. 95(9): p. 2278-84., https://www.ncbi.nlm.nih.gov/pubmed/11007229
387. Ganpathi, I. S., So, J. B., Ho, K. Y., Endoscopic ultrasonography for gastric cancer: does it influence treatment?, Surg Endosc, 2006. 20(4): p. 559-62., https://www.ncbi.nlm.nih.gov/pubmed/16446988
388. Hollerbach, S., Willert, J., Topalidis, T., Reiser, M., Schmiegel, W., Endoscopic ultrasound-guided fine-needle aspiration biopsy of liver lesions: histological and cytological assessment, Endoscopy, 2003. 35(9): p. 743-9., https://www.ncbi.nlm.nih.gov/pubmed/12929021
389. Kaushik, N., Khalid, A., Brody, D., McGrath, K., EUS-guided paracentesis for the diagnosis of malignant ascites, Gastrointest Endosc, 2006. 64(6): p. 908-13., https://www.ncbi.nlm.nih.gov/pubmed/17140897
390. McGrath, K., Brody, D., Luketich, J., Khalid, A., Detection of unsuspected left hepatic lobe metastases during EUS staging of cancer of the esophagus and cardia, Am J Gastroenterol, 2006. 101(8): p. 1742-6., https://www.ncbi.nlm.nih.gov/pubmed/16790035
391. Meining, A., Dittler, H. J., Wolf, A., Lorenz, R., Schusdziarra, V., Siewert, J. R., et.al. You get what you expect? A critical appraisal of imaging methodology in endosonographic cancer staging, Gut, 2002. 50(5): p. 599-603., https://www.ncbi.nlm.nih.gov/pubmed/11950802
392. Mortensen, M. B., Pless, T., Durup, J., Ainsworth, A. P., Plagborg, G. J., Hovendal, C., Clinical impact of endoscopic ultrasound-guided fine needle aspiration biopsy in patients with upper gastrointestinal tract malignancies. A prospective study, Endoscopy, 2001. 33(6): p. 478-83., https://www.ncbi.nlm.nih.gov/pubmed/11437039
393. Nguyen, P., Feng, J. C., Chang, K. J., Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration (FNA) of liver lesions, Gastrointest Endosc, 1999. 50(3): p. 357-61., https://www.ncbi.nlm.nih.gov/pubmed/10462656
394. Nguyen, P. T., Chang, K. J., EUS in the detection of ascites and EUS-guided paracentesis, Gastrointest Endosc, 2001. 54(3): p. 336-9., https://www.ncbi.nlm.nih.gov/pubmed/11522974
395. Power, D. G., Schattner, M. A., Gerdes, H., Brenner, B., Markowitz, A. J., Capanu, M., et.al. Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer, J Am Coll Surg, 2009. 208(2): p. 173-8., https://www.ncbi.nlm.nih.gov/pubmed/19228527
396. Prasad, P., Schmulewitz, N., Patel, A., Varadarajulu, S., Wildi, S. M., Roberts, S., et.al. Detection of occult liver metastases during EUS for staging of malignancies, Gastrointest Endosc, 2004. 59(1): p. 49-53., https://www.ncbi.nlm.nih.gov/pubmed/14722547
397. Singh, P., Mukhopadhyay, P., Bhatt, B., Patel, T., Kiss, A., Gupta, R., et.al. Endoscopic ultrasound versus CT scan for detection of the metastases to the liver: results of a prospective comparative study, J Clin Gastroenterol, 2009. 43(4): p. 367-73., https://www.ncbi.nlm.nih.gov/pubmed/18981929
398. Sultan, J., Robinson, S., Hayes, N., Griffin, S. M., Richardson, D. L., Preston, S. R., Endoscopic ultrasonography-detected low-volume ascites as a predictor of inoperability for oesophagogastric cancer, Br J Surg, 2008. 95(9): p. 1127-30., https://www.ncbi.nlm.nih.gov/pubmed/18655220
399. tenBerge, J., Hoffman, B. J., Hawes, R. H., Van Enckevort, C., Giovannini, M., Erickson, R. A., et.al. EUS-guided fine needle aspiration of the liver: indications, yield, and safety based on an international survey of 167 cases, Gastrointest Endosc, 2002. 55(7): p. 859-62., https://www.ncbi.nlm.nih.gov/pubmed/12024141
400. Mocellin, S., Pasquali, S., Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer, Cochrane Database Syst Rev, 2015. p. CD009944., https://www.ncbi.nlm.nih.gov/pubmed/25914908
401. Pei, Q., Wang, L., Pan, J., Ling, T., Lv, Y., Zou, X., Endoscopic ultrasonography for staging depth of invasion in early gastric cancer: A meta-analysis, J Gastroenterol Hepatol, 2015. 30(11): p. 1566-73., https://www.ncbi.nlm.nih.gov/pubmed/26094975
402. Shi, D, Xi, XX, Factors Affecting the Accuracy of Endoscopic Ultrasonography in the Diagnosis of Early Gastric Cancer Invasion Depth: A Meta-analysis., Gastroenterol Res Pract, 2019. 2019 (): p. 8241381., https://pubmed.ncbi.nlm.nih.gov/31933632/
403. Ungureanu, BS, Sacerdotianu, VM, Turcu-Stiolica, A, Cazacu, IM, Saftoiu, A, Endoscopic Ultrasound vs. Computed Tomography for Gastric Cancer Staging: A Network Meta-Analysis., Diagnostics (Basel), 2021. 11 (1)(1):, https://pubmed.ncbi.nlm.nih.gov/33467164/
404. Giganti, F., Orsenigo, E., Arcidiacono, P. G., Nicoletti, R., Albarello, L., Ambrosi, A., et.al. Preoperative locoregional staging of gastric cancer: is there a place for magnetic resonance imaging? Prospective comparison with EUS and multidetector computed tomography, Gastric Cancer, 2016. 19(1): p. 216-25., https://www.ncbi.nlm.nih.gov/pubmed/25614468
405. Kim, J. H., Song, K. S., Youn, Y. H., Lee, Y. C., Cheon, J. H., Song, S. Y., et.al. Clinicopathologic factors influence accurate endosonographic assessment for early gastric cancer, Gastrointest Endosc, 2007. 66(5): p. 901-8., https://www.ncbi.nlm.nih.gov/pubmed/17963876
406. Nie, R. C., Yuan, S. Q., Chen, X. J., Chen, S., Xu, L. P., Chen, Y. M., et.al. Endoscopic ultrasonography compared with multidetector computed tomography for the preoperative staging of gastric cancer: a meta-analysis, World J Surg Oncol, 2017. 15(1): p. 113., https://www.ncbi.nlm.nih.gov/pubmed/28577563
407. Chen, C, Song, YL, Wu, ZY, Chen, J, Zhang, Y, Chen, L, Diagnostic value of conventional endoscopic ultrasound for lymph node metastasis in upper gastrointestinal neoplasia: A meta-analysis., World J Gastroenterol, 2023. 29 (30)(30): p. 4685-4700., https://pubmed.ncbi.nlm.nih.gov/37662859/
408. Chen, J, Zhou, C, He, M, Zhen, Z, Wang, J, Hu, X, A Meta-Analysis And Systematic Review Of Accuracy Of Endoscopic Ultrasound For N Staging Of Gastric Cancers., Cancer Manag Res, 2019. 11 (): p. 8755-8764., https://pubmed.ncbi.nlm.nih.gov/31632135/
409. Gleeson, F. C., Kipp, B. R., Caudill, J. L., Clain, J. E., Clayton, A. C., Halling, K. C., et.al. False positive endoscopic ultrasound fine needle aspiration cytology: incidence and risk factors, Gut, 2010. 59(5): p. 586-93., https://www.ncbi.nlm.nih.gov/pubmed/20427392
410. Levy, M. J., Gleeson, F. C., Campion, M. B., Caudill, J. L., Clain, J. E., Halling, K., et.al. Prospective cytological assessment of gastrointestinal luminal fluid acquired during EUS: a potential source of false-positive FNA and needle tract seeding, Am J Gastroenterol, 2010. 105(6): p. 1311-8., https://www.ncbi.nlm.nih.gov/pubmed/20197762
411. Dumonceau, J. M., Deprez, P. H., Jenssen, C., Iglesias-Garcia, J., Larghi, A., Vanbiervliet, G., et.al. Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated January 2017, Endoscopy, 2017. 49(7): p. 695-714., https://www.ncbi.nlm.nih.gov/pubmed/28511234
412. Jenssen, C., Hocke, M., Fusaroli, P., Gilja, O. H., Buscarini, E., Havre, R. F., et.al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part IV - EUS-guided interventions: General Aspects and EUS-guided Sampling (Short Version), Ultraschall Med, 2016. 37(2): p. 157-69., https://www.ncbi.nlm.nih.gov/pubmed/27058434
413. Jenssen, C., Hocke, M., Fusaroli, P., Gilja, O. H., Buscarini, E., Havre, R. F., et.al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part IV - EUS-guided Interventions: General aspects and EUS-guided sampling (Long Version), Ultraschall Med, 2016. 37(2): p. E33-76., https://www.ncbi.nlm.nih.gov/pubmed/26515966
414. Lee, J. H., Han, H. S., Lee, J. H., A prospective randomized study comparing open vs laparoscopy-assisted distal gastrectomy in early gastric cancer: early results, Surg Endosc, 2005. 19(2): p. 168-73., https://www.ncbi.nlm.nih.gov/pubmed/15580441
415. Levy, M. J., Abu Dayyeh, B. K., Fujii, L. L., Clayton, A. C., Reynolds, J. P., Lopes, T. L., et.al. Detection of peritoneal carcinomatosis by EUS fine-needle aspiration: impact on staging and resectability (with videos), Gastrointest Endosc, 2015. 81(5): p. 1215-24., https://www.ncbi.nlm.nih.gov/pubmed/25660979
416. Rana, S. S., Bhasin, D. K., Srinivasan, R., Singh, K., Endoscopic ultrasound-guided fine needle aspiration of peritoneal nodules in patients with ascites of unknown cause, Endoscopy, 2011. 43(11): p. 1010-3., https://www.ncbi.nlm.nih.gov/pubmed/21833905
417. DeWitt, J., LeBlanc, J., McHenry, L., Ciaccia, D., Imperiale, T., Chappo, J., et.al. Endoscopic ultrasound-guided fine needle aspiration cytology of solid liver lesions: a large single-center experience, Am J Gastroenterol, 2003. 98(9): p. 1976-81., https://www.ncbi.nlm.nih.gov/pubmed/14499774
418. Fujii-Lau, L. L., Abu Dayyeh, B. K., Bruno, M. J., Chang, K. J., DeWitt, J. M., Fockens, P., et.al. EUS-derived criteria for distinguishing benign from malignant metastatic solid hepatic masses, Gastrointest Endosc, 2015. 81(5): p. 1188-96 e1-7., https://www.ncbi.nlm.nih.gov/pubmed/25660980
419. Lee, Y. N., Moon, J. H., Kim, H. K., Choi, H. J., Choi, M. H., Kim, D. C., et.al. Usefulness of endoscopic ultrasound-guided sampling using core biopsy needle as a percutaneous biopsy rescue for diagnosis of solid liver mass: Combined histological-cytological analysis, J Gastroenterol Hepatol, 2015. 30(7): p. 1161-6., https://www.ncbi.nlm.nih.gov/pubmed/25684303
420. Okasha, HH, Wifi, MN, Awad, A, Abdelfatah, Y, Abdelfatah, D, El-Sawy, SS, et.al. Role of EUS in detection of liver metastasis not seen by computed tomography or magnetic resonance imaging during staging of pancreatic, gastrointestinal, and thoracic malignancies., Endosc Ultrasound, 2021. 10 (5)(5): p. 344-354., https://pubmed.ncbi.nlm.nih.gov/34558421/
421. Gadour, E, Awad, A, Hassan, Z, Shrwani, KJ, Miutescu, B, Okasha, HH, Diagnostic and therapeutic role of endoscopic ultrasound in liver diseases: A systematic review and meta-analysis., World J Gastroenterol, 2024. 30 (7)(7): p. 742-758., https://pubmed.ncbi.nlm.nih.gov/38515947/
422. Jurgensen, C., Brand, J., Nothnagel, M., Arlt, A., Neser, F., Habeck, J. O., et.al. Prognostic relevance of gastric cancer staging by endoscopic ultrasound, Surg Endosc, 2013. 27(4): p. 1124-9., https://www.ncbi.nlm.nih.gov/pubmed/23052533
423. Merkow, R. P., Herrera, G., Goldman, D. A., Gerdes, H., Schattner, M. A., Markowitz, A. J., et.al. Endoscopic Ultrasound as a Pretreatment Clinical Staging Tool for Gastric Cancer: Association with Pathology and Outcome, Ann Surg Oncol, 2017. 24(12): p. 3658-3666., https://www.ncbi.nlm.nih.gov/pubmed/28815443
424. Kinkel, K., Lu, Y., Both, M., Warren, R. S., Thoeni, R. F., Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis, Radiology, 2002. 224(3): p. 748-56., https://www.ncbi.nlm.nih.gov/pubmed/12202709
425. van Vliet, E. P., Eijkemans, M. J., Poley, J. W., Steyerberg, E. W., Kuipers, E. J., Siersema, P. D., Staging of esophageal carcinoma in a low-volume EUS center compared with reported results from high-volume centers, Gastrointest Endosc, 2006. 63(7): p. 938-47., https://www.ncbi.nlm.nih.gov/pubmed/16733107
426. Laghi, A., Bellini, D., Rengo, M., Accarpio, F., Caruso, D., Biacchi, D., et.al. Diagnostic performance of computed tomography and magnetic resonance imaging for detecting peritoneal metastases: systematic review and meta-analysis, Radiol Med, 2017. 122(1): p. 1-15., https://www.ncbi.nlm.nih.gov/pubmed/27647163
427. Anzidei, M., Napoli, A., Zaccagna, F., Di Paolo, P., Zini, C., Cavallo Marincola, B., et.al. Diagnostic performance of 64-MDCT and 1.5-T MRI with high-resolution sequences in the T staging of gastric cancer: a comparative analysis with histopathology, Radiol Med, 2009. 114(7): p. 1065-79., https://www.ncbi.nlm.nih.gov/pubmed/19774440
428. Giganti, F., De Cobelli, F., Canevari, C., Orsenigo, E., Gallivanone, F., Esposito, A., et.al. Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and (18) F-FDG-PET/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade, J Magn Reson Imaging, 2014. 40(5): p. 1147-57., https://www.ncbi.nlm.nih.gov/pubmed/24214734
429. Kang, B. C., Kim, J. H., Kim, K. W., Lee, D. Y., Baek, S. Y., Lee, S. W., et.al. Value of the dynamic and delayed MR sequence with Gd-DTPA in the T-staging of stomach cancer: correlation with the histopathology, Abdom Imaging, 2000. 25(1): p. 14-24., https://www.ncbi.nlm.nih.gov/pubmed/10652915
430. Sohn, K. M., Lee, J. M., Lee, S. Y., Ahn, B. Y., Park, S. M., Kim, K. M., Comparing MR imaging and CT in the staging of gastric carcinoma, AJR Am J Roentgenol, 2000. 174(6): p. 1551-7., https://www.ncbi.nlm.nih.gov/pubmed/10845479
431. Kim, A. Y., Han, J. K., Seong, C. K., Kim, T. K., Choi, B. I., MRI in staging advanced gastric cancer: is it useful compared with spiral CT?, J Comput Assist Tomogr, 2000. 24(3): p. 389-94., https://www.ncbi.nlm.nih.gov/pubmed/10864073
432. Allum, W. H., Blazeby, J. M., Griffin, S. M., Cunningham, D., Jankowski, J. A., Wong, R., et.al. Guidelines for the management of oesophageal and gastric cancer, Gut, 2011. 60(11): p. 1449-72., https://www.ncbi.nlm.nih.gov/pubmed/21705456
433. Lerut, T., Clinical Practice Guidelines Upper Gastrointestinal Cancer - update., KCE, 2012.
434. Wang, C., Guo, W., Zhou, M., Zhu, X., Ji, D., Li, W., et.al. The Predictive and Prognostic Value of Early Metabolic Response Assessed by Positron Emission Tomography in Advanced Gastric Cancer Treated with Chemotherapy, Clin Cancer Res, 2016. 22(7): p. 1603-10., https://www.ncbi.nlm.nih.gov/pubmed/26607599
435. Na, S. J., o, J. H., Park, J. M., Lee, H. H., Lee, S. H., Song, K. Y., et.al. Prognostic value of metabolic parameters on preoperative 18F-fluorodeoxyglucose positron emission tomography/ computed tomography in patients with stage III gastric cancer, Oncotarget, 2016. 7(39): p. 63968-63980., https://www.ncbi.nlm.nih.gov/pubmed/27564108
436. Lehmann, K., Eshmuminov, D., Bauerfeind, P., Gubler, C., Veit-Haibach, P., Weber, A., et.al. (18)FDG-PET-CT improves specificity of preoperative lymph-node staging in patients with intestinal but not diffuse-type esophagogastric adenocarcinoma, Eur J Surg Oncol, 2017. 43(1): p. 196-202., https://www.ncbi.nlm.nih.gov/pubmed/27692533
437. Li, P., Liu, Q., Wang, C., Wang, T., Liu, J., Huang, G., et.al. Fluorine-18-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer after surgical resection: a systematic review and meta-analysis, Ann Nucl Med, 2016. 30(3): p. 179-87., https://www.ncbi.nlm.nih.gov/pubmed/26830546
438. Zou, H., Zhao, Y., 18FDG PET-CT for detecting gastric cancer recurrence after surgical resection: a meta-analysis, Surg Oncol, 2013. 22(3): p. 162-6., https://www.ncbi.nlm.nih.gov/pubmed/23747134
439. Ramos, R. F., Scalon, F. M., Scalon, M. M., Dias, D. I., Staging laparoscopy in gastric cancer to detect peritoneal metastases: A systematic review and meta-analysis, Eur J Surg Oncol, 2016. 42(9): p. 1315-21., https://www.ncbi.nlm.nih.gov/pubmed/27432515
440. Cotte, E., Peyrat, P., Piaton, E., Chapuis, F., Rivoire, M., Glehen, O., et.al. Lack of prognostic significance of conventional peritoneal cytology in colorectal and gastric cancers: results of EVOCAPE 2 multicentre prospective study, Eur J Surg Oncol, 2013. 39(7): p. 707-14., https://www.ncbi.nlm.nih.gov/pubmed/23601984
441. Tamura, S., Fujiwara, Y., Kimura, Y., Fujita, J., Imamura, H., Kinuta, M., et.al. Prognostic information derived from RT-PCR analysis of peritoneal fluid in gastric cancer patients: results from a prospective multicenter clinical trial, J Surg Oncol, 2014. 109(2): p. 75-80., https://www.ncbi.nlm.nih.gov/pubmed/24155213
442. Burbidge, S., Mahady, K., Naik, K., The role of CT and staging laparoscopy in the staging of gastric cancer, Clin Radiol, 2013. 68(3): p. 251-5., https://www.ncbi.nlm.nih.gov/pubmed/22985749
443. Lordick, F, Carneiro, F, Cascinu, S, Fleitas, T, Haustermans, K, Piessen, G, et.al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up., Ann Oncol, 2022. 33 (10)(10): p. 1005-1020., https://pubmed.ncbi.nlm.nih.gov/35914639/
444. Rawicz-Pruszyński, K, Erodotou, M, Pelc, Z, Sędłak, K, Polkowski, W, Pawlik, TM, et.al. Techniques of staging laparoscopy and peritoneal fluid assessment in gastric cancer: a systematic review., Int J Surg, 2023. 109 (11)(11): p. 3578-3589., https://pubmed.ncbi.nlm.nih.gov/37581636/
445. Gertsen, EC, Brenkman, HJF, van Hillegersberg, R, van Sandick, JW, van Berge Henegouwen, MI, Gisbertz, SS, et.al. 18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer: A Multicenter Prospective Dutch Cohort Study (PLASTIC)., JAMA Surg, 2021. 156 (12)(12): p. e215340., https://pubmed.ncbi.nlm.nih.gov/34705049/
446. Hu, Y. F., Deng, Z. W., Liu, H., Mou, T. Y., Chen, T., Lu, X., et.al. Staging laparoscopy improves treatment decision-making for advanced gastric cancer, World J Gastroenterol, 2016. 22(5): p. 1859-68., https://www.ncbi.nlm.nih.gov/pubmed/26855545
447. Glehen, O., Gilly, F. N., Arvieux, C., Cotte, E., Boutitie, F., Mansvelt, B., et.al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy, Ann Surg Oncol, 2010. 17(9): p. 2370-7., https://www.ncbi.nlm.nih.gov/pubmed/20336386
448. Spiliotis, J, Halkia, EE, Kalantzi, N, Giassas, S, Lianos, E, Efstathiou, E, et.al. Mapping the location of peritoneal metastases using the peritoneal cancer index and the correlation with overall survival: a retrospective study., J BUON, 2015. 20 Suppl 1 (): p. S64-70., https://pubmed.ncbi.nlm.nih.gov/26051335/
449. Harmon, R. L., Sugarbaker, P. H., Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer, Int Semin Surg Oncol, 2005. 2(1): p. 3., https://www.ncbi.nlm.nih.gov/pubmed/15701175
450. Jacquet, P., Sugarbaker, P. H., Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis, Cancer Treat Res, 1996. 82: p. 359-74., https://www.ncbi.nlm.nih.gov/pubmed/8849962
451. Jamel, S., Markar, S. R., Malietzis, G., Acharya, A., Athanasiou, T., Hanna, G. B., Prognostic significance of peritoneal lavage cytology in staging gastric cancer: systematic review and meta-analysis, Gastric Cancer, 2018. 21(1): p. 10-18., https://www.ncbi.nlm.nih.gov/pubmed/28779261
452. Chia, C. S., You, B., Decullier, E., Vaudoyer, D., Lorimier, G., Abboud, K., et.al. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?, Ann Surg Oncol, 2016. 23(6): p. 1971-9., https://www.ncbi.nlm.nih.gov/pubmed/26753751
453. Liu, L., Ma, X. L., Xiao, Z. L., Li, M., Cheng, S. H., Wei, Y. Q., Prognostic value of vascular endothelial growth factor expression in resected gastric cancer, Asian Pac J Cancer Prev, 2012. 13(7): p. 3089-97., https://www.ncbi.nlm.nih.gov/pubmed/22994715
454. Zhang, C. T., He, K. C., Pan, F., Li, Y., Wu, J., Prognostic value of Muc5AC in gastric cancer: A meta-analysis, World J Gastroenterol, 2015. 21(36): p. 10453-60., https://www.ncbi.nlm.nih.gov/pubmed/26420972
455. Ji, K., Zhang, L., Zhang, M., Chu, Q., Li, X., Wang, W., Prognostic Value and Clinicopathological Significance of p-stat3 Among Gastric Carcinoma Patients: A Systematic Review and Meta-Analysis, Medicine (Baltimore), 2016. 95(5): p. e2641., https://www.ncbi.nlm.nih.gov/pubmed/26844481
456. Kanetaka, K., Ito, S., Susumu, S., Yoneda, A., Fujita, F., Takatsuki, M., et.al. Clinical significance of carcinoembryonic antigen in peritoneal lavage from patients with gastric cancer, Surgery, 2013. 154(3): p. 563-72., https://www.ncbi.nlm.nih.gov/pubmed/23806263
457. Di Bartolomeo, M., Pietrantonio, F., Pellegrinelli, A., Martinetti, A., Mariani, L., Daidone, M. G., et.al. Osteopontin, E-cadherin, and beta-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer, Gastric Cancer, 2016. 19(2): p. 412-20., https://www.ncbi.nlm.nih.gov/pubmed/25862567
458. Fristedt, R., Borg, D., Hedner, C., Berntsson, J., Nodin, B., Eberhard, J., et.al. Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma, J Gastrointest Oncol, 2016. 7(6): p. 848-859., https://www.ncbi.nlm.nih.gov/pubmed/28078109
459. Jagadesham, V. P., Lagarde, S. M., Immanuel, A., Griffin, S. M., Systemic inflammatory markers and outcome in patients with locally advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction, Br J Surg, 2017. 104(4): p. 401-407., https://www.ncbi.nlm.nih.gov/pubmed/28072456
460. Kawazoe, A., Kuwata, T., Kuboki, Y., Shitara, K., Nagatsuma, A. K., Aizawa, M., et.al. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients, Gastric Cancer, 2017. 20(3): p. 407-415., https://www.ncbi.nlm.nih.gov/pubmed/27629881
461. Schlosser, H. A., Drebber, U., Kloth, M., Thelen, M., Rothschild, S. I., Haase, S., et.al. Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma, Oncoimmunology, 2016. 5(5): p. e1100789., https://www.ncbi.nlm.nih.gov/pubmed/27467911
462. Boger, C., Behrens, H. M., Mathiak, M., Kruger, S., Kalthoff, H., Rocken, C., PD-L1 is an independent prognostic predictor in gastric cancer of Western patients, Oncotarget, 2016. 7(17): p. 24269-83., https://www.ncbi.nlm.nih.gov/pubmed/27009855
463. Yan, P., Li, Y. H., Tang, Z. J., Shu, X., Liu, X., High monocarboxylate transporter 4 protein expression in stromal cells predicts adverse survival in gastric cancer, Asian Pac J Cancer Prev, 2014. 15(20): p. 8923-9., https://www.ncbi.nlm.nih.gov/pubmed/25374230
464. Zhang, J., Jin, H. C., Zhu, A. K., Ying, R. C., Wei, W., Zhang, F. J., Prognostic significance of plasma chemerin levels in patients with gastric cancer, Peptides, 2014. 61: p. 7-11., https://www.ncbi.nlm.nih.gov/pubmed/25152503
465. Deng, Q., Yang, H., Lin, Y., Qiu, Y., Gu, X., He, P., et.al. Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China, Int J Clin Exp Pathol, 2014. 7(12): p. 8312-21., https://www.ncbi.nlm.nih.gov/pubmed/25674197
466. Mu, Y. P., Tang, S., Sun, W. J., Gao, W. M., Wang, M., Su, X. L., Association of miR-193b down-regulation and miR-196a up-regulation with clinicopathological features and prognosis in gastric cancer, Asian Pac J Cancer Prev, 2014. 15(20): p. 8893-900., https://www.ncbi.nlm.nih.gov/pubmed/25374225
467. Jiang, W., Jin, Z., Zhou, F., Cui, J., Wang, L., Wang, L., High co-expression of Sp1 and HER-2 is correlated with poor prognosis of gastric cancer patients, Surg Oncol, 2015. 24(3): p. 220-5., https://www.ncbi.nlm.nih.gov/pubmed/26096373
468. Nie, RC, Chen, GM, Yuan, SQ, Kim, JW, Zhou, J, Nie, M, et.al. Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis., Ann Surg Oncol, 2022. 29 (4)(4): p. 2324-2331., https://pubmed.ncbi.nlm.nih.gov/34796431/
469. Pietrantonio, F, Miceli, R, Raimondi, A, Kim, YW, Kang, WK, Langley, RE, et.al. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer., J Clin Oncol, 2019. 37 (35)(35): p. 3392-3400., https://pubmed.ncbi.nlm.nih.gov/31513484/
470. Ren, J, He, Q, Yin, H, Zheng, L, Li, L, Wu, X, Prognostic role and clinical significance of tumor-infiltrating lymphocyte (TIL) and programmed death ligand 1 (PD-L1) expression in gastric cancer: a systematic review and meta-analysis., Clin Transl Oncol, 2023. 25 (5)(5): p. 1436-1445., https://pubmed.ncbi.nlm.nih.gov/36528835/
471. Wang, Y, He, L, Cheng, Y, An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis., Clin Transl Oncol, 2018. 20 (2)(2): p. 212-220., https://pubmed.ncbi.nlm.nih.gov/28681313/
472. Polom, K, Marano, L, Marrelli, D, De Luca, R, Roviello, G, Savelli, V, et.al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer., Br J Surg, 2018. 105 (3)(3): p. 159-167., https://pubmed.ncbi.nlm.nih.gov/29091259/
473. Pietrantonio, F, Randon, G, Di Bartolomeo, M, Luciani, A, Chao, J, Smyth, EC, et.al. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials., ESMO Open, 2021. 6 (1)(1): p. 100036., https://pubmed.ncbi.nlm.nih.gov/33460964/
474. Yoon, HH, Jin, Z, Kour, O, Kankeu Fonkoua, LA, Shitara, K, Gibson, MK, et.al. Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials., JAMA Oncol, 2022. 8 (10)(10): p. 1456-1465., https://pubmed.ncbi.nlm.nih.gov/36006624/
475. Zhuo, ZG, Deng, HY, Song, TN, Alai, GH, Shen, X, Lin, YD, Predictors for the clinical benefit of anti-PD-1/PD-L1 therapy in advanced gastroesophageal cancer: a meta-analysis of clinical trials., Ann Palliat Med, 2020. 9 (5)(5): p. 2524-2537., https://pubmed.ncbi.nlm.nih.gov/33065778/
476. Janjigian, YY, Shitara, K, Moehler, M, Garrido, M, Salman, P, Shen, L, et.al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial., Lancet, 2021. 398 (10294)(10294): p. 27-40., https://pubmed.ncbi.nlm.nih.gov/34102137/
477. Sun, JM, Shen, L, Shah, MA, Enzinger, P, Adenis, A, Doi, T, et.al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study., Lancet, 2021. 398 (10302)(10302): p. 759-771., https://pubmed.ncbi.nlm.nih.gov/34454674/
478. Rha, SY, Oh, DY, Yañez, P, Bai, Y, Ryu, MH, Lee, J, et.al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial., Lancet Oncol, 2023. 24 (11)(11): p. 1181-1195., https://pubmed.ncbi.nlm.nih.gov/37875143/
479. Janjigian, YY, Kawazoe, A, Bai, Y, Xu, J, Lonardi, S, Metges, JP, et.al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial., Lancet, 2023. 402 (10418)(10418): p. 2197-2208., https://pubmed.ncbi.nlm.nih.gov/37871604/
480. Fei, S, Lu, Y, Chen, J, Qi, J, Wu, W, Wang, B, et.al. Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis., Chemotherapy, 2023. 68 (4)(4): p. 197-209., https://pubmed.ncbi.nlm.nih.gov/37331333/
481. Bang, Y. J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., et.al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet 376(9742): p. 687-97., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20728210
482. Xue, C, Xu, YH, Trastuzumab combined chemotherapy for the treatment of HER2-positive advanced gastric cancer: A systematic review and meta-analysis of randomized controlled trial., Medicine (Baltimore), 2022. 101 (34)(34): p. e29992., https://pubmed.ncbi.nlm.nih.gov/36042610/
483. Pietrantonio, F, Miceli, R, Raimondi, A, Kim, YW, Kang, WK, Langley, RE, et.al. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer., J Clin Oncol, 2019. 37 (35)(35): p. 3392-3400., https://pubmed.ncbi.nlm.nih.gov/31513484/
484. Petrelli, F, Antista, M, Marra, F, Cribiu, FM, Rampulla, V, Pietrantonio, F, et.al. Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-analysis., Ther Adv Med Oncol, 2024. 16 (): p. 17588359241231259., https://pubmed.ncbi.nlm.nih.gov/38435432/
485. Hofheinz, RD, Hegewisch-Becker, S, Kunzmann, V, Thuss-Patience, P, Fuchs, M, Homann, N, et.al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group., Int J Cancer, 2021. 149 (6)(6): p. 1322-1331., https://pubmed.ncbi.nlm.nih.gov/34019698/
486. Hofheinz, RD, Merx, K, Haag, GM, Springfeld, C, Ettrich, T, Borchert, K, et.al. FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group., J Clin Oncol, 2022. 40 (32)(32): p. 3750-3761., https://pubmed.ncbi.nlm.nih.gov/35709415/
487. Vasilevska Nikodinovska, V, Ivanoski, S, Sarcopenia, More Than Just Muscle Atrophy: Imaging Methods for the Assessment of Muscle Quantity and Quality., Rofo, 2023. 195 (9)(9): p. 777-789., https://pubmed.ncbi.nlm.nih.gov/37160148/
488. Mourtzakis, M, Prado, CM, Lieffers, JR, Reiman, T, McCargar, LJ, Baracos, VE, A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care., Appl Physiol Nutr Metab, 2008. 33 (5)(5): p. 997-1006., https://pubmed.ncbi.nlm.nih.gov/18923576/
489. Borggreve, AS, den Boer, RB, van Boxel, GI, de Jong, PA, Veldhuis, WB, Steenhagen, E, et.al. The Predictive Value of Low Muscle Mass as Measured on CT Scans for Postoperative Complications and Mortality in Gastric Cancer Patients: A Systematic Review and Meta-Analysis., J Clin Med, 2020. 9 (1)(1):, https://pubmed.ncbi.nlm.nih.gov/31940770/
490. Kamarajah, SK, Bundred, J, Tan, BHL, Body composition assessment and sarcopenia in patients with gastric cancer: a systematic review and meta-analysis., Gastric Cancer, 2019. 22 (1)(1): p. 10-22., https://pubmed.ncbi.nlm.nih.gov/30276574/
491. Rinninella, E, Cintoni, M, Raoul, P, Pozzo, C, Strippoli, A, Bria, E, et.al. Muscle mass, assessed at diagnosis by L3-CT scan as a prognostic marker of clinical outcomes in patients with gastric cancer: A systematic review and meta-analysis., Clin Nutr, 2020. 39 (7)(7): p. 2045-2054., https://pubmed.ncbi.nlm.nih.gov/31718876/
492. He, X, Zhou, S, Li, H, Gou, Y, Jia, D, Prognostic role of pretreatment skeletal muscle index in gastric cancer patients: A meta-analysis., Pathol Oncol Res, 2023. 29 (): p. 1611055., https://pubmed.ncbi.nlm.nih.gov/37168049/
493. Salavatizadeh, M, Soltanieh, S, Radkhah, N, Ataei Kachouei, AH, Bahrami, A, Khalesi, S, et.al. The association between skeletal muscle mass index (SMI) and survival after gastrectomy: A systematic review and meta-analysis of cohort studies., Eur J Surg Oncol, 2023. 49 (11)(11): p. 106980., https://pubmed.ncbi.nlm.nih.gov/37451925/
494. Meyer, HJ, Wienke, A, Surov, A, Sarcopenia as a Prognostic Marker for Survival in Gastric Cancer Patients Undergoing Palliative Chemotherapy. A Systematic Review and Meta Analysis., Nutr Cancer, 2022. 74 (10)(10): p. 3518-3526., https://pubmed.ncbi.nlm.nih.gov/35603926/
495. Probst, A., Schneider, A., Schaller, T., Anthuber, M., Ebigbo, A., Messmann, H., Endoscopic submucosal dissection for early gastric cancer: are expanded resection criteria safe for Western patients?, Endoscopy, 2017. 49(9): p. 855-865., https://www.ncbi.nlm.nih.gov/pubmed/28564714
496. Gotoda, T., Jung, H. Y., Endoscopic resection (endoscopic mucosal resection/ endoscopic submucosal dissection) for early gastric cancer, Dig Endosc, 2013. 25 Suppl 1: p. 55-63., https://www.ncbi.nlm.nih.gov/pubmed/23362925
497. Pimentel-Nunes, P., Dinis-Ribeiro, M., Ponchon, T., Repici, A., Vieth, M., De Ceglie, A., et.al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, Endoscopy, 2015. 47(9): p. 829-54., https://www.ncbi.nlm.nih.gov/pubmed/26317585
498. Song, W. C., Qiao, X. L., Gao, X. Z., A comparison of endoscopic submucosal dissection (ESD) and radical surgery for early gastric cancer: a retrospective study, World J Surg Oncol, 2015. 13: p. 309., https://www.ncbi.nlm.nih.gov/pubmed/26537433
499. Park, Y. M., Cho, E., Kang, H. Y., Kim, J. M., The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis, Surg Endosc, 2011. 25(8): p. 2666-77., https://www.ncbi.nlm.nih.gov/pubmed/21424201
500. Facciorusso, A., Antonino, M., Di Maso, M., Muscatiello, N., Endoscopic submucosal dissection vs endoscopic mucosal resection for early gastric cancer: A meta-analysis, World J Gastrointest Endosc, 2014. 6(11): p. 555-63., https://www.ncbi.nlm.nih.gov/pubmed/25400870
501. Soetikno, R., Kaltenbach, T., Yeh, R., Gotoda, T., Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract, J Clin Oncol, 2005. 23(20): p. 4490-8., https://www.ncbi.nlm.nih.gov/pubmed/16002839
502. Gotoda, T., Yanagisawa, A., Sasako, M., Ono, H., Nakanishi, Y., Shimoda, T., et.al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers, Gastric Cancer, 2000. 3(4): p. 219-225., https://www.ncbi.nlm.nih.gov/pubmed/11984739
503. Hirasawa, T., Gotoda, T., Miyata, S., Kato, Y., Shimoda, T., Taniguchi, H., et.al. Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer, Gastric Cancer, 2009. 12(3): p. 148-52., https://www.ncbi.nlm.nih.gov/pubmed/19890694
504. Yamao, T., Shirao, K., Ono, H., Kondo, H., Saito, D., Yamaguchi, H., et.al. Risk factors for lymph node metastasis from intramucosal gastric carcinoma, Cancer, 1996. 77(4): p. 602-6., https://www.ncbi.nlm.nih.gov/pubmed/8616749
505. Folli, S., Morgagni, P., Roviello, F., De Manzoni, G., Marrelli, D., Saragoni, L., et.al. Risk factors for lymph node metastases and their prognostic significance in early gastric cancer (EGC) for the Italian Research Group for Gastric Cancer (IRGGC), Jpn J Clin Oncol, 2001. 31(10): p. 495-9., https://www.ncbi.nlm.nih.gov/pubmed/11696619
506. Abdelfatah, M. M., Barakat, M., Lee, H., Kim, J. J., Uedo, N., Grimm, I., et.al. The incidence of lymph node metastasis in early gastric cancer according to the expanded criteria in comparison with the absolute criteria of the Japanese Gastric Cancer Association: a systematic review of the literature and meta-analysis, Gastrointest Endosc, 2017., https://www.ncbi.nlm.nih.gov/pubmed/28966062
507. Pimentel-Nunes, P, Libânio, D, Bastiaansen, BAJ, Bhandari, P, Bisschops, R, Bourke, MJ, et.al. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022., Endoscopy, 2022. 54 (6)(6): p. 591-622., https://pubmed.ncbi.nlm.nih.gov/35523224/
508. Isomoto, H., Shikuwa, S., Yamaguchi, N., Fukuda, E., Ikeda, K., Nishiyama, H., et.al. Endoscopic submucosal dissection for early gastric cancer: a large-scale feasibility study, Gut, 2009. 58(3): p. 331-6., https://www.ncbi.nlm.nih.gov/pubmed/19001058
509. Yamaguchi, N., Isomoto, H., Fukuda, E., Ikeda, K., Nishiyama, H., Akiyama, M., et.al. Clinical outcomes of endoscopic submucosal dissection for early gastric cancer by indication criteria, Digestion, 2009. 80(3): p. 173-81., https://www.ncbi.nlm.nih.gov/pubmed/19776581
510. Hitomi, G., Watanabe, H., Tominaga, K., Yoshitake, N., Suzuki, M., Maeda, M., et.al. Endoscopic submucosal dissection in 100 lesions with early gastric carcinoma, Hepatogastroenterology, 2009. 56(89): p. 254-60., https://www.ncbi.nlm.nih.gov/pubmed/19453070
511. Ahn, J. Y., Jung, H. Y., Choi, K. D., Choi, J. Y., Kim, M. Y., Lee, J. H., et.al. Endoscopic and oncologic outcomes after endoscopic resection for early gastric cancer: 1370 cases of absolute and extended indications, Gastrointest Endosc, 2011. 74(3): p. 485-93., https://www.ncbi.nlm.nih.gov/pubmed/21741645
512. Park, C. H., Shin, S., Park, J. C., Shin, S. K., Lee, S. K., Lee, Y. C., et.al. Long-term outcome of early gastric cancer after endoscopic submucosal dissection: expanded indication is comparable to absolute indication, Dig Liver Dis, 2013. 45(8): p. 651-6., https://www.ncbi.nlm.nih.gov/pubmed/23422031
513. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)., Gastric Cancer, 2023. 26 (1)(1): p. 1-25., https://pubmed.ncbi.nlm.nih.gov/36342574/
514. Chiu, P. W., Teoh, A. Y., To, K. F., Wong, S. K., Liu, S. Y., Lam, C. C., et.al. Endoscopic submucosal dissection (ESD) compared with gastrectomy for treatment of early gastric neoplasia: a retrospective cohort study, Surg Endosc, 2012. 26(12): p. 3584-91., https://www.ncbi.nlm.nih.gov/pubmed/22678176
515. Choi, J. H., Kim, E. S., Lee, Y. J., Cho, K. B., Park, K. S., Jang, B. K., et.al. Comparison of quality of life and worry of cancer recurrence between endoscopic and surgical treatment for early gastric cancer, Gastrointest Endosc, 2015. 82(2): p. 299-307., https://www.ncbi.nlm.nih.gov/pubmed/25892060
516. Kim, S. G., Ji, S. M., Lee, N. R., Park, S. H., You, J. H., Choi, I. J., et.al. Quality of Life after Endoscopic Submucosal Dissection for Early Gastric Cancer: A Prospective Multicenter Cohort Study, Gut Liver, 2017. 11(1): p. 87-92., https://www.ncbi.nlm.nih.gov/pubmed/27282267
517. Manner, H., Rabenstein, T., May, A., Pech, O., Gossner, L., Werk, D., et.al. Long-term results of endoscopic resection in early gastric cancer: the Western experience, Am J Gastroenterol, 2009. 104(3): p. 566-73., https://www.ncbi.nlm.nih.gov/pubmed/19223887
518. Lian, J., Chen, S., Zhang, Y., Qiu, F., A meta-analysis of endoscopic submucosal dissection and EMR for early gastric cancer, Gastrointest Endosc, 2012. 76(4): p. 763-70., https://www.ncbi.nlm.nih.gov/pubmed/22884100
519. Ahn, J. Y., Jung, H. Y., Choi, J. Y., Kim, M. Y., Lee, J. H., Choi, K. S., et.al. Natural course of noncurative endoscopic resection of differentiated early gastric cancer, Endoscopy, 2012. 44(12): p. 1114-20., https://www.ncbi.nlm.nih.gov/pubmed/23188661
520. Yokoi, C., Gotoda, T., Hamanaka, H., Oda, I., Endoscopic submucosal dissection allows curative resection of locally recurrent early gastric cancer after prior endoscopic mucosal resection, Gastrointest Endosc, 2006. 64(2): p. 212-8., https://www.ncbi.nlm.nih.gov/pubmed/16860071
521. Oda, I., Gotoda, T., Sasako, M., Sano, T., Katai, H., Fukagawa, T., et.al. Treatment strategy after non-curative endoscopic resection of early gastric cancer, Br J Surg, 2008. 95(12): p. 1495-500., https://www.ncbi.nlm.nih.gov/pubmed/18942058
522. Figueiredo, PC, Pimentel-Nunes, P, Libânio, D, Dinis-Ribeiro, M, A systematic review and meta-analysis on outcomes after Rx or R1 endoscopic resection of superficial gastric cancer., Eur J Gastroenterol Hepatol, 2015. 27 (11)(11): p. 1249-58., https://pubmed.ncbi.nlm.nih.gov/26225870/
523. Jeon, MY, Park, JC, Hahn, KY, Shin, SK, Lee, SK, Lee, YC, Long-term outcomes after noncurative endoscopic resection of early gastric cancer: the optimal time for additional endoscopic treatment., Gastrointest Endosc, 2018. 87 (4)(4): p. 1003-1013.e2., https://pubmed.ncbi.nlm.nih.gov/29031882/
524. Nagano, H., Ohyama, S., Fukunaga, T., Seto, Y., Fujisaki, J., Yamaguchi, T., et.al. Indications for gastrectomy after incomplete EMR for early gastric cancer, Gastric Cancer, 2005. 8(3): p. 149-54., https://www.ncbi.nlm.nih.gov/pubmed/16086117
525. Tanabe, S., Ishido, K., Higuchi, K., Sasaki, T., Katada, C., Azuma, M., et.al. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a retrospective comparison with conventional endoscopic resection in a single center, Gastric Cancer, 2014. 17(1): p. 130-6., https://www.ncbi.nlm.nih.gov/pubmed/23576197
526. Yamamoto, S., Uedo, N., Ishihara, R., Kajimoto, N., Ogiyama, H., Fukushima, Y., et.al. Endoscopic submucosal dissection for early gastric cancer performed by supervised residents: assessment of feasibility and learning curve, Endoscopy, 2009. 41(11): p. 923-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19802773
527. Probst, A., Golger, D., Arnholdt, H., Messmann, H., Endoscopic submucosal dissection of early cancers, flat adenomas, and submucosal tumors in the gastrointestinal tract, Clin Gastroenterol Hepatol, 2009. 7(2): p. 149-55., https://www.ncbi.nlm.nih.gov/pubmed/19032991
528. Song, K. Y., Park, S. M., Kim, S. N., Park, C. H., The role of surgery in the treatment of recurrent gastric cancer, Am J Surg, 2008. 196(1): p. 19-22., https://www.ncbi.nlm.nih.gov/pubmed/18417082
529. Ishikawa, S., Togashi, A., Inoue, M., Honda, S., Nozawa, F., Toyama, E., et.al. Indications for EMR/ESD in cases of early gastric cancer: relationship between histological type, depth of wall invasion, and lymph node metastasis, Gastric Cancer, 2007. 10(1): p. 35-8., https://www.ncbi.nlm.nih.gov/pubmed/17334716
530. Chung, I. K., Lee, J. H., Lee, S. H., Kim, S. J., Cho, J. Y., Cho, W. Y., et.al. Therapeutic outcomes in 1000 cases of endoscopic submucosal dissection for early gastric neoplasms: Korean ESD Study Group multicenter study, Gastrointest Endosc, 2009. 69(7): p. 1228-35., https://www.ncbi.nlm.nih.gov/pubmed/19249769
531. Abe, N., Gotoda, T., Hirasawa, T., Hoteya, S., Ishido, K., Ida, Y., et.al. Multicenter study of the long-term outcomes of endoscopic submucosal dissection for early gastric cancer in patients 80 years of age or older, Gastric Cancer, 2012. 15(1): p. 70-5., https://www.ncbi.nlm.nih.gov/pubmed/21667133
532. Gotoda, T., Yamamoto, H., Soetikno, R. M., Endoscopic submucosal dissection of early gastric cancer, J Gastroenterol, 2006. 41(10): p. 929-42., https://www.ncbi.nlm.nih.gov/pubmed/17096062
533. Fleischmann, C, Probst, A, Ebigbo, A, Faiss, S, Schumacher, B, Allgaier, HP, et.al. Endoscopic Submucosal Dissection in Europe: Results of 1000 Neoplastic Lesions From the German Endoscopic Submucosal Dissection Registry., Gastroenterology, 2021. 161 (4)(4): p. 1168-1178., https://pubmed.ncbi.nlm.nih.gov/34182002/
534. Uedo, N., Takeuchi, Y., Yamada, T., Ishihara, R., Ogiyama, H., Yamamoto, S., et.al. Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial, Am J Gastroenterol, 2007. 102(8): p. 1610-6., https://www.ncbi.nlm.nih.gov/pubmed/17403076
535. Yamaguchi, Y., Katsumi, N., Tauchi, M., Toki, M., Nakamura, K., Aoki, K., et.al. A prospective randomized trial of either famotidine or omeprazole for the prevention of bleeding after endoscopic mucosal resection and the healing of endoscopic mucosal resection-induced ulceration, Aliment Pharmacol Ther, 2005. 21 Suppl 2: p. 111-5., https://www.ncbi.nlm.nih.gov/pubmed/15943857
536. Watanabe, Y., Kato, N., Maehata, T., Okamoto, M., Tsuda, T., Hattori, S., et.al. Safer endoscopic gastric mucosal resection: preoperative proton pump inhibitor administration, J Gastroenterol Hepatol, 2006. 21(11): p. 1675-80., https://www.ncbi.nlm.nih.gov/pubmed/16984588
537. Ono, S., Kato, M., Ono, Y., Nakagawa, M., Nakagawa, S., Shimizu, Y., et.al. Effects of preoperative administration of omeprazole on bleeding after endoscopic submucosal dissection: a prospective randomized controlled trial, Endoscopy, 2009. 41(4): p. 299-303., https://www.ncbi.nlm.nih.gov/pubmed/19340731
538. Ikehara, H., Gotoda, T., Ono, H., Oda, I., Saito, D., Gastric perforation during endoscopic resection for gastric carcinoma and the risk of peritoneal dissemination, Br J Surg, 2007. 94(8): p. 992-5., https://www.ncbi.nlm.nih.gov/pubmed/17535014
539. Kato, M., Nishida, T., Yamamoto, K., Hayashi, S., Kitamura, S., Yabuta, T., et.al. Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer: a multicentre retrospective cohort study by Osaka University ESD study group, Gut, 2013. 62(10): p. 1425-32., https://www.ncbi.nlm.nih.gov/pubmed/22914298
540. Association, Japanese Gastric Cancer, Japanese gastric cancer treatment guidelines 2010 (ver. 3), Gastric Cancer, 2011. 2011; 14: 113–123.:, https://pubmed.ncbi.nlm.nih.gov/21573742/
541. Ono, H., Yao, K., Fujishiro, M., Oda, I., Nimura, S., Yahagi, N., et.al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer, Dig Endosc, 2016. 28(1): p. 3-15., https://www.ncbi.nlm.nih.gov/pubmed/26234303
542. Mitsuhashi, T., Lauwers, G. Y., Ban, S., Mino-Kenudson, M., Shimizu, Y., Ogawa, F., et.al. Post-gastric endoscopic mucosal resection surveillance biopsies: evaluation of mucosal changes and recognition of potential mimics of residual adenocarcinoma, Am J Surg Pathol, 2006. 30(5): p. 650-6., https://www.ncbi.nlm.nih.gov/pubmed/16699321
543. Horiki, N., Omata, F., Uemura, M., Suzuki, S., Ishii, N., Fukuda, K., et.al. Risk for local recurrence of early gastric cancer treated with piecemeal endoscopic mucosal resection during a 10-year follow-up period, Surg Endosc, 2012. 26(1): p. 72-8., https://www.ncbi.nlm.nih.gov/pubmed/21792719
544. Yoon, H., Kim, S. G., Choi, J., Im, J. P., Kim, J. S., Kim, W. H., et.al. Risk factors of residual or recurrent tumor in patients with a tumor-positive resection margin after endoscopic resection of early gastric cancer, Surg Endosc, 2013. 27(5): p. 1561-8., https://www.ncbi.nlm.nih.gov/pubmed/23263643
545. Best, L. M., Mughal, M., Gurusamy, K. S., Laparoscopic versus open gastrectomy for gastric cancer, Cochrane Database Syst Rev, 2016. 3: p. CD011389., https://www.ncbi.nlm.nih.gov/pubmed/27030300
546. Cui, M., Li, Z., Xing, J., Yao, Z., Liu, M., Chen, L., et.al. A prospective randomized clinical trial comparing D2 dissection in laparoscopic and open gastrectomy for gastric cancer, Med Oncol, 2015. 32(10): p. 241., https://www.ncbi.nlm.nih.gov/pubmed/26350550
547. Hu, Y., Huang, C., Sun, Y., Su, X., Cao, H., Hu, J., et.al. Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial, J Clin Oncol, 2016. 34(12): p. 1350-7., https://www.ncbi.nlm.nih.gov/pubmed/26903580
548. Park, Y. K., Yoon, H. M., Kim, Y. W., Park, J. Y., Ryu, K. W., Lee, Y. J., et.al. Laparoscopy-Assisted versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: Results from a Randomized Phase II Multicenter Clinical Trial (COACT 1001), Ann Surg, 2017., https://www.ncbi.nlm.nih.gov/pubmed/28187041
549. Kitano, S., Shiraishi, N., Fujii, K., Yasuda, K., Inomata, M., Adachi, Y., A randomized controlled trial comparing open vs laparoscopy-assisted distal gastrectomy for the treatment of early gastric cancer: an interim report, Surgery, 2002. 131(1 Suppl): p. S306-11., https://www.ncbi.nlm.nih.gov/pubmed/11821829
550. Hayashi, H., Ochiai, T., Shimada, H., Gunji, Y., Prospective randomized study of open versus laparoscopy-assisted distal gastrectomy with extraperigastric lymph node dissection for early gastric cancer, Surg Endosc, 2005. 19(9): p. 1172-6., https://www.ncbi.nlm.nih.gov/pubmed/16132323
551. Kim, Y. W., Baik, Y. H., Yun, Y. H., Nam, B. H., Kim, D. H., Choi, I. J., et.al. Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial, Ann Surg, 2008. 248(5): p. 721-7., https://www.ncbi.nlm.nih.gov/pubmed/18948798
552. Sakuramoto, S., Yamashita, K., Kikuchi, S., Futawatari, N., Katada, N., Watanabe, M., et.al. Laparoscopy versus open distal gastrectomy by expert surgeons for early gastric cancer in Japanese patients: short-term clinical outcomes of a randomized clinical trial, Surg Endosc, 2013. 27(5): p. 1695-705., https://www.ncbi.nlm.nih.gov/pubmed/23247737
553. Takiguchi, S., Fujiwara, Y., Yamasaki, M., Miyata, H., Nakajima, K., Sekimoto, M., et.al. Laparoscopy-assisted distal gastrectomy versus open distal gastrectomy. A prospective randomized single-blind study, World J Surg, 2013. 37(10): p. 2379-86., https://www.ncbi.nlm.nih.gov/pubmed/23783252
554. Hosono, S., Arimoto, Y., Ohtani, H., Kanamiya, Y., Meta-analysis of short-term outcomes after laparoscopy-assisted distal gastrectomy, World J Gastroenterol, 2006. 12(47): p. 7676-83., https://www.ncbi.nlm.nih.gov/pubmed/17171799
555. Memon, M. A., Khan, S., Yunus, R. M., Barr, R., Memon, B., Meta-analysis of laparoscopic and open distal gastrectomy for gastric carcinoma, Surg Endosc, 2008. 22(8): p. 1781-9., https://www.ncbi.nlm.nih.gov/pubmed/18437472
556. Chen, X. Z., Hu, J. K., Yang, K., Wang, L., Lu, Q. C., Short-term evaluation of laparoscopy-assisted distal gastrectomy for predictive early gastric cancer: a meta-analysis of randomized controlled trials, Surg Laparosc Endosc Percutan Tech, 2009. 19(4): p. 277-84., https://www.ncbi.nlm.nih.gov/pubmed/19692873
557. Yakoub, D., Athanasiou, T., Tekkis, P., Hanna, G. B., Laparoscopic assisted distal gastrectomy for early gastric cancer: is it an alternative to the open approach?, Surg Oncol, 2009. 18(4): p. 322-33., https://www.ncbi.nlm.nih.gov/pubmed/18922689
558. Vinuela, E. F., Gonen, M., Brennan, M. F., Coit, D. G., Strong, V. E., Laparoscopic versus open distal gastrectomy for gastric cancer: a meta-analysis of randomized controlled trials and high-quality nonrandomized studies, Ann Surg, 2012. 255(3): p. 446-56., https://www.ncbi.nlm.nih.gov/pubmed/22330034
559. Zeng, Y. K., Yang, Z. L., Peng, J. S., Lin, H. S., Cai, L., Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: evidence from randomized and nonrandomized clinical trials, Ann Surg, 2012. 256(1): p. 39-52., https://www.ncbi.nlm.nih.gov/pubmed/22664559
560. Deng, Y., Zhang, Y., Guo, T. K., Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: A meta-analysis based on seven randomized controlled trials, Surg Oncol, 2015. 24(2): p. 71-7., https://www.ncbi.nlm.nih.gov/pubmed/25791201
561. Kim, Y. W., Yoon, H. M., Yun, Y. H., Nam, B. H., Eom, B. W., Baik, Y. H., et.al. Long-term outcomes of laparoscopy-assisted distal gastrectomy for early gastric cancer: result of a randomized controlled trial (COACT 0301), Surg Endosc, 2013. 27(11): p. 4267-76., https://www.ncbi.nlm.nih.gov/pubmed/23793805
562. Lee, J. H., Yom, C. K., Han, H. S., Comparison of long-term outcomes of laparoscopy-assisted and open distal gastrectomy for early gastric cancer, Surg Endosc, 2009. 23(8): p. 1759-63., https://www.ncbi.nlm.nih.gov/pubmed/19057958
563. Shinohara, T., Satoh, S., Kanaya, S., Ishida, Y., Taniguchi, K., Isogaki, J., et.al. Laparoscopic versus open D2 gastrectomy for advanced gastric cancer: a retrospective cohort study, Surg Endosc, 2013. 27(1): p. 286-94., https://www.ncbi.nlm.nih.gov/pubmed/22733201
564. Zou, Z. H., Zhao, L. Y., Mou, T. Y., Hu, Y. F., Yu, J., Liu, H., et.al. Laparoscopic vs open D2 gastrectomy for locally advanced gastric cancer: a meta-analysis, World J Gastroenterol, 2014. 20(44): p. 16750-64., https://www.ncbi.nlm.nih.gov/pubmed/25469048
565. Huscher, C. G., Mingoli, A., Sgarzini, G., Sansonetti, A., Di Paola, M., Recher, A., et.al. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial, Ann Surg, 2005. 241(2): p. 232-7., https://www.ncbi.nlm.nih.gov/pubmed/15650632
566. Edge, S. B., Compton, C. C., The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM, Ann Surg Oncol, 2010. 17(6): p. 1471-4., https://www.ncbi.nlm.nih.gov/pubmed/20180029
567. Hornig D, Hermanek P, Gall FP, The Significance of the Extent of Proximal Margins of Clearance in Gastric Cancer Surgery, Scnad J Gastroenterol, 1987. 1987(22):69-71.:
568. Hermanek, P., pTNM and residual tumor classifications: problems of assessment and prognostic significance, World J Surg, 1995. 19(2): p. 184-90., https://www.ncbi.nlm.nih.gov/pubmed/7754621
569. Postlewait, L. M., Squires, M. H., 3rd, Kooby, D. A., Poultsides, G. A., Weber, S. M., Bloomston, M., et.al. The importance of the proximal resection margin distance for proximal gastric adenocarcinoma: A multi-institutional study of the US Gastric Cancer Collaborative, J Surg Oncol, 2015. 112(2): p. 203-7., https://www.ncbi.nlm.nih.gov/pubmed/26272801
570. Squires, M. H., 3rd, Kooby, D. A., Poultsides, G. A., Pawlik, T. M., Weber, S. M., Schmidt, C. R., et.al. Is it time to abandon the 5-cm margin rule during resection of distal gastric adenocarcinoma? A multi-institution study of the U.S. Gastric Cancer Collaborative, Ann Surg Oncol, 2015. 22(4): p. 1243-51., https://www.ncbi.nlm.nih.gov/pubmed/25316491
571. Squires, M. H., 3rd, Kooby, D. A., Pawlik, T. M., Weber, S. M., Poultsides, G., Schmidt, C., et.al. Utility of the proximal margin frozen section for resection of gastric adenocarcinoma: a 7-Institution Study of the US Gastric Cancer Collaborative, Ann Surg Oncol, 2014. 21(13): p. 4202-10., https://www.ncbi.nlm.nih.gov/pubmed/25047464
572. Kim, M. G., Lee, J. H., Ha, T. K., Kwon, S. J., The distance of proximal resection margin dose not significantly influence on the prognosis of gastric cancer patients after curative resection, Ann Surg Treat Res, 2014. 87(5): p. 223-31., https://www.ncbi.nlm.nih.gov/pubmed/25368847
573. Bozzetti, F., Marubini, E., Bonfanti, G., Miceli, R., Piano, C., Crose, N., et.al. Total versus subtotal gastrectomy: surgical morbidity and mortality rates in a multicenter Italian randomized trial. The Italian Gastrointestinal Tumor Study Group, Ann Surg, 1997. 226(5): p. 613-20., https://www.ncbi.nlm.nih.gov/pubmed/9389395
574. Mine, S., Sano, T., Hiki, N., Yamada, K., Kosuga, T., Nunobe, S., et.al. Proximal margin length with transhiatal gastrectomy for Siewert type II and III adenocarcinomas of the oesophagogastric junction, Br J Surg, 2013. 100(8): p. 1050-4., https://www.ncbi.nlm.nih.gov/pubmed/23754647
575. Ajani, J. A., D'Amico, T. A., Almhanna, K., Bentrem, D. J., Chao, J., Das, P., et.al. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw, 2016. 14(10): p. 1286-1312., https://www.ncbi.nlm.nih.gov/pubmed/27697982
576. SIGN, Management of esophageal and gastric Cancer, SIGN clinical practice guidelines, 2006. p. 87.
577. Lee, J. H., Ahn, S. H., Park, D. J., Kim, H. H., Lee, H. J., Yang, H. K., Clinical impact of tumor infiltration at the transected surgical margin during gastric cancer surgery, J Surg Oncol, 2012. 106(6): p. 772-6., https://www.ncbi.nlm.nih.gov/pubmed/22488368
578. Woo, J. W., Ryu, K. W., Park, J. Y., Eom, B. W., Kim, M. J., Yoon, H. M., et.al. Prognostic impact of microscopic tumor involved resection margin in advanced gastric cancer patients after gastric resection, World J Surg, 2014. 38(2): p. 439-46., https://www.ncbi.nlm.nih.gov/pubmed/24132828
579. Liang, Y., Ding, X., Wang, X., Wang, B., Deng, J., Zhang, L., et.al. Prognostic value of surgical margin status in gastric cancer patients, ANZ J Surg, 2015. 85(9): p. 678-84., https://www.ncbi.nlm.nih.gov/pubmed/24438078
580. Pasquer, A., Renaud, F., Hec, F., Gandon, A., Vanderbeken, M., Drubay, V., et.al. Is Centralization Needed for Esophageal and Gastric Cancer Patients With Low Operative Risk?: A Nationwide Study, Ann Surg, 2016. 264(5): p. 823-830., https://www.ncbi.nlm.nih.gov/pubmed/27429033
581. Halm, E. A., Lee, C., Chassin, M. R., Is volume related to outcome in health care? A systematic review and methodologic critique of the literature, Ann Intern Med, 2002. 137(6): p. 511-20., https://www.ncbi.nlm.nih.gov/pubmed/12230353
582. Killeen, S. D., O'Sullivan, M. J., Coffey, J. C., Kirwan, W. O., Redmond, H. P., Provider volume and outcomes for oncological procedures, Br J Surg, 2005. 92(4): p. 389-402., https://www.ncbi.nlm.nih.gov/pubmed/15786424
583. Meyer, H. J., The influence of case load and the extent of resection on the quality of treatment outcome in gastric cancer, Eur J Surg Oncol, 2005. 31(6): p. 595-604., https://www.ncbi.nlm.nih.gov/pubmed/15919174
584. Callahan, M. A., Christos, P. J., Gold, H. T., Mushlin, A. I., Daly, J. M., Influence of surgical subspecialty training on in-hospital mortality for gastrectomy and colectomy patients, Ann Surg, 2003. 238(4): p. 629-36; discussion 636-9., https://www.ncbi.nlm.nih.gov/pubmed/14530734
585. Damhuis, R. A., Meurs, C. J., Dijkhuis, C. M., Stassen, L. P., Wiggers, T., Hospital volume and post-operative mortality after resection for gastric cancer, Eur J Surg Oncol, 2002. 28(4): p. 401-5., https://www.ncbi.nlm.nih.gov/pubmed/12099650
586. Lehnert, T., Buhl, K., Techniques of reconstruction after total gastrectomy for cancer, Br J Surg, 2004. 91(5): p. 528-39., https://www.ncbi.nlm.nih.gov/pubmed/15122602
587. Syn, N. L., Wee, I., Shabbir, A., Kim, G., So, J. B., Pouch Versus No Pouch Following Total gastrectomy: Meta-analysis of Randomized and Non-randomized Studies, Ann Surg, 2018., https://www.ncbi.nlm.nih.gov/pubmed/30571657
588. Chen, W., Jiang, X., Huang, H., Ding, Z., Li, C., Jejunal pouch reconstruction after total gastrectomy is associated with better short-term absorption capacity and quality of life in early-stage gastric cancer patients, BMC Surg, 2018. 18(1): p. 63., https://www.ncbi.nlm.nih.gov/pubmed/30126403
589. Siewert, J. R., Stein, H. J., Classification of adenocarcinoma of the oesophagogastric junction, Br J Surg, 1998. 85(11): p. 1457-9., https://www.ncbi.nlm.nih.gov/pubmed/9823902
590. Sasako, M., Sano, T., Yamamoto, S., Sairenji, M., Arai, K., Kinoshita, T., et.al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial, Lancet Oncol, 2006. 7(8): p. 644-51., https://www.ncbi.nlm.nih.gov/pubmed/16887481
591. Fuchs, H., Holscher, A. H., Leers, J., Bludau, M., Brinkmann, S., Schroder, W., et.al. Long-term quality of life after surgery for adenocarcinoma of the esophagogastric junction: extended gastrectomy or transthoracic esophagectomy?, Gastric Cancer, 2016. 19(1): p. 312-7., https://www.ncbi.nlm.nih.gov/pubmed/25627475
592. Biere, S. S., van Berge Henegouwen, M. I., Maas, K. W., Bonavina, L., Rosman, C., Garcia, J. R., et.al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial, Lancet, 2012. 379(9829): p. 1887-92., https://www.ncbi.nlm.nih.gov/pubmed/22552194
593. (AB), Alberta Health Services. Edmonton, Gastric cancer, clinical practice guideline GI-008, Accessed 2017 Feb 10].
594. Waddell, T., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., Arnold, D., et.al. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2013. 24 Suppl 6: p. vi57-63., https://www.ncbi.nlm.nih.gov/pubmed/24078663
595. Siewert, J. R., Bottcher, K., Stein, H. J., Roder, J. D., Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study, Ann Surg, 1998. 228(4): p. 449-61., https://www.ncbi.nlm.nih.gov/pubmed/9790335
596. Wagner, P. K., Ramaswamy, A., Ruschoff, J., Schmitz-Moormann, P., Rothmund, M., Lymph node counts in the upper abdomen: anatomical basis for lymphadenectomy in gastric cancer, Br J Surg, 1991. 78(7): p. 825-7., https://www.ncbi.nlm.nih.gov/pubmed/1873712
597. Edwards, P., Blackshaw, G. R., Lewis, W. G., Barry, J. D., Allison, M. C., Jones, D. R., Prospective comparison of D1 vs modified D2 gastrectomy for carcinoma, Br J Cancer, 2004. 90(10): p. 1888-92., https://www.ncbi.nlm.nih.gov/pubmed/15138467
598. Degiuli, M., Sasako, M., Ponti, A., Calvo, F., Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer, Br J Cancer, 2004. 90(9): p. 1727-32., https://www.ncbi.nlm.nih.gov/pubmed/15150592
599. Bonenkamp, J. J., Hermans, J., Sasako, M., van de Velde, C. J., Welvaart, K., Songun, I., et.al. Extended lymph-node dissection for gastric cancer, N Engl J Med, 1999. 340(12): p. 908-14., https://www.ncbi.nlm.nih.gov/pubmed/10089184
600. Cuschieri, A., Weeden, S., Fielding, J., Bancewicz, J., Craven, J., Joypaul, V., et.al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group, Br J Cancer, 1999. 79(9-10): p. 1522-30., https://www.ncbi.nlm.nih.gov/pubmed/10188901
601. Hartgrink, H. H., van de Velde, C. J., Putter, H., Bonenkamp, J. J., Klein Kranenbarg, E., Songun, I., et.al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial, J Clin Oncol, 2004. 22(11): p. 2069-77., https://www.ncbi.nlm.nih.gov/pubmed/15082726
602. Hartgrink, H. H., van de Velde, C. J., Status of extended lymph node dissection: locoregional control is the only way to survive gastric cancer, J Surg Oncol, 2005. 90(3): p. 153-65., https://www.ncbi.nlm.nih.gov/pubmed/15895448
603. Songun, I., Putter, H., Kranenbarg, E. M., Sasako, M., van de Velde, C. J., Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial, Lancet Oncol, 2010. 11(5): p. 439-49., https://www.ncbi.nlm.nih.gov/pubmed/20409751
604. McCulloch, P., Nita, M. E., Kazi, H., Gama-Rodrigues, J., Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach, Cochrane Database Syst Rev, 2004. p. CD001964., https://www.ncbi.nlm.nih.gov/pubmed/15495024
605. Coburn, N., Cosby, R., Klein, L., Knight, G., Malthaner, R., Mamazza, J., et.al. Staging and surgical approaches in gastric cancer: A systematic review, Cancer Treat Rev, 2018. 63: p. 104-115., https://www.ncbi.nlm.nih.gov/pubmed/29275224
606. Fujitani, K., Yang, H. K., Mizusawa, J., Kim, Y. W., Terashima, M., Han, S. U., et.al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial, Lancet Oncol, 2016. 17(3): p. 309-18., https://www.ncbi.nlm.nih.gov/pubmed/26822397
607. Lasithiotakis, K., Antoniou, S. A., Antoniou, G. A., Kaklamanos, I., Zoras, O., Gastrectomy for stage IV gastric cancer. a systematic review and meta-analysis, Anticancer Res, 2014. 34(5): p. 2079-85., https://www.ncbi.nlm.nih.gov/pubmed/24778009
608. Sun, J., Song, Y., Wang, Z., Chen, X., Gao, P., Xu, Y., et.al. Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis, BMC Cancer, 2013. 13: p. 577., https://www.ncbi.nlm.nih.gov/pubmed/24304886
609. Al-Batran, S. E., Homann, N., Pauligk, C., Illerhaus, G., Martens, U. M., Stoehlmacher, J., et.al. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial, JAMA Oncol, 2017. 3(9): p. 1237-1244., https://www.ncbi.nlm.nih.gov/pubmed/28448662
610. Miki, K., Fujishiro, M., Kodashima, S., Yahagi, N., Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population, Dig Endosc, 2009. 21(2): p. 78-81., https://www.ncbi.nlm.nih.gov/pubmed/19691778
611. Al-Batran, S. E., Goetze, T. O., Mueller, D. W., Vogel, A., Winkler, M., Lorenzen, S., et.al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI, BMC Cancer, 2017. 17(1): p. 893., https://www.ncbi.nlm.nih.gov/pubmed/29282088
612. Stiekema, J., Trip, A. K., Jansen, E. P., Boot, H., Cats, A., Ponz, O. B., et.al. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy, Ann Surg Oncol, 2014. 21(4): p. 1107-14., https://www.ncbi.nlm.nih.gov/pubmed/24306660
613. Gertler, R., Richter, J., Stecher, L., Nitsche, U., Feith, M., What to do after R1-resection of adenocarcinomas of the esophagogastric junction?, J Surg Oncol, 2016. 114(4): p. 428-33., https://www.ncbi.nlm.nih.gov/pubmed/27333949
614. Aurello, P., Magistri, P., Nigri, G., Petrucciani, N., Novi, L., Antolino, L., et.al. Surgical management of microscopic positive resection margin after gastrectomy for gastric cancer: a systematic review of gastric R1 management, Anticancer Res, 2014. 34(11): p. 6283-8., https://www.ncbi.nlm.nih.gov/pubmed/25368226
615. Lordick, F., Ott, K., Novotny, A., Schuhmacher, C., Siewert, J. R., [R1 resection in the surgery of upper gastrointestinal tumors: relevance and therapeutic consequences], Chirurg, 2007. 78(9): p. 792-801., https://www.ncbi.nlm.nih.gov/pubmed/17676284
616. Bissolati, M., Desio, M., Rosa, F., Rausei, S., Marrelli, D., Baiocchi, G. L., et.al. Risk factor analysis for involvement of resection margins in gastric and esophagogastric junction cancer: an Italian multicenter study, Gastric Cancer, 2017. 20(1): p. 70-82., https://www.ncbi.nlm.nih.gov/pubmed/26732876
617. Raziee, H. R., Cardoso, R., Seevaratnam, R., Mahar, A., Helyer, L., Law, C., et.al. Systematic review of the predictors of positive margins in gastric cancer surgery and the effect on survival, Gastric Cancer, 2012. 15 Suppl 1: p. S116-24., https://www.ncbi.nlm.nih.gov/pubmed/22138928
618. Stiekema, J., Trip, A. K., Jansen, E. P., Aarts, M. J., Boot, H., Cats, A., et.al. Does adjuvant chemoradiotherapy improve the prognosis of gastric cancer after an r1 resection? Results from a dutch cohort study, Ann Surg Oncol, 2015. 22(2): p. 581-8., https://www.ncbi.nlm.nih.gov/pubmed/25164039
619. Ho, V. K. Y., Jansen, E. P. M., Wijnhoven, B. P. L., Neelis, K. J., van Sandick, J. W., Verhoeven, R. H. A., et.al. Adjuvant Chemoradiotherapy for Non-Pretreated Gastric Cancer, Ann Surg Oncol, 2017. 24(12): p. 3647-3657., https://www.ncbi.nlm.nih.gov/pubmed/28831737
620. Henning, G. T., Schild, S. E., Stafford, S. L., Donohue, J. H., Burch, P. A., Haddock, M. G., et.al. Results of irradiation or chemoirradiation for primary unresectable, locally recurrent, or grossly incomplete resection of gastric adenocarcinoma, Int J Radiat Oncol Biol Phys, 2000. 46(1): p. 109-18., https://www.ncbi.nlm.nih.gov/pubmed/10656381
621. Kim, E. R., Lee, H., Min, B. H., Lee, J. H., Rhee, P. L., Kim, J. J., et.al. Effect of rescue surgery after non-curative endoscopic resection of early gastric cancer, Br J Surg, 2015. 102(11): p. 1394-401., https://www.ncbi.nlm.nih.gov/pubmed/26313295
622. Bali, C., Ziogas, D., Fatouros, E., Fatouros, M., Is there a role for surgery in recurrent gastric cancer, Ann Surg Oncol, 2009. 16(4): p. 1074-5; author reply 1076., https://www.ncbi.nlm.nih.gov/pubmed/19184233
623. Badgwell, B., Cormier, J. N., Xing, Y., Yao, J., Bose, D., Krishnan, S., et.al. Attempted salvage resection for recurrent gastric or gastroesophageal cancer, Ann Surg Oncol, 2009. 16(1): p. 42-50., https://www.ncbi.nlm.nih.gov/pubmed/18985270
624. de Liano, A. D., Yarnoz, C., Aguilar, R., Artieda, C., Ortiz, H., Surgical treatment of recurrent gastric cancer, Gastric Cancer, 2008. 11(1): p. 10-4., https://www.ncbi.nlm.nih.gov/pubmed/18373172
625. Sjoquist, K. M., Burmeister, B. H., Smithers, B. M., Zalcberg, J. R., Simes, R. J., Barbour, A., et.al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis, Lancet Oncol, 2011. 12(7): p. 681-92., https://www.ncbi.nlm.nih.gov/pubmed/21684205
626. Gebski, V., Burmeister, B., Smithers, B. M., Foo, K., Zalcberg, J., Simes, J., et.al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis, Lancet Oncol, 2007. 8(3): p. 226-34., https://www.ncbi.nlm.nih.gov/pubmed/17329193
627. Kim, M. M., Mansfield, P. F., Das, P., Janjan, N. A., Badgwell, B. D., Phan, A. T., et.al. Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery, Int J Radiat Oncol Biol Phys, 2008. 71(1): p. 167-72., https://www.ncbi.nlm.nih.gov/pubmed/18406886
628. Zhang, Z. X., Gu, X. Z., Yin, W. B., Huang, G. J., Zhang, D. W., Zhang, R. G., Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)--report on 370 patients, Int J Radiat Oncol Biol Phys, 1998. 42(5): p. 929-34., https://www.ncbi.nlm.nih.gov/pubmed/9869212
629. Liu, Y., Zhao, G., Xu, Y., He, X., Li, X., Chen, H., et.al. Multicenter Phase 2 Study of Peri-Irradiation Chemotherapy Plus Intensity Modulated Radiation Therapy With Concurrent Weekly Docetaxel for Inoperable or Medically Unresectable Nonmetastatic Gastric Cancer, Int J Radiat Oncol Biol Phys, 2017. 98(5): p. 1096-1105., https://www.ncbi.nlm.nih.gov/pubmed/28721893
630. Porschen, R, Fischbach, W, Gockel, I, Hollerbach, S, Hölscher, A, Jansen, PL, et.al. S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus, Z Gastroenterol, 2023. 61 (6)(6): p. 701-745., https://pubmed.ncbi.nlm.nih.gov/37285870/
631. Buergy, D., Lohr, F., Baack, T., Siebenlist, K., Haneder, S., Michaely, H., et.al. Radiotherapy for tumors of the stomach and gastroesophageal junction--a review of its role in multimodal therapy, Radiat Oncol, 2012. 7: p. 192., https://www.ncbi.nlm.nih.gov/pubmed/23157945
632. Hawrylewicz, L., Leszczynski, W., Namysl-Kaletka, A., Bronclik, I., Wydmanski, J., Protection of organs at risk during neoadjuvant chemoradiotherapy for gastric cancer based on a comparison between conformal and intensity-modulated radiation therapy, Oncol Lett, 2016. 12(1): p. 692-698., https://www.ncbi.nlm.nih.gov/pubmed/27347202
633. Trip, A. K., Nijkamp, J., van Tinteren, H., Cats, A., Boot, H., Jansen, E. P., et.al. IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer, Radiother Oncol, 2014. 112(2): p. 289-94., https://www.ncbi.nlm.nih.gov/pubmed/25241995
634. Wu, A. J., Bosch, W. R., Chang, D. T., Hong, T. S., Jabbour, S. K., Kleinberg, L. R., et.al. Expert Consensus Contouring Guidelines for Intensity Modulated Radiation Therapy in Esophageal and Gastroesophageal Junction Cancer, Int J Radiat Oncol Biol Phys, 2015. 92(4): p. 911-20., https://www.ncbi.nlm.nih.gov/pubmed/26104943
635. Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J., Nicolson, M., et.al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer, N Engl J Med, 2006. 355(1): p. 11-20., https://www.ncbi.nlm.nih.gov/pubmed/16822992
636. Ychou, M., Boige, V., Pignon, J. P., Conroy, T., Bouche, O., Lebreton, G., et.al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial, J Clin Oncol, 2011. 29(13): p. 1715-21., https://www.ncbi.nlm.nih.gov/pubmed/21444866
637. Boige V, Pignon JP, Saint-Aubert JB, Lasser P, Conroy T, Bouché O, et al, Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus., J Clin Oncol, 2007. 2007;25:No. 18S.:, https://ascopubs.org/doi/10.1200/jco.2007.25.18_suppl.4510
638. Al-Batran, S. E., Hofheinz, R. D., Pauligk, C., Kopp, H. G., Haag, G. M., Luley, K. B., et.al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial, Lancet Oncol, 2016. 17(12): p. 1697-1708., https://www.ncbi.nlm.nih.gov/pubmed/27776843
639. Allum, W. H., Stenning, S. P., Bancewicz, J., Clark, P. I., Langley, R. E., Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer, J Clin Oncol, 2009. 27(30): p. 5062-7., https://www.ncbi.nlm.nih.gov/pubmed/19770374
640. Kelsen, D. P., Winter, K. A., Gunderson, L. L., Mortimer, J., Estes, N. C., Haller, D. G., et.al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer, J Clin Oncol, 2007. 25(24): p. 3719-25., https://www.ncbi.nlm.nih.gov/pubmed/17704421
641. Schuhmacher, C., Gretschel, S., Lordick, F., Reichardt, P., Hohenberger, W., Eisenberger, C. F., et.al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954, J Clin Oncol, 2010. 28(35): p. 5210-8., https://www.ncbi.nlm.nih.gov/pubmed/21060024
642. Kelsen, D. P., Ginsberg, R., Pajak, T. F., Sheahan, D. G., Gunderson, L., Mortimer, J., et.al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer, N Engl J Med, 1998. 339(27): p. 1979-84., https://www.ncbi.nlm.nih.gov/pubmed/9869669
643. Kang, Y. K., Kang, W. K., Shin, D. B., Chen, J., Xiong, J., Wang, J., et.al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial, Ann Oncol, 2009. 20(4): p. 666-73., https://www.ncbi.nlm.nih.gov/pubmed/19153121
644. Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., et.al. Capecitabine and oxaliplatin for advanced esophagogastric cancer, N Engl J Med, 2008. 358(1): p. 36-46., https://www.ncbi.nlm.nih.gov/pubmed/18172173
645. Okines, A. F., Norman, A. R., McCloud, P., Kang, Y. K., Cunningham, D., Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer, Ann Oncol, 2009. 20(9): p. 1529-34., https://www.ncbi.nlm.nih.gov/pubmed/19474114
646. Al-Batran, S. E., Hartmann, J. T., Probst, S., Schmalenberg, H., Hollerbach, S., Hofheinz, R., et.al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie, J Clin Oncol, 2008. 26(9): p. 1435-42., https://www.ncbi.nlm.nih.gov/pubmed/18349393
647. Schurr, P. G., Yekebas, E. F., Kaifi, J. T., Lasch, S., Strate, T., Kutup, A., et.al. Lymphatic spread and microinvolvement in adenocarcinoma of the esophago-gastric junction, J Surg Oncol, 2006. 94(4): p. 307-15., https://www.ncbi.nlm.nih.gov/pubmed/16917878
648. Thirion PG, Michiels S, Maitre L., Individual patients data-based meta-analysis assessing preoperative chemotherapy in resectable oesophageal carcinoma., J Clin Oncol, 2007. 25:, https://ascopubs.org/doi/abs/10.1200/jco.2007.25.18_suppl.4512
649. Crehange, G., Bonnetain, F., Chauffert, B., Rat, P., Bedenne, L., Maingon, P., [Resectable adenocarcinoma of the oesophagogastric junction care: which perioperative treatment?], Cancer Radiother, 2008. 12(5): p. 365-73., https://www.ncbi.nlm.nih.gov/pubmed/18420440
650. Walsh, T. N., Noonan, N., Hollywood, D., Kelly, A., Keeling, N., Hennessy, T. P., A comparison of multimodal therapy and surgery for esophageal adenocarcinoma, N Engl J Med, 1996. 335(7): p. 462-7., https://www.ncbi.nlm.nih.gov/pubmed/8672151
651. Urba, S. G., Orringer, M. B., Turrisi, A., Iannettoni, M., Forastiere, A., Strawderman, M., Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma, J Clin Oncol, 2001. 19(2): p. 305-13., https://www.ncbi.nlm.nih.gov/pubmed/11208820
652. Burmeister, B. H., Smithers, B. M., Gebski, V., Fitzgerald, L., Simes, R. J., Devitt, P., et.al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial, Lancet Oncol, 2005. 6(9): p. 659-68., https://www.ncbi.nlm.nih.gov/pubmed/16129366
653. Tepper, J., Krasna, M. J., Niedzwiecki, D., Hollis, D., Reed, C. E., Goldberg, R., et.al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781, J Clin Oncol, 2008. 26(7): p. 1086-92., https://www.ncbi.nlm.nih.gov/pubmed/18309943
654. Fiorica, F., Di Bona, D., Schepis, F., Licata, A., Shahied, L., Venturi, A., et.al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis, Gut, 2004. 53(7): p. 925-30., https://www.ncbi.nlm.nih.gov/pubmed/15194636
655. Geh, J. I., Bond, S. J., Bentzen, S. M., Glynne-Jones, R., Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response, Radiother Oncol, 2006. 78(3): p. 236-44., https://www.ncbi.nlm.nih.gov/pubmed/16545878
656. Malthaner, R. A., Wong, R. K., Rumble, R. B., Zuraw, L., Members of the Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based, Care, Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis, BMC Med, 2004. 2: p. 35., https://www.ncbi.nlm.nih.gov/pubmed/15447788
657. Urschel, J. D., Vasan, H., A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer, Am J Surg, 2003. 185(6): p. 538-43., https://www.ncbi.nlm.nih.gov/pubmed/12781882
658. M., Stuschke, Neoadjuvante Radiochemotherapie und Responseprädiktion., Der Onkologe, 2004. p. 1179-90.
659. Nygaard, K., Hagen, S., Hansen, H. S., Hatlevoll, R., Hultborn, R., Jakobsen, A., et.al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer, World J Surg, 1992. 16(6): p. 1104-9; discussion 1110., https://www.ncbi.nlm.nih.gov/pubmed/1455880
660. Bosset, J. F., Gignoux, M., Triboulet, J. P., Tiret, E., Mantion, G., Elias, D., et.al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus, N Engl J Med, 1997. 337(3): p. 161-7., https://www.ncbi.nlm.nih.gov/pubmed/9219702
661. Dahn, D., Martell, J., Vorwerk, H., Hess, C. F., Becker, H., Jung, K., et.al. Influence of irradiated lung volumes on perioperative morbidity and mortality in patients after neoadjuvant radiochemotherapy for esophageal cancer, Int J Radiat Oncol Biol Phys, 2010. 77(1): p. 44-52., https://www.ncbi.nlm.nih.gov/pubmed/19679407
662. Ronellenfitsch, U., Schwarzbach, M., Hofheinz, R., Kienle, P., Kieser, M., Slanger, T. E., et.al. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data, Eur J Cancer, 2013. 49(15): p. 3149-58., https://www.ncbi.nlm.nih.gov/pubmed/23800671
663. Fu, T., Bu, Z. D., Li, Z. Y., Zhang, L. H., Wu, X. J., Wu, A. W., et.al. Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials, BMC Cancer, 2015. 15: p. 322., https://www.ncbi.nlm.nih.gov/pubmed/25928286
664. Pasquali, S., Yim, G., Vohra, R. S., Mocellin, S., Nyanhongo, D., Marriott, P., et.al. Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis, Ann Surg, 2017. 265(3): p. 481-491., https://www.ncbi.nlm.nih.gov/pubmed/27429017
665. Wong, R., Malthaner, R., Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus, Cochrane Database Syst Rev, 2006. p. CD002092., https://www.ncbi.nlm.nih.gov/pubmed/16437440
666. Arnott, S. J., Duncan, W., Gignoux, M., Hansen, H. S., Launois, B., Nygaard, K., et.al. Preoperative radiotherapy for esophageal carcinoma, Cochrane Database Syst Rev, 2005. p. CD001799., https://www.ncbi.nlm.nih.gov/pubmed/16235286
667. van Hagen, P., Hulshof, M. C., van Lanschot, J. J., Steyerberg, E. W., van Berge Henegouwen, M. I., Wijnhoven, B. P., et.al. Preoperative chemoradiotherapy for esophageal or junctional cancer, N Engl J Med, 2012. 366(22): p. 2074-84., https://www.ncbi.nlm.nih.gov/pubmed/22646630
668. Shapiro, J., van Lanschot, J. J. B., Hulshof, Mccm, van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., et.al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial, Lancet Oncol, 2015. 16(9): p. 1090-1098., https://www.ncbi.nlm.nih.gov/pubmed/26254683
669. Oppedijk, V., van der Gaast, A., van Lanschot, J. J., van Hagen, P., van Os, R., van Rij, C. M., et.al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials, J Clin Oncol, 2014. 32(5): p. 385-91., https://www.ncbi.nlm.nih.gov/pubmed/24419108
670. Klevebro, F., Alexandersson von Dobeln, G., Wang, N., Johnsen, G., Jacobsen, A. B., Friesland, S., et.al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction, Ann Oncol, 2016. 27(4): p. 660-7., https://www.ncbi.nlm.nih.gov/pubmed/26782957
671. Stahl, M., Walz, M. K., Riera-Knorrenschild, J., Stuschke, M., Sandermann, A., Bitzer, M., et.al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial, Eur J Cancer, 2017. 81: p. 183-190., https://www.ncbi.nlm.nih.gov/pubmed/28628843
672. Kumagai, K., Rouvelas, I., Tsai, J. A., Mariosa, D., Lind, P. A., Lindblad, M., et.al. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis, Eur J Surg Oncol, 2015. 41(3): p. 282-94., https://www.ncbi.nlm.nih.gov/pubmed/25491892
673. Urschel, J. D., Vasan, H., Blewett, C. J., A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer, Am J Surg, 2002. 183(3): p. 274-9., https://www.ncbi.nlm.nih.gov/pubmed/11943125
674. Reynolds, JV, Preston, SR, O'Neill, B, Lowery, MA, Baeksgaard, L, Crosby, T, et.al. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial., Lancet Gastroenterol Hepatol, 2023. 8 (11)(11): p. 1015-1027., https://pubmed.ncbi.nlm.nih.gov/37734399/
675. Hoeppner, Jens, Brunner, Thomas, Lordick, Florian, Schmoor, Claudia, Kulemann, Birte, Neumann, Ulf Peter, et.al. Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial).Wolters Kluwer, Journal of Clinical Oncology, 2024. 42(17_suppl): p. LBA1 - LBA1., https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA1
676. Hoeppner, J, Brunner, T, Schmoor, C, Bronsert, P, Kulemann, B, Claus, R, et.al. Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer., N Engl J Med, 2025. 392 (4)(4): p. 323-335., https://pubmed.ncbi.nlm.nih.gov/39842010/
677. Kelly, RJ, Ajani, JA, Kuzdzal, J, Zander, T, Van Cutsem, E, Piessen, G, et.al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer., N Engl J Med, 2021. 384 (13)(13): p. 1191-1203., https://pubmed.ncbi.nlm.nih.gov/33789008/
678. Messager, M, Mirabel, X, Tresch, E, Paumier, A, Vendrely, V, Dahan, L, et.al. Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial., BMC Cancer, 2016. 16 (): p. 318., https://pubmed.ncbi.nlm.nih.gov/27194176/
679. Ohri, N., Garg, M. K., Aparo, S., Kaubisch, A., Tome, W., Kennedy, T. J., et.al. Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis, Int J Radiat Oncol Biol Phys, 2013. 86(2): p. 330-5., https://www.ncbi.nlm.nih.gov/pubmed/23523184
680. Newton, A. D., Datta, J., Loaiza-Bonilla, A., Karakousis, G. C., Roses, R. E., Neoadjuvant therapy for gastric cancer: current evidence and future directions, J Gastrointest Oncol, 2015. 6(5): p. 534-43., https://www.ncbi.nlm.nih.gov/pubmed/26487948
681. Ajani, J. A., Winter, K., Okawara, G. S., Donohue, J. H., Pisters, P. W., Crane, C. H., et.al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response, J Clin Oncol, 2006. 24(24): p. 3953-8., https://www.ncbi.nlm.nih.gov/pubmed/16921048
682. Safran, H., Wanebo, H. J., Hesketh, P. J., Akerman, P., Ianitti, D., Cioffi, W., et.al. Paclitaxel and concurrent radiation for gastric cancer, Int J Radiat Oncol Biol Phys, 2000. 46(4): p. 889-94., https://www.ncbi.nlm.nih.gov/pubmed/10705010
683. Lorenzen, S, Götze, TO, Thuss-Patience, P, Biebl, M, Homann, N, Schenk, M, et.al. Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial., J Clin Oncol, 2024. 42 (4)(4): p. 410-420., https://pubmed.ncbi.nlm.nih.gov/37963317/
684. Shitara, K, Rha, SY, Wyrwicz, LS, Oshima, T, Karaseva, N, Osipov, M, et.al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study., Lancet Oncol, 2024. 25 (2)(2): p. 212-224., https://pubmed.ncbi.nlm.nih.gov/38134948/
685. Janjigian, Y.Y., Al-Batran, S-E., Wainberg, Z.A., Van Cutsem, E., Molena, D., Muro, K., et.al. LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN studyElsevier, Annals of Oncology, 2023. 34: p. S1315 - S1316., https://doi.org/10.1016/j.annonc.2023.10.074
686. Wagner, Anna Dorothea, Grabsch, Heike I., Mauer, Murielle, Fumagalli Romario, Uberto, Kang, Yoon-Koo, Bouche, Olivier, et.al. Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive gastric (GC) and esophagogastric junction cancer (EGJC): First results of the EORTC 1203 INNOVATION study, in collaboration with the Korean Cancer Study Group, and the Dutch Upper GI Cancer group.Wolters Kluwer, Journal of Clinical Oncology, 2023. 41(16_suppl): p. 4057 - 4057., https://doi.org/10.1200/JCO.2023.41.16_suppl.4057
687. Smyth, EC, Nilsson, M, Grabsch, HI, van Grieken, NC, Lordick, F, Gastric cancer., Lancet, 2020. 396 (10251)(10251): p. 635-648., https://pubmed.ncbi.nlm.nih.gov/32861308/
688. Yoshikawa, T., Tanabe, K., Nishikawa, K., Ito, Y., Matsui, T., Kimura, Y., et.al. Accuracy of CT staging of locally advanced gastric cancer after neoadjuvant chemotherapy: cohort evaluation within a randomized phase II study, Ann Surg Oncol, 2014. 21 Suppl 3: p. S385-9., https://www.ncbi.nlm.nih.gov/pubmed/24595801
689. Heger, U., Bader, F., Lordick, F., Burian, M., Langer, R., Dobritz, M., et.al. Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis, Gastric Cancer, 2014. 17(3): p. 478-88., https://www.ncbi.nlm.nih.gov/pubmed/23996162
690. Park, S. R., Choi, I. J., Kim, C. G., Kim, Y. W., Ryu, K. W., Lee, J. H., et.al. Use of a combination of computed tomography and endoscopy to assess the response to 5-fluorouracil/cisplatin and predict survival in gastric cancer, J Gastroenterol, 2006. 41(4): p. 339-46., https://www.ncbi.nlm.nih.gov/pubmed/16741613
691. Guo, T., Yao, F., Yang, A. M., Li, X. Y., Zhong, D. R., Wu, D. S., et.al. Endoscopic ultrasound in restaging and predicting pathological response for advanced gastric cancer patients after neoadjuvant chemotherapy, Asia Pac J Clin Oncol, 2014. 10(2): p. e28-32., https://www.ncbi.nlm.nih.gov/pubmed/23279745
692. Park, S. R., Lee, J. S., Kim, C. G., Kim, H. K., Kook, M. C., Kim, Y. W., et.al. Endoscopic ultrasound and computed tomography in restaging and predicting prognosis after neoadjuvant chemotherapy in patients with locally advanced gastric cancer, Cancer, 2008. 112(11): p. 2368-76., https://www.ncbi.nlm.nih.gov/pubmed/18404697
693. Bohle, W., Zachmann, R., Zoller, W. G., Sequential endoscopic ultrasound identifies predictive variables for relapse-free follow-up after neoadjuvant chemotherapy in gastric cancer, Scand J Gastroenterol, 2017. 52(6-7): p. 754-761., https://www.ncbi.nlm.nih.gov/pubmed/28355948
694. Beer, A. J., Wieder, H. A., Lordick, F., Ott, K., Fischer, M., Becker, K., et.al. Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy, Radiology, 2006. 239(2): p. 472-80., https://www.ncbi.nlm.nih.gov/pubmed/16543584
695. Lee, S. M., Kim, S. H., Lee, J. M., Im, S. A., Bang, Y. J., Kim, W. H., et.al. Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer, Abdom Imaging, 2009. 34(4): p. 430-40., https://www.ncbi.nlm.nih.gov/pubmed/18546037
696. Park, S. R., Kim, M. J., Ryu, K. W., Lee, J. H., Lee, J. S., Nam, B. H., et.al. Prognostic value of preoperative clinical staging assessed by computed tomography in resectable gastric cancer patients: a viewpoint in the era of preoperative treatment, Ann Surg, 2010. 251(3): p. 428-35., https://www.ncbi.nlm.nih.gov/pubmed/20179530
697. Park, S., Ha, S., Kwon, H. W., Kim, W. H., Kim, T. Y., Oh, D. Y., et.al. Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication, J Nucl Med, 2017. 58(6): p. 899-904., https://www.ncbi.nlm.nih.gov/pubmed/28572288
698. Mesenas, S., Vu, C., McStay, M., Forshaw, M., Doig, L., Mason, R., et.al. A large series, resection controlled study to assess the value of radial EUS in restaging gastroesophageal cancer following neoadjuvant chemotherapy, Dis Esophagus, 2008. 21(1): p. 37-42., https://www.ncbi.nlm.nih.gov/pubmed/18197937
699. Patel, P. R., Mansfield, P. F., Crane, C. H., Wu, T. T., Lee, J. H., Lynch, P. M., et.al. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer, Cancer, 2007. 110(5): p. 989-95., https://www.ncbi.nlm.nih.gov/pubmed/17636525
700. Wang, Z. C., Wang, C., Ding, Y., Ji, Y., Zeng, M. S., Rao, S. X., CT volumetry can potentially predict the local stage for gastric cancer after chemotherapy, Diagn Interv Radiol, 2017. 23(4): p. 257-262., https://www.ncbi.nlm.nih.gov/pubmed/28703101
701. Japanese Gastric Cancer, Association, Japanese classification of gastric carcinoma: 3rd English edition, Gastric Cancer, 2011. 14(2): p. 101-12., https://www.ncbi.nlm.nih.gov/pubmed/21573743
702. Nakatani, K., Koizumi, W., Higuchi, K., Katada, C., Sasaki, T., Nakayama, N., et.al. Clinical significance of evaluating primary lesions in patients with gastric cancer who receive chemotherapy, Gastric Cancer, 2010. 13(1): p. 36-42., https://www.ncbi.nlm.nih.gov/pubmed/20373074
703. Tahara, T., Shibata, T., Okubo, M., Kawamura, T., Horiguchi, N., Yoshida, D., et.al. Evaluations of primary lesions by endoscopy clearly distinguishes prognosis in patients with gastric cancer who receive chemotherapy, PLoS One, 2017. 12(3): p. e0173663., https://www.ncbi.nlm.nih.gov/pubmed/28288188
704. Weber, W. A., Ott, K., Becker, K., Dittler, H. J., Helmberger, H., Avril, N. E., et.al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging, J Clin Oncol, 2001. 19(12): p. 3058-65., https://www.ncbi.nlm.nih.gov/pubmed/11408502
705. Ott, K., Fink, U., Becker, K., Stahl, A., Dittler, H. J., Busch, R., et.al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial, J Clin Oncol, 2003. 21(24): p. 4604-10., https://www.ncbi.nlm.nih.gov/pubmed/14673049
706. Lordick, F., Ott, K., Krause, B. J., Weber, W. A., Becker, K., Stein, H. J., et.al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial, Lancet Oncol, 2007. 8(9): p. 797-805., https://www.ncbi.nlm.nih.gov/pubmed/17693134
707. Ott, K., Herrmann, K., Lordick, F., Wieder, H., Weber, W. A., Becker, K., et.al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study, Clin Cancer Res, 2008. 14(7): p. 2012-8., https://www.ncbi.nlm.nih.gov/pubmed/18381939
708. Vallbohmer, D., Holscher, A. H., Schneider, P. M., Schmidt, M., Dietlein, M., Bollschweiler, E., et.al. [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer, J Surg Oncol, 2010. 102(2): p. 135-40., https://www.ncbi.nlm.nih.gov/pubmed/20648583
709. Ott, K., Herrmann, K., Schuster, T., Langer, R., Becker, K., Wieder, H. A., et.al. Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer, Ann Surg Oncol, 2011. 18(12): p. 3316-23., https://www.ncbi.nlm.nih.gov/pubmed/21537865
710. Manoharan, V., Lee, S., Chong, S., Yap, J., Coupe, N., Wilson, R., et.al. Serial imaging using [18F]Fluorodeoxyglucose positron emission tomography and histopathologic assessment in predicting survival in a population of surgically resectable distal oesophageal and gastric adenocarcinoma following neoadjuvant therapy, Ann Nucl Med, 2017. 31(4): p. 315-323., https://www.ncbi.nlm.nih.gov/pubmed/28299585
711. Lundsgaard Hansen, M., Fallentin, E., Lauridsen, C., Law, I., Federspiel, B., Baeksgaard, L., et.al. Computed tomography (CT) perfusion as an early predictive marker for treatment response to neoadjuvant chemotherapy in gastroesophageal junction cancer and gastric cancer--a prospective study, PLoS One, 2014. 9(5): p. e97605., https://www.ncbi.nlm.nih.gov/pubmed/24845062
712. Sun, Z. Q., Yan, G., Ge, Y. X., Li, J., Jin, L. F., Xie, Z. H., et.al. Can low-dose CT perfusion imaging accurately assess response of advanced gastric cancer with neoadjuvant chemotherapy?, J Xray Sci Technol, 2017., https://www.ncbi.nlm.nih.gov/pubmed/28697579
713. Ang, J., Hu, L., Huang, P. T., Wu, J. X., Huang, L. N., Cao, C. H., et.al. Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy, World J Gastroenterol, 2012. 18(47): p. 7026-32., https://www.ncbi.nlm.nih.gov/pubmed/23323004
714. Matsui, S., Kudo, M., Kitano, M., Asakuma, Y., Evaluation of the Response to Chemotherapy in Advanced Gastric Cancer by Contrast-Enhanced Harmonic EUS, Hepatogastroenterology, 2015. 62(139): p. 595-8., https://www.ncbi.nlm.nih.gov/pubmed/26897935
715. Becker, K., Reim, D., Novotny, A., Zum Buschenfelde, C. M., Engel, J., Friess, H., et.al. Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery, Ann Surg, 2012. 256(6): p. 1002-7., https://www.ncbi.nlm.nih.gov/pubmed/22968067
716. Ott, K., Blank, S., Becker, K., Langer, R., Weichert, W., Roth, W., et.al. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor, Langenbecks Arch Surg, 2013. 398(2): p. 239-49., https://www.ncbi.nlm.nih.gov/pubmed/23269519
717. Schmidt, T., Sicic, L., Blank, S., Becker, K., Weichert, W., Bruckner, T., et.al. Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas, Br J Cancer, 2014. 110(7): p. 1712-20., https://www.ncbi.nlm.nih.gov/pubmed/24569472
718. Koh, Y. W., Park, Y. S., Ryu, M. H., Ryoo, B. Y., Park, H. J., Yook, J. H., et.al. Postoperative nodal status and diffuse-type histology are independent prognostic factors in resectable advanced gastric carcinomas after preoperative chemotherapy, Am J Surg Pathol, 2013. 37(7): p. 1022-9., https://www.ncbi.nlm.nih.gov/pubmed/23715160
719. Becker, K., Mueller, J. D., Schulmacher, C., Ott, K., Fink, U., Busch, R., et.al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy, Cancer, 2003. 98(7): p. 1521-30., https://www.ncbi.nlm.nih.gov/pubmed/14508841
720. Tischoff, I., Tannapfel, A., [Regression grading in gastrointestinal tumors], Pathologe, 2012. 33(1): p. 53-60., https://www.ncbi.nlm.nih.gov/pubmed/22293790
721. Ruschoff, J., Dietel, M., Baretton, G., Arbogast, S., Walch, A., Monges, G., et.al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing, Virchows Arch, 2010. 457(3): p. 299-307., https://www.ncbi.nlm.nih.gov/pubmed/20665045
722. Bang, Y. J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., et.al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 2010. 376(9742): p. 687-97., https://www.ncbi.nlm.nih.gov/pubmed/20728210
723. D'Ugo, D., Persiani, R., Rausei, S., Biondi, A., Vigorita, V., Boccia, S., et.al. Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer, Eur J Surg Oncol, 2006. 32(10): p. 1105-9., https://www.ncbi.nlm.nih.gov/pubmed/16930932
724. Scartozzi, M., Galizia, E., Freddari, F., Berardi, R., Cellerino, R., Cascinu, S., Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches, Cancer Treat Rev, 2004. 30(5): p. 451-9., https://www.ncbi.nlm.nih.gov/pubmed/15245777
725. Nitti, D., Mocellin, S., Marchet, A., Pilati, P., Lise, M., Recent advances in conventional and molecular prognostic factors for gastric carcinoma, Surg Oncol Clin N Am, 2008. 17(3): p. 467-83, vii., https://www.ncbi.nlm.nih.gov/pubmed/18486878
726. Spoerl, S., Novotny, A., Al-Batran, S. E., Lordick, F., Thuss-Patience, P., Pauligk, C., et.al. Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma, Eur J Cancer, 2017. 90: p. 26-33., https://www.ncbi.nlm.nih.gov/pubmed/29272782
727. Lorenzen, S., Thuss-Patience, P., Al-Batran, S. E., Lordick, F., Haller, B., Schuster, T., et.al. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy, Ann Oncol, 2013. 24(8): p. 2068-73., https://www.ncbi.nlm.nih.gov/pubmed/23592699
728. Smyth, E. C., Fassan, M., Cunningham, D., Allum, W. H., Okines, A. F., Lampis, A., et.al. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial, J Clin Oncol, 2016. 34(23): p. 2721-7., https://www.ncbi.nlm.nih.gov/pubmed/27298411
729. Cunningham, D., Stenning, S. P., Smyth, E. C., Okines, A. F., Allum, W. H., Rowley, S., et.al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial, Lancet Oncol, 2017. 18(3): p. 357-370., https://www.ncbi.nlm.nih.gov/pubmed/28163000
730. Stahl, M., Walz, M. K., Stuschke, M., Lehmann, N., Meyer, H. J., Riera-Knorrenschild, J., et.al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction, J Clin Oncol, 2009. 27(6): p. 851-6., https://www.ncbi.nlm.nih.gov/pubmed/19139439
731. Becker, K., Mueller, J., Fink, U., Busch, R., Siewert, J. R., Hofler, H., [Morphologic response evaluation of neoadjuvant chemotherapy of gastric carcinoma], Verh Dtsch Ges Pathol, 2000. 84: p. 164-74., https://www.ncbi.nlm.nih.gov/pubmed/11217437
732. Ryan, R., Gibbons, D., Hyland, J. M., Treanor, D., White, A., Mulcahy, H. E., et.al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer, Histopathology, 2005. 47(2): p. 141-6., https://www.ncbi.nlm.nih.gov/pubmed/16045774
733. Kim, S. H., Chang, H. J., Kim, D. Y., Park, J. W., Baek, J. Y., Kim, S. Y., et.al. What Is the Ideal Tumor Regression Grading System in Rectal Cancer Patients after Preoperative Chemoradiotherapy?, Cancer Res Treat, 2016. 48(3): p. 998-1009., https://www.ncbi.nlm.nih.gov/pubmed/26511803
734. Moertel, C. G., Childs, D. S., O'Fallon, J. R., Holbrook, M. A., Schutt, A. J., Reitemeier, R. J., Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma, J Clin Oncol, 1984. 2(11): p. 1249-54., https://www.ncbi.nlm.nih.gov/pubmed/6491703
735. Macdonald, J. S., Smalley, S. R., Benedetti, J., Hundahl, S. A., Estes, N. C., Stemmermann, G. N., et.al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction, N Engl J Med, 2001. 345(10): p. 725-30., https://www.ncbi.nlm.nih.gov/pubmed/11547741
736. Smalley, S. R., Benedetti, J. K., Haller, D. G., Hundahl, S. A., Estes, N. C., Ajani, J. A., et.al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection, J Clin Oncol, 2012. 30(19): p. 2327-33., https://www.ncbi.nlm.nih.gov/pubmed/22585691
737. MacDonald JS, Smally S, Benedetti J., Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction, ASCO, 2004.
738. Kim, S., Lim, D. H., Lee, J., Kang, W. K., MacDonald, J. S., Park, C. H., et.al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach, Int J Radiat Oncol Biol Phys, 2005. 63(5): p. 1279-85., https://www.ncbi.nlm.nih.gov/pubmed/16099596
739. Kollmannsberger, C., Budach, W., Stahl, M., Schleucher, N., Hehr, T., Wilke, H., et.al. Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO, Ann Oncol, 2005. 16(8): p. 1326-33., https://www.ncbi.nlm.nih.gov/pubmed/15919686
740. Soon, Y. Y., Leong, C. N., Tey, J. C., Tham, I. W., Lu, J. J., Postoperative chemo-radiotherapy versus chemotherapy for resected gastric cancer: a systematic review and meta-analysis, J Med Imaging Radiat Oncol, 2014. 58(4): p. 483-96., https://www.ncbi.nlm.nih.gov/pubmed/24995607
741. Park, S. H., Sohn, T. S., Lee, J., Lim, D. H., Hong, M. E., Kim, K. M., et.al. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses, J Clin Oncol, 2015. 33(28): p. 3130-6., https://www.ncbi.nlm.nih.gov/pubmed/25559811
742. Cats, A., Jansen, E. P. M., van Grieken, N. C. T., Sikorska, K., Lind, P., Nordsmark, M., et.al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial, Lancet Oncol, 2018., https://www.ncbi.nlm.nih.gov/pubmed/29650363
743. Matzinger, O., Gerber, E., Bernstein, Z., Maingon, P., Haustermans, K., Bosset, J. F., et.al. EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach, Radiother Oncol, 2009. 92(2): p. 164-75., https://www.ncbi.nlm.nih.gov/pubmed/19375186
744. Boda-Heggemann, J., Weiss, C., Schneider, V., Hofheinz, R. D., Haneder, S., Michaely, H., et.al. Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer, Strahlenther Onkol, 2013. 189(5): p. 417-23., https://www.ncbi.nlm.nih.gov/pubmed/23558673
745. Van Cutsem E, Dicato M, Arber N, Benson A, Cunningham D, Diaz-Rubio E, et al., The neoadjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005., Ann Oncol, 2006. Jun 17(Suppl 6): p. vi13-18., https://pubmed.ncbi.nlm.nih.gov/16809641/
746. Oechsle, K., Bokemeyer, C., Hartmann, J. T., Budach, W., Trarbach, T., Stahl, M., et.al. Four consecutive multicenter phase II trials of adjuvant chemoradiation in patients with completely resected high-risk gastric cancer: the experience of the German AIO/ARO/CAO group, J Cancer Res Clin Oncol, 2009. 135(2): p. 163-72., https://www.ncbi.nlm.nih.gov/pubmed/18825411
747. Welz, S., Hehr, T., Kollmannsberger, C., Bokemeyer, C., Belka, C., Budach, W., Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer, Int J Radiat Oncol Biol Phys, 2007. 69(5): p. 1429-35., https://www.ncbi.nlm.nih.gov/pubmed/17692474
748. Wagner, A. D., Unverzagt, S., Grothe, W., Kleber, G., Grothey, A., Haerting, J., et.al. Chemotherapy for advanced gastric cancer, Cochrane Database Syst Rev, 2010. 3: p. CD004064., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20238327
749. Glimelius, B., Ekstrom, K., Hoffman, K., Graf, W., Sjoden, P. O., Haglund, U., et.al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer, Ann Oncol, 1997. 8(2): p. 163-8., https://www.ncbi.nlm.nih.gov/pubmed/9093725
750. Murad, A. M., Santiago, F. F., Petroianu, A., Rocha, P. R., Rodrigues, M. A., Rausch, M., Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer, Cancer, 1993. 72(1): p. 37-41., https://www.ncbi.nlm.nih.gov/pubmed/8508427
751. Wagner, A. D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., Fleig, W. E., Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data, J Clin Oncol, 2006. 24(18): p. 2903-9., https://www.ncbi.nlm.nih.gov/pubmed/16782930
752. Findlay, M., Cunningham, D., Norman, A., Mansi, J., Nicolson, M., Hickish, T., et.al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF), Ann Oncol, 1994. 5(7): p. 609-16., https://www.ncbi.nlm.nih.gov/pubmed/7993836
753. Kim, R., Nishimoto, N., Inoue, H., Yoshida, K., Toge, T., An analysis of the therapeutic efficacy of protracted infusion of low-dose 5-fluorouracil and cisplatin in advanced gastric cancer, J Infect Chemother, 2000. 6(4): p. 222-8., https://www.ncbi.nlm.nih.gov/pubmed/11810570
754. Al-Batran, S. E., Ajani, J. A., Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer, Cancer, 2010. 116(11): p. 2511-8., https://www.ncbi.nlm.nih.gov/pubmed/20301114
755. Lee, J. L., Kang, Y. K., Kang, H. J., Lee, K. H., Zang, D. Y., Ryoo, B. Y., et.al. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer, Br J Cancer, 2008. 99(4): p. 584-90., https://www.ncbi.nlm.nih.gov/pubmed/18665164
756. Koizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., et.al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial, Lancet Oncol, 2008. 9(3): p. 215-21., https://www.ncbi.nlm.nih.gov/pubmed/18282805
757. Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B. C., et.al. Chemotherapy for advanced gastric cancer, Cochrane Database Syst Rev, 2017. 8: p. CD004064., https://www.ncbi.nlm.nih.gov/pubmed/28850174
758. Thuss-Patience, P. C., Kretzschmar, A., Bichev, D., Deist, T., Hinke, A., Breithaupt, K., et.al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO), Eur J Cancer, 2011. 47(15): p. 2306-14., https://www.ncbi.nlm.nih.gov/pubmed/21742485
759. Janowitz, T., Thuss-Patience, P., Marshall, A., Kang, J. H., Connell, C., Cook, N., et.al. Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data, Br J Cancer, 2016. 114(4): p. 381-7., https://www.ncbi.nlm.nih.gov/pubmed/26882063
760. Groene, O., Crosby, T., Hardwick, R. H., Riley, S., Greenaway, K., Cromwell, D., A population-based observational study on the factors associated with the completion of palliative chemotherapy among patients with oesophagogastric cancer, BMJ Open, 2015. 5(3): p. e006724., https://www.ncbi.nlm.nih.gov/pubmed/25740023
761. Robert-Koch-Institut, Krebs in Deutschland, 2008., http://infomed.mds-ev.de/sindbad.nsf/f79a8096ad98496fc12571e700442be0/9aaf657d5981d884c12573f80063fe33?OpenDocument
762. Lawton, M. P., Brody, E. M., Assessment of older people: self-maintaining and instrumental activities of daily living, Gerontologist, 1969. 9(3): p. 179-86., https://www.ncbi.nlm.nih.gov/pubmed/5349366
763. Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., et.al. Development and validation of a geriatric depression screening scale: a preliminary report, J Psychiatr Res, 1982. 17(1): p. 37-49., https://www.ncbi.nlm.nih.gov/pubmed/7183759
764. Watson, Y. I., Arfken, C. L., Birge, S. J., Clock completion: an objective screening test for dementia, J Am Geriatr Soc, 1993. 41(11): p. 1235-40., https://www.ncbi.nlm.nih.gov/pubmed/8227899
765. Folstein, M. F., Folstein, S. E., McHugh, P. R., "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, 1975. 12(3): p. 189-98., https://www.ncbi.nlm.nih.gov/pubmed/1202204
766. Kalbe, E., Kessler, J., Calabrese, P., Smith, R., Passmore, A. P., Brand, M., et.al. DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia, Int J Geriatr Psychiatry, 2004. 19(2): p. 136-43., https://www.ncbi.nlm.nih.gov/pubmed/14758579
767. Cohendy, R., Rubenstein, L. Z., Eledjam, J. J., The Mini Nutritional Assessment-Short Form for preoperative nutritional evaluation of elderly patients, Aging (Milano), 2001. 13(4): p. 293-7., https://www.ncbi.nlm.nih.gov/pubmed/11695498
768. Tinetti, M. E., Performance-oriented assessment of mobility problems in elderly patients, J Am Geriatr Soc, 1986. 34(2): p. 119-26., https://www.ncbi.nlm.nih.gov/pubmed/3944402
769. Podsiadlo, D., Richardson, S., The timed "Up & Go": a test of basic functional mobility for frail elderly persons, J Am Geriatr Soc, 1991. 39(2): p. 142-8., https://www.ncbi.nlm.nih.gov/pubmed/1991946
770. Nikolaus, T., Specht-Leible, N., Bach, M., Oster, P., Schlierf, G., [Social aspects in diagnosis and therapy of very elderly patients. Initial experiences with a newly developed questionnaire within the scope of geriatric assessment], Z Gerontol, 1994. 27(4): p. 240-5., https://www.ncbi.nlm.nih.gov/pubmed/7975814
771. Sommer, G., Fydrich, T., Unterstützung: Diagnostik, Konzepte, F-SOZUDeutsche Gesellschaft für Verhaltenstherapie, 1989.
772. Mahoney, F. I., Barthel, D. W., Functional Evaluation: The Barthel Index, Md State Med J, 1965. 14: p. 61-5., https://www.ncbi.nlm.nih.gov/pubmed/14258950
773. Lee, K. W., Lee, J. H., Kim, J. W., Kim, J. W., Ahn, S., Kim, J. H., Population-based outcomes research on treatment patterns and impact of chemotherapy in older patients with metastatic gastric cancer, J Cancer Res Clin Oncol, 2016. 142(3): p. 687-97., https://www.ncbi.nlm.nih.gov/pubmed/26567125
774. Kripp, M., Al-Batran, S. E., Rosowski, J., Pauligk, C., Homann, N., Hartmann, J. T., et.al. Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO), Gastric Cancer, 2014. 17(1): p. 181-7., https://www.ncbi.nlm.nih.gov/pubmed/23455717
775. Mahoney, F.I., Barthel, D.W., Functional evaluation, Md Med J, 1965. 14: p. 61-65., https://pubmed.ncbi.nlm.nih.gov/14258950/
776. Al-Batran, S. E., Hartmann, J. T., Hofheinz, R., Homann, N., Rethwisch, V., Probst, S., et.al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie, Ann Oncol, 2008. 19(11): p. 1882-7., https://www.ncbi.nlm.nih.gov/pubmed/18669868
777. Van Cutsem, E., Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in firstline human epidermal growth factor receptor 2 (HER2) - positive advances gastric cancer (GC), Gastric Cancer, 2009. p. 29.
778. Dank, M., Zaluski, J., Barone, C., Valvere, V., Yalcin, S., Peschel, C., et.al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction, Ann Oncol, 2008. 19(8): p. 1450-7., https://www.ncbi.nlm.nih.gov/pubmed/18558665
779. Lutz, M. P., Wilke, H., Wagener, D. J., Vanhoefer, U., Jeziorski, K., Hegewisch-Becker, S., et.al. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie, J Clin Oncol, 2007. 25(18): p. 2580-5., https://www.ncbi.nlm.nih.gov/pubmed/17577037
780. Ochenduszko, S., Puskulluoglu, M., Konopka, K., Fijorek, K., Urbanczyk, K., Budzynski, A., et.al. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial, Med Oncol, 2015. 32(10): p. 242., https://www.ncbi.nlm.nih.gov/pubmed/26354521
781. Satoh, T., Bang, Y. J., Gotovkin, E. A., Hamamoto, Y., Kang, Y. K., Moiseyenko, V. M., et.al. Quality of life in the trastuzumab for gastric cancer trial, Oncologist, 2014. 19(7): p. 712-9., https://www.ncbi.nlm.nih.gov/pubmed/24951609
782. Gubanski, M., Glimelius, B., Lind, P. A., Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin), Med Oncol, 2014. 31(4): p. 906., https://www.ncbi.nlm.nih.gov/pubmed/24627237
783. Shitara, K, Lordick, F, Bang, YJ, Enzinger, P, Ilson, D, Shah, MA, et.al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial., Lancet, 2023. 401 (10389)(10389): p. 1655-1668., https://pubmed.ncbi.nlm.nih.gov/37068504/
784. Shah, MA, Shitara, K, Ajani, JA, Bang, YJ, Enzinger, P, Ilson, D, et.al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial., Nat Med, 2023. 29 (8)(8): p. 2133-2141., https://pubmed.ncbi.nlm.nih.gov/37524953/
785. Lordick, F., Al-Batran, S. E., Dietel, M., Gaiser, T., Hofheinz, R. D., Kirchner, T., et.al. HER2 testing in gastric cancer: results of a German expert meeting, J Cancer Res Clin Oncol, 2017. 143(5): p. 835-841., https://www.ncbi.nlm.nih.gov/pubmed/28285403
786. Qiu, MZ, Oh, DY, Kato, K, Arkenau, T, Tabernero, J, Correa, MC, et.al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial., BMJ, 2024. 385 (): p. e078876., https://pubmed.ncbi.nlm.nih.gov/38806195/
787. Liu, C, Fang, F, Kong, Y, ElGabry, EA, Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring., Diagn Pathol, 2023. 18 (1)(1): p. 48., https://pubmed.ncbi.nlm.nih.gov/37076889/
788. Moehler, M, Oh, DY, Kato, K, Arkenau, T, Tabernero, J, Lee, KW, et.al. First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305., Adv Ther, 2025. ():, https://pubmed.ncbi.nlm.nih.gov/40075025/
789. Bermúdez, A, Arranz-Salas, I, Mercado, S, López-Villodres, JA, González, V, Ríus, F, et.al. Her2-Positive and Microsatellite Instability Status in Gastric Cancer-Clinicopathological Implications., Diagnostics (Basel), 2021. 11 (6)(6):, https://pubmed.ncbi.nlm.nih.gov/34070574/
790. Le, DT, Durham, JN, Smith, KN, Wang, H, Bartlett, BR, Aulakh, LK, et.al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade., Science, 2017. 357 (6349)(6349): p. 409-413., https://pubmed.ncbi.nlm.nih.gov/28596308/
791. Shitara, K, Van Cutsem, E, Bang, YJ, Fuchs, C, Wyrwicz, L, Lee, KW, et.al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial., JAMA Oncol, 2020. 6 (10)(10): p. 1571-1580., https://pubmed.ncbi.nlm.nih.gov/32880601/
792. Janjigian, YY, Ajani, JA, Moehler, M, Shen, L, Garrido, M, Gallardo, C, et.al. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial., J Clin Oncol, 2024. 42 (17)(17): p. 2012-2020., https://pubmed.ncbi.nlm.nih.gov/38382001/
793. Rueschoff, J., HER diagnostics in gastric gancer - Guideline validation and development of standardtized immunohistochemical testing., 2010., https://www.ncbi.nlm.nih.gov/pubmed/20665045
794. DGP, Qualitätssicherungsmaßnahmen - Übersicht laufende Ringversuche, 2010.
795. Wagner, A. D., Moehler, M., Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era, Curr Opin Oncol, 2009. 21(4): p. 381-5., https://www.ncbi.nlm.nih.gov/pubmed/19412098
796. Bouche, O., Raoul, J. L., Bonnetain, F., Giovannini, M., Etienne, P. L., Lledo, G., et.al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803, J Clin Oncol, 2004. 22(21): p. 4319-28., https://www.ncbi.nlm.nih.gov/pubmed/15514373
797. Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., et.al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group, J Clin Oncol, 2006. 24(31): p. 4991-7., https://www.ncbi.nlm.nih.gov/pubmed/17075117
798. Roth, A. D., Fazio, N., Stupp, R., Falk, S., Bernhard, J., Saletti, P., et.al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research, J Clin Oncol, 2007. 25(22): p. 3217-23., https://www.ncbi.nlm.nih.gov/pubmed/17664469
799. Guimbaud, R., Louvet, C., Ries, P., Ychou, M., Maillard, E., Andre, T., et.al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study, J Clin Oncol, 2014. 32(31): p. 3520-6., https://www.ncbi.nlm.nih.gov/pubmed/25287828
800. Petrelli, F., Zaniboni, A., Coinu, A., Cabiddu, M., Ghilardi, M., Sgroi, G., et.al. Cisplatin or not in advanced gastric cancer: a systematic review and meta-analysis, PLoS One, 2013. 8(12): p. e83022., https://www.ncbi.nlm.nih.gov/pubmed/24386137
801. Al-Batran, S. E., Pauligk, C., Homann, N., Hartmann, J. T., Moehler, M., Probst, S., et.al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+), Eur J Cancer, 2013. 49(4): p. 835-42., https://www.ncbi.nlm.nih.gov/pubmed/23063354
802. Shah, M. A., Janjigian, Y. Y., Stoller, R., Shibata, S., Kemeny, M., Krishnamurthi, S., et.al. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium, J Clin Oncol, 2015. 33(33): p. 3874-9., https://www.ncbi.nlm.nih.gov/pubmed/26438119
803. Wang, J., Xu, R., Li, J., Bai, Y., Liu, T., Jiao, S., et.al. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer, Gastric Cancer, 2016. 19(1): p. 234-44., https://www.ncbi.nlm.nih.gov/pubmed/25604851
804. Zaanan, A., Bouche, O., de la Fouchardiere, C., Samalin-Scalzi, E., Le Malicot, K., Pernot, S., et.al. LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCDElsevier, Annals of Oncology, 2023. 34: p. S1318., https://doi.org/10.1016/j.annonc.2023.10.078
805. Yamada, Y, Boku, N, Mizusawa, J, Iwasa, S, Kadowaki, S, Nakayama, N, et.al. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial., Lancet Gastroenterol Hepatol, 2019. 4 (7)(7): p. 501-510., https://pubmed.ncbi.nlm.nih.gov/31101534/
806. Lorenzen, S, Hentrich, M, Haberl, C, Heinemann, V, Schuster, T, Seroneit, T, et.al. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial., Ann Oncol, 2007. 18 (10)(10): p. 1673-9., https://pubmed.ncbi.nlm.nih.gov/17660494/
807. Zaanan, A., Bouché, Olivier, De la Fouchardière, Christelle, Samalin-Scalzi, E., Le Malicot, Karine, Pernot, Simon, et.al. LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD, 2023/10/01. 34: p. S1318.
808. Trumper, M., Ross, P.J., Cunningham, D., Norman, A.R., Hawkins, R., Seymour, M., et.al. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials, Eur J Cancer, 2006. p. 827-34., https://www.ncbi.nlm.nih.gov/pubmed/16466913
809. Liu, G., Franssen, E., Fitch, M. I., Warner, E., Patient preferences for oral versus intravenous palliative chemotherapy, J Clin Oncol, 1997. 15(1): p. 110-5., https://www.ncbi.nlm.nih.gov/pubmed/8996131
810. Ajani, J. A., Rodriguez, W., Bodoky, G., Moiseyenko, V., Lichinitser, M., Gorbunova, V., et.al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial, J Clin Oncol, 2010. 28(9): p. 1547-53., https://www.ncbi.nlm.nih.gov/pubmed/20159816
811. Bang, Y., Pathological features of advanced gastric cancer (GC): Reletationship to human epidermal growth factor receptor 2 (HER2) positivy in the global screening programme of the ToGA trial., J Clin Oncol, 2009. 27:, https://ascopubs.org/doi/10.1200/jco.2009.27.15_suppl.4556
812. Kang, J. H., Lee, S. I., Lim, D. H., Park, K. W., Oh, S. Y., Kwon, H. C., et.al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone, J Clin Oncol, 2012. 30(13): p. 1513-8., https://www.ncbi.nlm.nih.gov/pubmed/22412140
813. Al-Batran, S., Kroening, H., Hannig, C.V., Hamm, T., Moorahrend, E., Petersen, V., et.al. Trastuzumab in Combination with Different First-Line Chemotherapies for Treatment of Her2-Positive Metastatic Gastric Cancer: Updated Findings from the German Non-Interventional Study HermesElsevier, Annals of Oncology, 2014. 25: p. iv220., https://doi.org/10.1093/annonc/mdu334.27
814. Janjigian, YY, Kawazoe, A, Bai, Y, Xu, J, Lonardi, S, Metges, JP, et.al. Pembrolizumab in HER2-Positive Gastric Cancer., N Engl J Med, 2024. 391 (14)(14): p. 1360-1362., https://pubmed.ncbi.nlm.nih.gov/39282917/
815. Leone, AG, Mai, AS, Fong, KY, Yap, DWT, Kato, K, Smyth, E, et.al. Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups., ESMO Open, 2024. 9 (11)(11): p. 103962., https://pubmed.ncbi.nlm.nih.gov/39426081/
816. Shitara, K, Shah, MA, Lordick, F, Van Cutsem, E, Ilson, DH, Klempner, SJ, et.al. Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma., N Engl J Med, 2024. 391 (12)(12): p. 1159-1162., https://pubmed.ncbi.nlm.nih.gov/39282934/
817. Ford, H. E., Marshall, A., Bridgewater, J. A., Janowitz, T., Coxon, F. Y., Wadsley, J., et.al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial, Lancet Oncol, 2014. 15(1): p. 78-86., https://www.ncbi.nlm.nih.gov/pubmed/24332238
818. Hironaka, S., Ueda, S., Yasui, H., Nishina, T., Tsuda, M., Tsumura, T., et.al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial, J Clin Oncol, 2013. 31(35): p. 4438-44., https://www.ncbi.nlm.nih.gov/pubmed/24190112
819. Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., et.al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial, Lancet, 2014. 383(9911): p. 31-39., https://www.ncbi.nlm.nih.gov/pubmed/24094768
820. Wilke, H., Muro, K., Van Cutsem, E., Oh, S. C., Bodoky, G., Shimada, Y., et.al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial, Lancet Oncol, 2014. 15(11): p. 1224-35., https://www.ncbi.nlm.nih.gov/pubmed/25240821
821. Kang, Y. K., Boku, N., Satoh, T., Ryu, M. H., Chao, Y., Kato, K., et.al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 2017. 390(10111): p. 2461-2471., https://www.ncbi.nlm.nih.gov/pubmed/28993052
822. Shitara, K, Bang, YJ, Iwasa, S, Sugimoto, N, Ryu, MH, Sakai, D, et.al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer., N Engl J Med, 2020. 382 (25)(25): p. 2419-2430., https://pubmed.ncbi.nlm.nih.gov/32469182/
823. Van Cutsem, E, di Bartolomeo, M, Smyth, E, Chau, I, Park, H, Siena, S, et.al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study., Lancet Oncol, 2023. 24 (7)(7): p. 744-756., https://pubmed.ncbi.nlm.nih.gov/37329891/
824. Makiyama, A, Sukawa, Y, Kashiwada, T, Kawada, J, Hosokawa, A, Horie, Y, et.al. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)., J Clin Oncol, 2020. 38 (17)(17): p. 1919-1927., https://pubmed.ncbi.nlm.nih.gov/32208960/
825. Marabelle, A, Le, DT, Ascierto, PA, Di Giacomo, AM, De Jesus-Acosta, A, Delord, JP, et.al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study., J Clin Oncol, 2020. 38 (1)(1): p. 1-10., https://pubmed.ncbi.nlm.nih.gov/31682550/
826. Maio, M, Ascierto, PA, Manzyuk, L, Motola-Kuba, D, Penel, N, Cassier, PA, et.al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study., Ann Oncol, 2022. 33 (9)(9): p. 929-938., https://pubmed.ncbi.nlm.nih.gov/35680043/
827. Fuchs, CS, Doi, T, Jang, RW, Muro, K, Satoh, T, Machado, M, et.al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial., JAMA Oncol, 2018. 4 (5)(5): p. e180013., https://pubmed.ncbi.nlm.nih.gov/29543932/
828. Shitara, K, Özgüroğlu, M, Bang, YJ, Di Bartolomeo, M, Mandalà, M, Ryu, MH, et.al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial., Lancet, 2018. 392 (10142)(10142): p. 123-133., https://pubmed.ncbi.nlm.nih.gov/29880231/
829. Chao, J, Fuchs, CS, Shitara, K, Tabernero, J, Muro, K, Van Cutsem, E, et.al. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials., JAMA Oncol, 2021. 7 (6)(6): p. 895-902., https://pubmed.ncbi.nlm.nih.gov/33792646/
830. Kang YK, Satoh T, Ryu MH et al., Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial., J Clin Oncol, 2017. 35, 2017 (suppl 4S; abstract 2):, https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.4_suppl.2
831. Seo, S, Ryu, MH, Park, YS, Ahn, JY, Park, Y, Park, SR, et.al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)., Gastric Cancer, 2019. 22 (3)(3): p. 527-535., https://pubmed.ncbi.nlm.nih.gov/30386954/
832. Saeki, H, Oki, E, Kashiwada, T, Arigami, T, Makiyama, A, Iwatsuki, M, et.al. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604)., Eur J Cancer, 2018. 105 (): p. 41-49., https://pubmed.ncbi.nlm.nih.gov/30391779/
833. Shitara, K, Doi, T, Dvorkin, M, Mansoor, W, Arkenau, HT, Prokharau, A, et.al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial., Lancet Oncol, 2018. 19 (11)(11): p. 1437-1448., https://pubmed.ncbi.nlm.nih.gov/30355453/
834. Tabernero, J, Shitara, K, Zaanan, A, Doi, T, Lorenzen, S, Van Cutsem, E, et.al. Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study., ESMO Open, 2021. 6 (4)(4): p. 100200., https://pubmed.ncbi.nlm.nih.gov/34175675/
835. Zheng, B., Wang, X., Ma, B., Tian, J., Jiang, L., Yang, K., Endoscopic stenting versus gastrojejunostomy for palliation of malignant gastric outlet obstruction, Dig Endosc, 2012. 24(2): p. 71-8., https://www.ncbi.nlm.nih.gov/pubmed/22348830
836. Hartgrink, H. H., Putter, H., Klein Kranenbarg, E., Bonenkamp, J. J., van de Velde, C. J., Dutch Gastric Cancer, Group, Value of palliative resection in gastric cancer, Br J Surg, 2002. 89(11): p. 1438-43., https://www.ncbi.nlm.nih.gov/pubmed/12390389
837. Jeurnink, S. M., van Eijck, C. H., Steyerberg, E. W., Kuipers, E. J., Siersema, P. D., Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review, BMC Gastroenterol, 2007. 7: p. 18., https://www.ncbi.nlm.nih.gov/pubmed/17559659
838. Hosono, S., Ohtani, H., Arimoto, Y., Kanamiya, Y., Endoscopic stenting versus surgical gastroenterostomy for palliation of malignant gastroduodenal obstruction: a meta-analysis, J Gastroenterol, 2007. 42(4): p. 283-90., https://www.ncbi.nlm.nih.gov/pubmed/17464457
839. Pavlidis, T. E., Pavlidis, E. T., Role of stenting in the palliation of gastroesophageal junction cancer: A brief review, World J Gastrointest Surg, 2014. 6(3): p. 38-41., https://www.ncbi.nlm.nih.gov/pubmed/24672648
840. Dai, Y., Li, C., Xie, Y., Liu, X., Zhang, J., Zhou, J., et.al. Interventions for dysphagia in oesophageal cancer, Cochrane Database Syst Rev, 2014. p. CD005048., https://www.ncbi.nlm.nih.gov/pubmed/25354795
841. Sur, R. K., Levin, C. V., Donde, B., Sharma, V., Miszczyk, L., Nag, S., Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma--an International Atomic Energy Agency study, Int J Radiat Oncol Biol Phys, 2002. 53(1): p. 127-33., https://www.ncbi.nlm.nih.gov/pubmed/12007950
842. Sur, R., Donde, B., Falkson, C., Ahmed, S. N., Levin, V., Nag, S., et.al. Randomized prospective study comparing high-dose-rate intraluminal brachytherapy (HDRILBT) alone with HDRILBT and external beam radiotherapy in the palliation of advanced esophageal cancer, Brachytherapy, 2004. 3(4): p. 191-5., https://www.ncbi.nlm.nih.gov/pubmed/15607150
843. Kunisaki, C., Makino, H., Takagawa, R., Oshima, T., Nagano, Y., Fujii, S., et.al. Impact of palliative gastrectomy in patients with incurable advanced gastric cancer, Anticancer Res, 2008. 28(2B): p. 1309-15., https://www.ncbi.nlm.nih.gov/pubmed/18505071
844. Krishnamoorthi, R, Bomman, S, Benias, P, Kozarek, RA, Peetermans, JA, McMullen, E, et.al. Efficacy and safety of endoscopic duodenal stent versus endoscopic or surgical gastrojejunostomy to treat malignant gastric outlet obstruction: systematic review and meta-analysis., Endosc Int Open, 2022. 10 (6)(6): p. E874-E897., https://pubmed.ncbi.nlm.nih.gov/35692924/
845. Tamura, T, Shimokawa, T, Yamashita, Y, Yamao, K, Kitano, M, Uncovered versus covered expandable metal stents for malignant gastric outlet obstruction caused by intrinsic and extrinsic tumors: meta-analysis and meta-regression analysis., Surg Endosc, 2023. 37 (4)(4): p. 2496-2507., https://pubmed.ncbi.nlm.nih.gov/36513783/
846. Tey, J., Soon, Y. Y., Koh, W. Y., Leong, C. N., Choo, B. A., Ho, F., et.al. Palliative radiotherapy for gastric cancer: a systematic review and meta-analysis, Oncotarget, 2017. 8(15): p. 25797-25805., https://www.ncbi.nlm.nih.gov/pubmed/28445941
847. Hiramoto, S, Kikuchi, A, Tetsuso, H, Yoshioka, A, Kohigashi, Y, Maeda, I, Efficacy of palliative radiotherapy and chemo-radiotherapy for unresectable gastric cancer demonstrating bleeding and obstruction., Int J Clin Oncol, 2018. 23 (6)(6): p. 1090-1094., https://pubmed.ncbi.nlm.nih.gov/30019177/
848. Tey, J., Back, M. F., Shakespeare, T. P., Mukherjee, R. K., Lu, J. J., Lee, K. M., et.al. The role of palliative radiation therapy in symptomatic locally advanced gastric cancer, Int J Radiat Oncol Biol Phys, 2007. 67(2): p. 385-8., https://www.ncbi.nlm.nih.gov/pubmed/17118569
849. Hashimoto, K., Mayahara, H., Takashima, A., Nakajima, T. E., Kato, K., Hamaguchi, T., et.al. Palliative radiation therapy for hemorrhage of unresectable gastric cancer: a single institute experience, J Cancer Res Clin Oncol, 2009. 135(8): p. 1117-23., https://www.ncbi.nlm.nih.gov/pubmed/19205735
850. Kondoh, C., Shitara, K., Nomura, M., Takahari, D., Ura, T., Tachibana, H., et.al. Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study, BMC Palliat Care, 2015. 14: p. 37., https://www.ncbi.nlm.nih.gov/pubmed/26238344
851. Cihoric, N, Crowe, S, Eychmüller, S, Aebersold, DM, Ghadjar, P, Clinically significant bleeding in incurable cancer patients: effectiveness of hemostatic radiotherapy., Radiat Oncol, 2012. 7 (): p. 132., https://pubmed.ncbi.nlm.nih.gov/22863072/
852. Katano, A, Yamashita, H, The Efficacy of Hemostatic Radiotherapy for Advanced Malignancies Assessed by World Health Organization Bleeding Status., Cureus, 2021. 13 (11)(11): p. e19939., https://pubmed.ncbi.nlm.nih.gov/34966621/
853. Guhlich, M, Maag, TE, Dröge, LH, Hille, A, Donath, S, Bendrich, S, et.al. Hemostatic radiotherapy in clinically significant tumor-related bleeding: excellent palliative results in a retrospective analysis of 77 patients., Radiat Oncol, 2023. 18 (1)(1): p. 203., https://pubmed.ncbi.nlm.nih.gov/38124078/
854. Rudloff, U., Langan, R. C., Mullinax, J. E., Beane, J. D., Steinberg, S. M., Beresnev, T., et.al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial, J Surg Oncol, 2014. 110(3): p. 275-84., https://www.ncbi.nlm.nih.gov/pubmed/25042700
855. Yang, X. J., Huang, C. Q., Suo, T., Mei, L. J., Yang, G. L., Cheng, F. L., et.al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial, Ann Surg Oncol, 2011. 18(6): p. 1575-81., https://www.ncbi.nlm.nih.gov/pubmed/21431408
856. Gill, R. S., Al-Adra, D. P., Nagendran, J., Campbell, S., Shi, X., Haase, E., et.al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity, J Surg Oncol, 2011. 104(6): p. 692-8., https://www.ncbi.nlm.nih.gov/pubmed/21713780
857. Grimes, N., Devlin, J., Dunne, D. F., Poston, G., Fenwick, S., Malik, H., The role of hepatectomy in the management of metastatic gastric adenocarcinoma: a systematic review, Surg Oncol, 2014. 23(4): p. 177-85., https://www.ncbi.nlm.nih.gov/pubmed/25263794
858. Coccolini, F., Cotte, E., Glehen, O., Lotti, M., Poiasina, E., Catena, F., et.al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials, Eur J Surg Oncol, 2014. 40(1): p. 12-26., https://www.ncbi.nlm.nih.gov/pubmed/24290371
859. Runyon, BA, Montano, AA, Akriviadis, EA, Antillon, MR, Irving, MA, McHutchison, JG, The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites., Ann Intern Med, 1992. 117 (3)(3): p. 215-20., https://pubmed.ncbi.nlm.nih.gov/1616215/
860. Paré, P, Talbot, J, Hoefs, JC, Serum-ascites albumin concentration gradient: a physiologic approach to the differential diagnosis of ascites., Gastroenterology, 1983. 85 (2)(2): p. 240-4., https://pubmed.ncbi.nlm.nih.gov/6862152/
861. Pockros, PJ, Esrason, KT, Nguyen, C, Duque, J, Woods, S, Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics., Gastroenterology, 1992. 103 (4)(4): p. 1302-6., https://pubmed.ncbi.nlm.nih.gov/1397889/
862. Stukan, M, Drainage of malignant ascites: patient selection and perspectives., Cancer Manag Res, 2017. 9 (): p. 115-130., https://pubmed.ncbi.nlm.nih.gov/28442933/
863. Petzold, G, Bremer, SCB, Heuschert, FC, Treiber, H, Ellenrieder, V, Kunsch, S, et.al. Tunnelled Peritoneal Catheter for Malignant Ascites-An Open-Label, Prospective, Observational Trial., Cancers (Basel), 2021. 13 (12)(12):, https://pubmed.ncbi.nlm.nih.gov/34208108/
864. Robson, PC, Gonen, M, Ni, A, Brody, L, Brown, KT, Getrajdman, G, et.al. Quality of life improves after palliative placement of percutaneous tunneled drainage catheter for refractory ascites in prospective study of patients with end-stage cancer., Palliat Support Care, 2019. 17 (6)(6): p. 677-685., https://pubmed.ncbi.nlm.nih.gov/30880658/
865. Courtney, A, Nemcek, AA, Rosenberg, S, Tutton, S, Darcy, M, Gordon, G, Prospective evaluation of the PleurX catheter when used to treat recurrent ascites associated with malignancy., J Vasc Interv Radiol, 2008. 19 (12)(12): p. 1723-31., https://pubmed.ncbi.nlm.nih.gov/18951041/
866. Filis, P, Kanellopoulou, A, Gogadis, A, Filis, N, Kamposioras, K, Kapoulitsa, F, et.al. Hyperthermic intraperitoneal chemotherapy for management of gastrointestinal and biliary tract malignancies: a systematic review and meta-analysis of randomized trials., Ann Gastroenterol, 2023. 36 (1)(1): p. 87-96., https://pubmed.ncbi.nlm.nih.gov/36593815/
867. Patel, M, Arora, A, Mukherjee, D, Mukherjee, S, Effect of hyperthermic intraperitoneal chemotherapy on survival and recurrence rates in advanced gastric cancer: a systematic review and meta-analysis., Int J Surg, 2023. 109 (8)(8): p. 2435-2450., https://pubmed.ncbi.nlm.nih.gov/37158149/
868. Reutovich, MY, Krasko, OV, Sukonko, OG, Hyperthermic intraperitoneal chemotherapy in serosa-invasive gastric cancer patients., Eur J Surg Oncol, 2019. 45 (12)(12): p. 2405-2411., https://pubmed.ncbi.nlm.nih.gov/31387756/
869. Rau, B, Lang, H, Koenigsrainer, A, Gockel, I, Rau, HG, Seeliger, H, et.al. Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial., J Clin Oncol, 2024. 42 (2)(2): p. 146-156., https://pubmed.ncbi.nlm.nih.gov/37906724/
870. Tempfer, C. B., Winnekendonk, G., Solass, W., Horvat, R., Giger-Pabst, U., Zieren, J., et.al. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study, Gynecol Oncol, 2015. 137(2): p. 223-8., https://www.ncbi.nlm.nih.gov/pubmed/25701703
871. Nadiradze, G., Giger-Pabst, U., Zieren, J., Strumberg, D., Solass, W., Reymond, M. A., Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis, J Gastrointest Surg, 2016. 20(2): p. 367-73., https://www.ncbi.nlm.nih.gov/pubmed/26511950
872. Impact of malnutrition on early outcomes after cancer surgery: an international, multicentre, prospective cohort study., Lancet Glob Health, 2023. 11 (3)(3): p. e341-e349., https://pubmed.ncbi.nlm.nih.gov/36796981/
873. Elia, M, Zellipour, L, Stratton, RJ, To screen or not to screen for adult malnutrition?, Clin Nutr, 2005. 24 (6)(6): p. 867-84., https://pubmed.ncbi.nlm.nih.gov/15893857/
874. Attar, A, Malka, D, Sabaté, JM, Bonnetain, F, Lecomte, T, Aparicio, T, et.al. Malnutrition is high and underestimated during chemotherapy in gastrointestinal cancer: an AGEO prospective cross-sectional multicenter study., Nutr Cancer, 2012. 64 (4)(4): p. 535-42., https://pubmed.ncbi.nlm.nih.gov/22494155/
875. Walsh, D, Szafranski, M, Aktas, A, Kadakia, KC, Malnutrition in Cancer Care: Time to Address the Elephant in the Room., J Oncol Pract, 2019. 15 (7)(7): p. 357-359., https://pubmed.ncbi.nlm.nih.gov/31188710/
876. Caccialanza, R, Goldwasser, F, Marschal, O, Ottery, F, Schiefke, I, Tilleul, P, et.al. Unmet needs in clinical nutrition in oncology: a multinational analysis of real-world evidence., Ther Adv Med Oncol, 2020. 12 (): p. 1758835919899852., https://pubmed.ncbi.nlm.nih.gov/32110247/
877. Lorton, CM, Griffin, O, Higgins, K, Roulston, F, Stewart, G, Gough, N, et.al. Late referral of cancer patients with malnutrition to dietitians: a prospective study of clinical practice., Support Care Cancer, 2020. 28 (5)(5): p. 2351-2360., https://pubmed.ncbi.nlm.nih.gov/31485981/
878. Arends, J., Klinische Ernährung in der Onkologie.DGEM Steering Committee., S3-Leitline der Deutschen Gesellschaft für Ernährungsmedizin e. V. (DGEM) in Kooperation mit der Deutschen Gesellschaft für Hämatologie und Onkologie e. V. (DGHO), der Arbeitsgemeinschaft „Supportive Maßnahmen in der Onkologie, Rehabilitation und Sozialmedizin“ der Deutschen Krebsgesellschaft (ASORS) und der Österreichischen Arbeitsgemeinschaft für klinische Ernährung (AKE), 2015. 40: p. e1–e74.., http://dx.doi.org/10.1055/s-0035-1552741
879. Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., et.al. ESPEN guidelines on nutrition in cancer patients, Clin Nutr, 2017. 36(1): p. 11-48., https://www.ncbi.nlm.nih.gov/pubmed/27637832
880. Arends, J, Strasser, F, Gonella, S, Solheim, TS, Madeddu, C, Ravasco, P, et.al. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines, ESMO Open, 2021. 6 (3)(3): p. 100092., https://pubmed.ncbi.nlm.nih.gov/34144781/
881. Präsidium und Kommission für die Krankenhausreform, Deutschen Gesellschaft für Ernährungsmedizin (DGEM) und, die mitunterzeichnenden Fachgesellschaften, Stellungnahme „Ernährungsmedizin im Krankenhaus stärken – Vorschläge für eine Verbesserung der Struktur- und Prozessqualität“ Adressiert von Medizinischen Fachgesellschaften unter Federführung der DGEM - Declaration “Strengthening Nutritional Medicine in Hospitals – Suggestions for Improving Structural and Process Quality” Addressed by Medical Professional Associations under the leadership of DGEM, Aktuelle Ernährungsmedizin, 2023. 48(03): p. 171 - 173., http://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-2065-1991
882. van Bokhorst-de van der Schueren, MA, Guaitoli, PR, Jansma, EP, de Vet, HC, Nutrition screening tools: does one size fit all? A systematic review of screening tools for the hospital setting., Clin Nutr, 2014. 33 (1)(1): p. 39-58., https://pubmed.ncbi.nlm.nih.gov/23688831/
883. Prado, CM, Lieffers, JR, McCargar, LJ, Reiman, T, Sawyer, MB, Martin, L, et.al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study., Lancet Oncol, 2008. 9 (7)(7): p. 629-35., https://pubmed.ncbi.nlm.nih.gov/18539529/
884. Palmela, C, Velho, S, Agostinho, L, Branco, F, Santos, M, Santos, MP, et.al. Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer., J Gastric Cancer, 2017. 17 (1)(1): p. 74-87., https://pubmed.ncbi.nlm.nih.gov/28337365/
885. Huang, DD, Cai, HY, Wang, WB, Song, HN, Luo, X, Dong, WX, et.al. Measurement of muscle quantity/quality has additional predictive value for postoperative complications and long-term survival after gastrectomy for gastric cancer in patients with probable sarcopenia as defined by the new EWGSOP2 consensus: Analysis from a large-scale prospective study., Nutrition, 2021. 86 (): p. 111156., https://pubmed.ncbi.nlm.nih.gov/33601124/
886. O'Brien, S, Twomey, M, Moloney, F, Kavanagh, RG, Carey, BW, Power, D, et.al. Sarcopenia and Post-Operative Morbidity and Mortality in Patients with Gastric Cancer., J Gastric Cancer, 2018. 18 (3)(3): p. 242-252., https://pubmed.ncbi.nlm.nih.gov/30276001/
887. Kuwada, K, Kikuchi, S, Kuroda, S, Yoshida, R, Takagi, K, Noma, K, et.al. Survival Impact of Postoperative Skeletal Muscle Loss in Gastric Cancer Patients Who Underwent Gastrectomy., Anticancer Res, 2023. 43 (1)(1): p. 223-230., https://pubmed.ncbi.nlm.nih.gov/36585161/
888. Kenny, E, Samavat, H, Touger-Decker, R, Parrott, JS, Byham-Gray, L, August, DA, Adverse perioperative outcomes among patients undergoing gastrointestinal cancer surgery: Quantifying attributable risk from malnutrition., JPEN J Parenter Enteral Nutr, 2022. 46 (3)(3): p. 517-525., https://pubmed.ncbi.nlm.nih.gov/34057749/
889. Dewys, W. D., Begg, C., Lavin, P. T., Band, P. R., Bennett, J. M., Bertino, J. R., et.al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group, Am J Med, 1980. 69(4): p. 491-7., https://www.ncbi.nlm.nih.gov/pubmed/7424938
890. Andreyev, H. J., Norman, A. R., Oates, J., Cunningham, D., Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?, Eur J Cancer, 1998. 34(4): p. 503-9., https://www.ncbi.nlm.nih.gov/pubmed/9713300
891. Martin, L., Birdsell, L., Macdonald, N., Reiman, T., Clandinin, M. T., McCargar, L. J., et.al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index, J Clin Oncol, 2013. 31(12): p. 1539-47., https://www.ncbi.nlm.nih.gov/pubmed/23530101
892. Jang, R. W., Caraiscos, V. B., Swami, N., Banerjee, S., Mak, E., Kaya, E., et.al. Simple prognostic model for patients with advanced cancer based on performance status, J Oncol Pract, 2014. 10(5): p. e335-41., https://www.ncbi.nlm.nih.gov/pubmed/25118208
893. McMillan, D. C., The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer, Cancer Treat Rev, 2013. 39(5): p. 534-40., https://www.ncbi.nlm.nih.gov/pubmed/22995477
894. Bozzetti, F., Nutritional support in patients with oesophageal cancer, Support Care Cancer, 2010. 18 Suppl 2: p. S41-50., https://www.ncbi.nlm.nih.gov/pubmed/19551411
895. Deutz, N. E., Bauer, J. M., Barazzoni, R., Biolo, G., Boirie, Y., Bosy-Westphal, A., et.al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group, Clin Nutr, 2014. 33(6): p. 929-36., https://www.ncbi.nlm.nih.gov/pubmed/24814383
896. Bauer, J., Biolo, G., Cederholm, T., Cesari, M., Cruz-Jentoft, A. J., Morley, J. E., et.al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group, J Am Med Dir Assoc, 2013. 14(8): p. 542-59., https://www.ncbi.nlm.nih.gov/pubmed/23867520
897. Biolo, G., Cederholm, T., Muscaritoli, M., Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia, Clin Nutr, 2014. 33(5): p. 737-48., https://www.ncbi.nlm.nih.gov/pubmed/24785098
898. English, K. L., Paddon-Jones, D., Protecting muscle mass and function in older adults during bed rest, Curr Opin Clin Nutr Metab Care, 2010. 13(1): p. 34-9., https://www.ncbi.nlm.nih.gov/pubmed/19898232
899. Lira, F. S., Neto, J. C., Seelaender, M., Exercise training as treatment in cancer cachexia, Appl Physiol Nutr Metab, 2014. 39(6): p. 679-86., https://www.ncbi.nlm.nih.gov/pubmed/24797380
900. Gould, D. W., Lahart, I., Carmichael, A. R., Koutedakis, Y., Metsios, G. S., Cancer cachexia prevention via physical exercise: molecular mechanisms, J Cachexia Sarcopenia Muscle, 2013. 4(2): p. 111-24., https://www.ncbi.nlm.nih.gov/pubmed/23239116
901. Gesellschaften für Ernährung in Deutschland (DGE) und Österreich (ÖGE), DACH-Referenzwerte für die Nährstoffzufuhr. 2. Auflage, 8. aktualisierte Ausgabe., 2024.
902. Blaauw, R, Osland, E, Sriram, K, Ali, A, Allard, JP, Ball, P, et.al. Parenteral Provision of Micronutrients to Adult Patients: An Expert Consensus Paper., JPEN J Parenter Enteral Nutr, 2019. 43 Suppl 1 (): p. S5-S23., https://pubmed.ncbi.nlm.nih.gov/30812055/
903. Berger, MM, Shenkin, A, Schweinlin, A, Amrein, K, Augsburger, M, Biesalski, HK, et.al. ESPEN micronutrient guideline., Clin Nutr, 2022. 41 (6)(6): p. 1357-1424., https://pubmed.ncbi.nlm.nih.gov/35365361/
904. Bassler, K. H., [Significance of vitamins in parenteral nutrition], Infusionstherapie, 1990. 17(1): p. 19-23., https://www.ncbi.nlm.nih.gov/pubmed/2110932
905. Bassler, K. H., [Recommendations for the provision of trace elements in the parenteral nutrition of adults], Klin Anasthesiol Intensivther, 1990. 40: p. 199-200., https://www.ncbi.nlm.nih.gov/pubmed/2127444
906. Shenkin, A., The key role of micronutrients, Clin Nutr, 2006. 25(1): p. 1-13., https://www.ncbi.nlm.nih.gov/pubmed/16376462
907. Biesalski HK, Bischoff SC, Böhles H et al., Wasser, Elektrolyte, Vitamine und Spurenelemente., Aktuel Ernahrungsmed, 2007. 32: p. 30-34.
908. Giovannucci, E., Chan, A. T., Role of vitamin and mineral supplementation and aspirin use in cancer survivors, J Clin Oncol, 2010. 28(26): p. 4081-5., https://www.ncbi.nlm.nih.gov/pubmed/20697066
909. Mamede, A. C., Tavares, S. D., Abrantes, A. M., Trindade, J., Maia, J. M., Botelho, M. F., The role of vitamins in cancer: a review, Nutr Cancer, 2011. 63(4): p. 479-94., https://www.ncbi.nlm.nih.gov/pubmed/21541902
910. Strohle, A., Zanker, K., Hahn, A., Nutrition in oncology: the case of micronutrients (review), Oncol Rep, 2010. 24(4): p. 815-28., https://www.ncbi.nlm.nih.gov/pubmed/20811659
911. Luczynska, A., Kaaks, R., Rohrmann, S., Becker, S., Linseisen, J., Buijsse, B., et.al. Plasma 25-hydroxyvitamin D concentration and lymphoma risk: results of the European Prospective Investigation into Cancer and Nutrition, Am J Clin Nutr, 2013. 98(3): p. 827-38., https://www.ncbi.nlm.nih.gov/pubmed/23885049
912. Drake, M. T., Maurer, M. J., Link, B. K., Habermann, T. M., Ansell, S. M., Micallef, I. N., et.al. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma, J Clin Oncol, 2010. 28(27): p. 4191-8., https://www.ncbi.nlm.nih.gov/pubmed/20713849
913. Arends, J., Vitamin D in oncology, Forsch Komplementmed, 2011. 18(4): p. 176-84., https://www.ncbi.nlm.nih.gov/pubmed/21934317
914. Zgaga, L., Theodoratou, E., Farrington, S. M., Din, F. V., Ooi, L. Y., Glodzik, D., et.al. Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer, J Clin Oncol, 2014. 32(23): p. 2430-9., https://www.ncbi.nlm.nih.gov/pubmed/25002714
915. Bairati, I., Meyer, F., Gelinas, M., Fortin, A., Nabid, A., Brochet, F., et.al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients, J Clin Oncol, 2005. 23(24): p. 5805-13., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16027437
916. Camphausen, K., Citrin, D., Krishna, M. C., Mitchell, J. B., Implications for tumor control during protection of normal tissues with antioxidants, J Clin Oncol, 2005. 23(24): p. 5455-7., https://www.ncbi.nlm.nih.gov/pubmed/16027436
917. Bairati, I., Meyer, F., Gelinas, M., Fortin, A., Nabid, A., Brochet, F., et.al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients, J Natl Cancer Inst, 2005. 97(7): p. 481-8., https://www.ncbi.nlm.nih.gov/pubmed/15812073
918. Argyriou, A. A., Chroni, E., Koutras, A., Iconomou, G., Papapetropoulos, S., Polychronopoulos, P., et.al. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results, Support Care Cancer, 2006. 14(11): p. 1134-40., https://www.ncbi.nlm.nih.gov/pubmed/16622646
919. Dennert, G., Horneber, M., Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients, Cochrane Database Syst Rev, 2006. 3: p. CD005037., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16856073
920. Roeland, EJ, Bohlke, K, Baracos, VE, Bruera, E, Del Fabbro, E, Dixon, S, et.al. Management of Cancer Cachexia: ASCO Guideline., J Clin Oncol, 2020. 38 (21)(21): p. 2438-2453., https://pubmed.ncbi.nlm.nih.gov/32432946/
921. Jandhyala, SM, Talukdar, R, Subramanyam, C, Vuyyuru, H, Sasikala, M, Nageshwar Reddy, D, Role of the normal gut microbiota., World J Gastroenterol, 2015. 21 (29)(29): p. 8787-803., https://pubmed.ncbi.nlm.nih.gov/26269668/
922. Thomas, S, Izard, J, Walsh, E, Batich, K, Chongsathidkiet, P, Clarke, G, et.al. The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists., Cancer Res, 2017. 77 (8)(8): p. 1783-1812., https://pubmed.ncbi.nlm.nih.gov/28292977/
923. Riquelme, E, Zhang, Y, Zhang, L, Montiel, M, Zoltan, M, Dong, W, et.al. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes., Cell, 2019. 178 (4)(4): p. 795-806.e12., https://pubmed.ncbi.nlm.nih.gov/31398337/
924. Peled, JU, Gomes, ALC, Devlin, SM, Littmann, ER, Taur, Y, Sung, AD, et.al. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation., N Engl J Med, 2020. 382 (9)(9): p. 822-834., https://pubmed.ncbi.nlm.nih.gov/32101664/
925. Gopalakrishnan, V, Spencer, CN, Nezi, L, Reuben, A, Andrews, MC, Karpinets, TV, et.al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients., Science, 2018. 359 (6371)(6371): p. 97-103., https://pubmed.ncbi.nlm.nih.gov/29097493/
926. Spencer, CN, McQuade, JL, Gopalakrishnan, V, McCulloch, JA, Vetizou, M, Cogdill, AP, et.al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response., Science, 2021. 374 (6575)(6575): p. 1632-1640., https://pubmed.ncbi.nlm.nih.gov/34941392/
927. Baruch, EN, Wang, J, Wargo, JA, Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect., Cancer Immunol Res, 2021. 9 (4)(4): p. 365-370., https://pubmed.ncbi.nlm.nih.gov/34003768/
928. Ni, Y, Lohinai, Z, Heshiki, Y, Dome, B, Moldvay, J, Dulka, E, et.al. Distinct composition and metabolic functions of human gut microbiota are associated with cachexia in lung cancer patients., ISME J, 2021. 15 (11)(11): p. 3207-3220., https://pubmed.ncbi.nlm.nih.gov/34002024/
929. Hakozaki, T, Nolin-Lapalme, A, Kogawa, M, Okuma, Y, Nakamura, S, Moreau-Amaru, D, et.al. Cancer Cachexia among Patients with Advanced Non-Small-Cell Lung Cancer on Immunotherapy: An Observational Study with Exploratory Gut Microbiota Analysis., Cancers (Basel), 2022. 14 (21)(21):, https://pubmed.ncbi.nlm.nih.gov/36358821/
930. Sędzikowska, A, Szablewski, L, Human Gut Microbiota in Health and Selected Cancers., Int J Mol Sci, 2021. 22 (24)(24):, https://pubmed.ncbi.nlm.nih.gov/34948234/
931. Davoodvandi, A, Fallahi, F, Tamtaji, OR, Tajiknia, V, Banikazemi, Z, Fathizadeh, H, et.al. An Update on the Effects of Probiotics on Gastrointestinal Cancers., Front Pharmacol, 2021. 12 (): p. 680400., https://pubmed.ncbi.nlm.nih.gov/34992527/
932. Panebianco, C, Villani, A, Potenza, A, Favaro, E, Finocchiaro, C, Perri, F, et.al. Targeting Gut Microbiota in Cancer Cachexia: Towards New Treatment Options., Int J Mol Sci, 2023. 24 (3)(3):, https://pubmed.ncbi.nlm.nih.gov/36768173/
933. Doron, S, Snydman, DR, Risk and safety of probiotics., Clin Infect Dis, 2015. 60 Suppl 2 (Suppl 2)(Suppl 2): p. S129-34., https://pubmed.ncbi.nlm.nih.gov/25922398/
934. Ligthart-Melis, G. C., Weijs, P. J., te Boveldt, N. D., Buskermolen, S., Earthman, C. P., Verheul, H. M., et.al. Dietician-delivered intensive nutritional support is associated with a decrease in severe postoperative complications after surgery in patients with esophageal cancer, Dis Esophagus, 2013. 26(6): p. 587-93., https://www.ncbi.nlm.nih.gov/pubmed/23237356
935. Deftereos, I, Yeung, JM, Arslan, J, Carter, VM, Isenring, E, Kiss, N, et.al. Preoperative Nutrition Intervention in Patients Undergoing Resection for Upper Gastrointestinal Cancer: Results from the Multi-Centre NOURISH Point Prevalence Study., Nutrients, 2021. 13 (9)(9):, https://pubmed.ncbi.nlm.nih.gov/34579082/
936. Lochs, H., Dejong, C., Hammarqvist, F., Hebuterne, X., Leon-Sanz, M., Schutz, T., et.al. ESPEN Guidelines on Enteral Nutrition: Gastroenterology, Clin Nutr, 2006. 25(2): p. 260-74., https://www.ncbi.nlm.nih.gov/pubmed/16698129
937. Weimann, A., Braga, M., Carli, F., Higashiguchi, T., Hubner, M., Klek, S., et.al. ESPEN guideline: Clinical nutrition in surgery, Clin Nutr, 2017. 36(3): p. 623-650., https://www.ncbi.nlm.nih.gov/pubmed/28385477
938. Kuppinger, D, Hartl, WH, Bertok, M, Hoffmann, JM, Cederbaum, J, Bender, A, et.al. Nutritional screening for risk prediction in patients scheduled for extra-abdominal surgery., Nutrition, 2013. 29 (2)(2): p. 399-404., https://pubmed.ncbi.nlm.nih.gov/23312761/
939. Elia, M., Normand, C., Norman, K., Laviano, A., A systematic review of the cost and cost effectiveness of using standard oral nutritional supplements in the hospital setting, Clin Nutr, 2016. 35(2): p. 370-380., https://www.ncbi.nlm.nih.gov/pubmed/26123475
940. Burden, S., Todd, C., Hill, J., Lal, S., Pre-operative nutrition support in patients undergoing gastrointestinal surgery, Cochrane Database Syst Rev, 2012. 11: p. CD008879., https://www.ncbi.nlm.nih.gov/pubmed/23152265
941. Song, GM, Tian, X, Zhang, L, Ou, YX, Yi, LJ, Shuai, T, et.al. Immunonutrition Support for Patients Undergoing Surgery for Gastrointestinal Malignancy: Preoperative, Postoperative, or Perioperative? A Bayesian Network Meta-Analysis of Randomized Controlled Trials., Medicine (Baltimore), 2015. 94 (29)(29): p. e1225., https://pubmed.ncbi.nlm.nih.gov/26200648/
942. Song, G. M., Tian, X., Liang, H., Yi, L. J., Zhou, J. G., Zeng, Z., et.al. Role of Enteral Immunonutrition in Patients Undergoing Surgery for Gastric Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Medicine (Baltimore), 2015. 94(31): p. e1311., https://www.ncbi.nlm.nih.gov/pubmed/26252314
943. Bruix, Jordi, Qin, Shukui, Merle, Philippe, Granito, Alessandro, Huang, Yi-Hsiang, Bodoky, György, et.al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet, 2017. 389(10064): p. 56-66., https://pubmed.ncbi.nlm.nih.gov/27932229/
944. Gianotti, L., Braga, M., Nespoli, L., Radaelli, G., Beneduce, A., Di Carlo, V., A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer, Gastroenterology, 2002. 122(7): p. 1763-70., https://www.ncbi.nlm.nih.gov/pubmed/12055582
945. Fujitani, K., Tsujinaka, T., Fujita, J., Miyashiro, I., Imamura, H., Kimura, Y., et.al. Prospective randomized trial of preoperative enteral immunonutrition followed by elective total gastrectomy for gastric cancer, Br J Surg, 2012. 99(5): p. 621-9., https://www.ncbi.nlm.nih.gov/pubmed/22367794
946. Ida, S., Hiki, N., Cho, H., Sakamaki, K., Ito, S., Fujitani, K., et.al. Randomized clinical trial comparing standard diet with perioperative oral immunonutrition in total gastrectomy for gastric cancer, Br J Surg, 2017. 104(4): p. 377-383., https://www.ncbi.nlm.nih.gov/pubmed/28072447
947. Adiamah, A, Skořepa, P, Weimann, A, Lobo, DN, The Impact of Preoperative Immune Modulating Nutrition on Outcomes in Patients Undergoing Surgery for Gastrointestinal Cancer: A Systematic Review and Meta-analysis., Ann Surg, 2019. 270 (2)(2): p. 247-256., https://pubmed.ncbi.nlm.nih.gov/30817349/
948. Buzquurz, F, Bojesen, RD, Grube, C, Madsen, MT, Gögenur, I, Impact of oral preoperative and perioperative immunonutrition on postoperative infection and mortality in patients undergoing cancer surgery: systematic review and meta-analysis with trial sequential analysis., BJS Open, 2020. 4 (5)(5): p. 764-775., https://pubmed.ncbi.nlm.nih.gov/32573977/
949. Slim, K, Badon, F, Vacheron, CH, Occean, BV, Dziri, C, Chambrier, C, Umbrella review of the efficacy of perioperative immunonutrition in visceral surgery., Clin Nutr ESPEN, 2022. 48 (): p. 99-108., https://pubmed.ncbi.nlm.nih.gov/35331540/
950. Mabvuure, N. T., Roman, A., Khan, O. A., Enteral immunonutrition versus standard enteral nutrition for patients undergoing oesophagogastric resection for cancer, Int J Surg, 2013. 11(2): p. 122-7., https://www.ncbi.nlm.nih.gov/pubmed/23274278
951. Wong, C. S., Aly, E. H., The effects of enteral immunonutrition in upper gastrointestinal surgery: A systematic review and meta-analysis, Int J Surg, 2016. 29: p. 137-50., https://www.ncbi.nlm.nih.gov/pubmed/27020765
952. Hegazi, R. A., Hustead, D. S., Evans, D. C., Preoperative standard oral nutrition supplements vs immunonutrition: results of a systematic review and meta-analysis, J Am Coll Surg, 2014. 219(5): p. 1078-87., https://www.ncbi.nlm.nih.gov/pubmed/25260681
953. Khan, A, Wong, J, Riedel, B, Laing, E, Beaumont, A, Kong, J, et.al. The Impact of Peri-operative Enteral Immunonutrition on Post-operative Complications in Gastrointestinal Cancer Surgery: A Meta-Analysis., Ann Surg Oncol, 2023. 30 (6)(6): p. 3619-3631., https://pubmed.ncbi.nlm.nih.gov/36820938/
954. Fukuda, Y., Yamamoto, K., Hirao, M., Nishikawa, K., Maeda, S., Haraguchi, N., et.al. Prevalence of Malnutrition Among Gastric Cancer Patients Undergoing Gastrectomy and Optimal Preoperative Nutritional Support for Preventing Surgical Site Infections, Ann Surg Oncol, 2015. 22 Suppl 3: p. S778-85., https://www.ncbi.nlm.nih.gov/pubmed/26286199
955. Meyer, L, Steinert, R, Nowak, L, Gellert, K, Ludwig, K, Saeger, D, et.al. [Prospective multicenter trial of gastric cancer surgery--a contribution to clinical research on quality control]., Zentralbl Chir, 2005. 130 (2)(2): p. 97-105., https://pubmed.ncbi.nlm.nih.gov/15849650/
956. Kong, SH, Lee, HJ, Na, JR, Kim, WG, Han, DS, Park, SH, et.al. Effect of perioperative oral nutritional supplementation in malnourished patients who undergo gastrectomy: A prospective randomized trial., Surgery, 2018. 164 (6)(6): p. 1263-1270., https://pubmed.ncbi.nlm.nih.gov/30055788/
957. Organization, World Health, Physical status: The use and interpretation of anthropometry, Report of a WHO expert committee, WHO Tech Rep Ser, 1995. 854: p. 423., https://pubmed.ncbi.nlm.nih.gov/8594834/
958. Lochs, H., Allison, S. P., Meier, R., Pirlich, M., Kondrup, J., Schneider, S., et.al. Introductory to the ESPEN Guidelines on Enteral Nutrition: Terminology, definitions and general topics, Clin Nutr, 2006. 25(2): p. 180-6., https://www.ncbi.nlm.nih.gov/pubmed/16697086
959. Khuri, S. F., Henderson, W. G., DePalma, R. G., Mosca, C., Healey, N. A., Kumbhani, D. J., et.al. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications, Ann Surg, 2005. 242(3): p. 326-41; discussion 341-3., https://www.ncbi.nlm.nih.gov/pubmed/16135919
960. Hennessey, D. B., Burke, J. P., Ni-Dhonochu, T., Shields, C., Winter, D. C., Mealy, K., Preoperative hypoalbuminemia is an independent risk factor for the development of surgical site infection following gastrointestinal surgery: a multi-institutional study, Ann Surg, 2010. 252(2): p. 325-9., https://www.ncbi.nlm.nih.gov/pubmed/20647925
961. Hu, W. H., Chen, H. H., Lee, K. C., Liu, L., Eisenstein, S., Parry, L., et.al. Assessment of the Addition of Hypoalbuminemia to ACS-NSQIP Surgical Risk Calculator in Colorectal Cancer, Medicine (Baltimore), 2016. 95(10): p. e2999., https://www.ncbi.nlm.nih.gov/pubmed/26962812
962. Ying, LD, Chao, GF, Canner, J, Graetz, E, Ghiassi, S, Schwartz, JS, et.al. The Degree of Preoperative Hypoalbuminemia Is Associated with Risk of Postoperative Complications in Metabolic and Bariatric Surgery Patients., Obes Surg, 2024. 34 (1)(1): p. 51-70., https://pubmed.ncbi.nlm.nih.gov/37994997/
963. Huang, ZX, Zhang, HH, Zhang, WT, Shi, MM, Ren, JH, Xu, LB, et.al. Effect of Short-Term Preoperative Parenteral Nutrition Support for Gastric Cancer Patients with Sarcopenia: a Propensity Score Matching Analysis., J Gastrointest Surg, 2022. 26 (7)(7): p. 1362-1372., https://pubmed.ncbi.nlm.nih.gov/35091860/
964. Heyland, D. K., Montalvo, M., MacDonald, S., Keefe, L., Su, X. Y., Drover, J. W., Total parenteral nutrition in the surgical patient: a meta-analysis, Can J Surg, 2001. 44(2): p. 102-11., https://www.ncbi.nlm.nih.gov/pubmed/11308231
965. Bozzetti, F., Gavazzi, C., Miceli, R., Rossi, N., Mariani, L., Cozzaglio, L., et.al. Perioperative total parenteral nutrition in malnourished, gastrointestinal cancer patients: a randomized, clinical trial, JPEN J Parenter Enteral Nutr, 2000. 24(1): p. 7-14., https://www.ncbi.nlm.nih.gov/pubmed/10638466
966. Jie, B., Jiang, Z. M., Nolan, M. T., Zhu, S. N., Yu, K., Kondrup, J., Impact of preoperative nutritional support on clinical outcome in abdominal surgical patients at nutritional risk, Nutrition, 2012. 28(10): p. 1022-7., https://www.ncbi.nlm.nih.gov/pubmed/22673593
967. Grande, A. J., Silva, V., Riera, R., Medeiros, A., Vitoriano, S. G., Peccin, M. S., et.al. Exercise for cancer cachexia in adults, Cochrane Database Syst Rev, 2014. p. CD010804., https://www.ncbi.nlm.nih.gov/pubmed/25424884
968. Ferriolli, E., Skipworth, R. J., Hendry, P., Scott, A., Stensteth, J., Dahele, M., et.al. Physical activity monitoring: a responsive and meaningful patient-centered outcome for surgery, chemotherapy, or radiotherapy?, J Pain Symptom Manage, 2012. 43(6): p. 1025-35., https://www.ncbi.nlm.nih.gov/pubmed/22269181
969. Dimeo, F. C., Stieglitz, R. D., Novelli-Fischer, U., Fetscher, S., Keul, J., Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy, Cancer, 1999. 85(10): p. 2273-7., https://www.ncbi.nlm.nih.gov/pubmed/10326708
970. Halle, M., Schoenberg, M. H., Physical activity in the prevention and treatment of colorectal carcinoma, Dtsch Arztebl Int, 2009. 106(44): p. 722-7., https://www.ncbi.nlm.nih.gov/pubmed/19997551
971. Oldervoll, L. M., Loge, J. H., Paltiel, H., Asp, M. B., Vidvei, U., Wiken, A. N., et.al. The effect of a physical exercise program in palliative care: A phase II study, J Pain Symptom Manage, 2006. 31(5): p. 421-30., https://www.ncbi.nlm.nih.gov/pubmed/16716872
972. Carli, F., Scheede-Bergdahl, C., Prehabilitation to enhance perioperative care, Anesthesiol Clin, 2015. 33(1): p. 17-33., https://www.ncbi.nlm.nih.gov/pubmed/25701926
973. Loughney, L, Bolger, J, Tully, R, Sorensen, J, Bambrick, M, Carroll, PA, et.al. The effect of a pre-operative and post-operative exercise programme versus standard care on physical fitness of patients with oesophageal and gastric cancer undergoing neoadjuvant treatment prior to surgery (the PERIOP-OG trial): a randomized controlled trial., Int J Surg, 2024. 110 (10)(10): p. 6632-6646., https://pubmed.ncbi.nlm.nih.gov/38935085/
974. Skořepa, P, Ford, KL, Alsuwaylihi, A, O'Connor, D, Prado, CM, Gomez, D, et.al. The impact of prehabilitation on outcomes in frail and high-risk patients undergoing major abdominal surgery: A systematic review and meta-analysis., Clin Nutr, 2024. 43 (3)(3): p. 629-648., https://pubmed.ncbi.nlm.nih.gov/38306891/
975. Yamamoto, K., Nagatsuma, Y., Fukuda, Y., Hirao, M., Nishikawa, K., Miyamoto, A., et.al. Effectiveness of a preoperative exercise and nutritional support program for elderly sarcopenic patients with gastric cancer, Gastric Cancer, 2017. 20(5): p. 913-918., https://www.ncbi.nlm.nih.gov/pubmed/28032232
976. Bausys, A, Luksta, M, Anglickiene, G, Maneikiene, VV, Kryzauskas, M, Rybakovas, A, et.al. Effect of home-based prehabilitation on postoperative complications after surgery for gastric cancer: randomized clinical trial., Br J Surg, 2023. 110 (12)(12): p. 1800-1807., https://pubmed.ncbi.nlm.nih.gov/37750588/
977. Shen, Y, Cong, Z, Ge, Q, Huang, H, Wei, W, Wang, C, et.al. Effect of nutrition-based prehabilitation on the postoperative outcomes of patients with esophagogastric cancer undergoing surgery: A systematic review and meta-analysis., Cancer Med, 2024. 13 (14)(14): p. e70023., https://pubmed.ncbi.nlm.nih.gov/39001679/
978. McIsaac, DI, Gill, M, Boland, L, Hutton, B, Branje, K, Shaw, J, et.al. Prehabilitation in adult patients undergoing surgery: an umbrella review of systematic reviews., Br J Anaesth, 2022. 128 (2)(2): p. 244-257., https://pubmed.ncbi.nlm.nih.gov/34922735/
979. Andersen, H. K., Lewis, S. J., Thomas, S., Early enteral nutrition within 24h of colorectal surgery versus later commencement of feeding for postoperative complications, Cochrane Database Syst Rev, 2006. p. CD004080., https://www.ncbi.nlm.nih.gov/pubmed/17054196
980. Mazaki, T., Ebisawa, K., Enteral versus parenteral nutrition after gastrointestinal surgery: a systematic review and meta-analysis of randomized controlled trials in the English literature, J Gastrointest Surg, 2008. 12(4): p. 739-55., https://www.ncbi.nlm.nih.gov/pubmed/17939012
981. Lewis, S. J., Andersen, H. K., Thomas, S., Early enteral nutrition within 24 h of intestinal surgery versus later commencement of feeding: a systematic review and meta-analysis, J Gastrointest Surg, 2009. 13(3): p. 569-75., https://www.ncbi.nlm.nih.gov/pubmed/18629592
982. Osland, E., Yunus, R. M., Khan, S., Memon, M. A., Early versus traditional postoperative feeding in patients undergoing resectional gastrointestinal surgery: a meta-analysis, JPEN J Parenter Enteral Nutr, 2011. 35(4): p. 473-87., https://www.ncbi.nlm.nih.gov/pubmed/21628607
983. Lassen, K., Kjaeve, J., Fetveit, T., Trano, G., Sigurdsson, H. K., Horn, A., et.al. Allowing normal food at will after major upper gastrointestinal surgery does not increase morbidity: a randomized multicenter trial, Ann Surg, 2008. 247(5): p. 721-9., https://www.ncbi.nlm.nih.gov/pubmed/18438106
984. Hur, H., Kim, S. G., Shim, J. H., Song, K. Y., Kim, W., Park, C. H., et.al. Effect of early oral feeding after gastric cancer surgery: a result of randomized clinical trial, Surgery, 2011. 149(4): p. 561-8., https://www.ncbi.nlm.nih.gov/pubmed/21146844
985. Willcutts, K. F., Chung, M. C., Erenberg, C. L., Finn, K. L., Schirmer, B. D., Byham-Gray, L. D., Early Oral Feeding as Compared With Traditional Timing of Oral Feeding After Upper Gastrointestinal Surgery: A Systematic Review and Meta-analysis, Ann Surg, 2016. 264(1): p. 54-63., https://www.ncbi.nlm.nih.gov/pubmed/26779983
986. Han-Geurts, I. J., Hop, W. C., Verhoef, C., Tran, K. T., Tilanus, H. W., Randomized clinical trial comparing feeding jejunostomy with nasoduodenal tube placement in patients undergoing oesophagectomy, Br J Surg, 2007. 94(1): p. 31-5., https://www.ncbi.nlm.nih.gov/pubmed/17117432
987. Wobith, M, Wehle, L, Haberzettl, D, Acikgöz, A, Weimann, A, Needle Catheter Jejunostomy in Patients Undergoing Surgery for Upper Gastrointestinal and Pancreato-Biliary Cancer-Impact on Nutritional and Clinical Outcome in the Early and Late Postoperative Period., Nutrients, 2020. 12 (9)(9):, https://pubmed.ncbi.nlm.nih.gov/32854177/
988. Deftereos, I, Yeung, JMC, Arslan, J, Carter, VM, Isenring, E, Kiss, N, et.al. Assessment of Nutritional Status and Nutrition Impact Symptoms in Patients Undergoing Resection for Upper Gastrointestinal Cancer: Results from the Multi-Centre NOURISH Point Prevalence Study., Nutrients, 2021. 13 (10)(10):, https://pubmed.ncbi.nlm.nih.gov/34684353/
989. Heneghan, H. M., Zaborowski, A., Fanning, M., McHugh, A., Doyle, S., Moore, J., et.al. Prospective Study of Malabsorption and Malnutrition After Esophageal and Gastric Cancer Surgery, Ann Surg, 2015. 262(5): p. 803-7; discussion 807-8., https://www.ncbi.nlm.nih.gov/pubmed/26583669
990. Hatao, F, Chen, KY, Wu, JM, Wang, MY, Aikou, S, Onoyama, H, et.al. Randomized controlled clinical trial assessing the effects of oral nutritional supplements in postoperative gastric cancer patients., Langenbecks Arch Surg, 2017. 402 (2)(2): p. 203-211., https://pubmed.ncbi.nlm.nih.gov/27807617/
991. Ryan, A. M., Rowley, S. P., Healy, L. A., Flood, P. M., Ravi, N., Reynolds, J. V., Post-oesophagectomy early enteral nutrition via a needle catheter jejunostomy: 8-year experience at a specialist unit, Clin Nutr, 2006. 25(3): p. 386-93., https://www.ncbi.nlm.nih.gov/pubmed/16697499
992. Falkner D, Plato R, Weimann A, Die Wertigkeit der Feinnadelkatheterjejunostomie in der postoperativen enteralen Ernährung nach Ösophagusresektion, DGCH, 2014., www.egms.de/static/en/meetings/dgch2014/14dgch567.shtml
993. Sica, G. S., Sujendran, V., Wheeler, J., Soin, B., Maynard, N., Needle catheter jejunostomy at esophagectomy for cancer, J Surg Oncol, 2005. 91(4): p. 276-9., https://www.ncbi.nlm.nih.gov/pubmed/16121345
994. Xueting, H, Li, L, Meng, Y, Yuqing, C, Yutong, H, Lihong, Q, et.al. Home enteral nutrition and oral nutritional supplements in postoperative patients with upper gastrointestinal malignancy: A systematic review and meta-analysis., Clin Nutr, 2021. 40 (5)(5): p. 3082-3093., https://pubmed.ncbi.nlm.nih.gov/33279310/
995. Li, X, Hu, J, Zhou, J, Fang, P, Yuan, Y, In patients undergoing oesophagectomy does postoperative home enteral nutrition have any impact on nutritional status?, Interact Cardiovasc Thorac Surg, 2022. 35 (3)(3):, https://pubmed.ncbi.nlm.nih.gov/35512385/
996. Komatsu, S, Konishi, T, Matsubara, D, Soga, K, Shimomura, K, Ikeda, J, et.al. Night home enteral nutrition as a novel enforced and physiologically effective nutrition therapy following total gastrectomy for gastric cancer., Sci Rep, 2022. 12 (1)(1): p. 14922., https://pubmed.ncbi.nlm.nih.gov/36056110/
997. Meng, Q, Tan, S, Jiang, Y, Han, J, Xi, Q, Zhuang, Q, et.al. Post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk after surgery for gastric cancer: A randomized clinical trial., Clin Nutr, 2021. 40 (1)(1): p. 40-46., https://pubmed.ncbi.nlm.nih.gov/32563598/
998. Miyazaki, Y, Omori, T, Fujitani, K, Fujita, J, Kawabata, R, Imamura, H, et.al. Oral nutritional supplements versus a regular diet alone for body weight loss after gastrectomy: a phase 3, multicenter, open-label randomized controlled trial., Gastric Cancer, 2021. 24 (5)(5): p. 1150-1159., https://pubmed.ncbi.nlm.nih.gov/33835329/
999. D'Ugo, D., Biondi, A., Tufo, A., Persiani, R., Follow-up: the evidence, Dig Surg, 2013. 30(2): p. 159-68., https://www.ncbi.nlm.nih.gov/pubmed/23867593
1000. Baiocchi, G. L., D'Ugo, D., Coit, D., Hardwick, R., Kassab, P., Nashimoto, A., et.al. Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference, Gastric Cancer, 2016. 19(1): p. 15-20., https://www.ncbi.nlm.nih.gov/pubmed/26140915
1001. Alexander, PE, Brito, JP, Neumann, I, Gionfriddo, MR, Bero, L, Djulbegovic, B, et.al. World Health Organization strong recommendations based on low-quality evidence (study quality) are frequent and often inconsistent with GRADE guidance., J Clin Epidemiol, 2016. 72 (): p. 98-106., https://pubmed.ncbi.nlm.nih.gov/25618534/
1002. Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline: 9. Vitamin B12, Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline, 1998., https://pubmed.ncbi.nlm.nih.gov/23193625/
1003. Aoyama, T, Hara, K, Maezawa, Y, Kazama, K, Hashimoto, I, Sawazaki, S, et.al. Clinical Course of Vitamin B12 Deficiency and Associated Risk Factors in Patients After Total Gastrectomy for Gastric Cancer., Anticancer Res, 2023. 43 (2)(2): p. 689-694., https://pubmed.ncbi.nlm.nih.gov/36697109/
1004. Namikawa, T, Maeda, M, Yokota, K, Iwabu, J, Munekage, M, Uemura, S, et.al. Enteral Vitamin B12 Supplementation Is Effective for Improving Anemia in Patients Who Underwent Total Gastrectomy., Oncology, 2021. 99 (4)(4): p. 225-233., https://pubmed.ncbi.nlm.nih.gov/33601391/
1005. Hu, Y, Kim, HI, Hyung, WJ, Song, KJ, Lee, JH, Kim, YM, et.al. Vitamin B(12) deficiency after gastrectomy for gastric cancer: an analysis of clinical patterns and risk factors., Ann Surg, 2013. 258 (6)(6): p. 970-5., https://pubmed.ncbi.nlm.nih.gov/24096753/
1006. Wang, H, Li, L, Qin, LL, Song, Y, Vidal-Alaball, J, Liu, TH, Oral vitamin B, Cochrane Database Syst Rev, 2018. 3 (3)(3): p. CD004655., https://pubmed.ncbi.nlm.nih.gov/29543316/
1007. Boddy K, King P, Mervyn I, Macleod A, Adams,JF, Retention of cyanocobalamin, hydroxocobalamin, and coenzyme B12 after parenteral administration, lancet, 1968. 292: p. 710-12., https://www.ncbi.nlm.nih.gov/pubmed/4175091
1008. Glass, G. B., Skeggs, H. R., Lee, D. H., Jones, E. L., Hardy, W. W., Hydroxocobalamin. I. Blood levels and urinary excretion of vitamin B12 in man after a single parenteral dose of aqueous hydroxocobalamin, aqueous cyanocobalamin and cyanocobalamin zinc-tannate complex, Blood, 1961. 18: p. 511-21., https://www.ncbi.nlm.nih.gov/pubmed/13899122
1009. Gimsing, P., Hippe, E., Helleberg-Rasmussen, I., Moesgaard, M., Nielsen, J. L., Bastrup-Madsen, P., et.al. Cobalamin forms in plasma and tissue during treatment of vitamin B12 deficiency, Scand J Haematol, 1982. 29(4): p. 311-8., https://www.ncbi.nlm.nih.gov/pubmed/7178836
1010. Braun-Falco, O., Lincke, H., [The problem of vitamin B6/B12 acne. A contribution on acne medicamentosa (author's transl)], MMW Munch Med Wochenschr, 1976. 118(6): p. 155-60., https://www.ncbi.nlm.nih.gov/pubmed/130553
1011. Balta, I, Ozuguz, P, Vitamin B12-induced acneiform eruption., Cutan Ocul Toxicol, 2014. 33 (2)(2): p. 94-5., https://pubmed.ncbi.nlm.nih.gov/23815241/
1012. Bowden, A, Ekeh, O, Brownstone, ND, Hsu, S, Acneiform Eruption Secondary to Over-the-Counter Vitamin B12., Cureus, 2023. 15 (8)(8): p. e43275., https://pubmed.ncbi.nlm.nih.gov/37692729/
1013. Straatman, J, Wiegel, J, van der Wielen, N, Jansma, EP, Cuesta, MA, van der Peet, DL, Systematic Review of Exocrine Pancreatic Insufficiency after Gastrectomy for Cancer., Dig Surg, 2017. 34 (5)(5): p. 364-370., https://pubmed.ncbi.nlm.nih.gov/28315875/
1014. Rino, Y, Oshima, T, Yoshikawa, T, Changes in fat-soluble vitamin levels after gastrectomy for gastric cancer., Surg Today, 2017. 47 (2)(2): p. 145-150., https://pubmed.ncbi.nlm.nih.gov/27226020/
1015. Layer, P, Kashirskaya, N, Gubergrits, N, Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency., World J Gastroenterol, 2019. 25 (20)(20): p. 2430-2441., https://pubmed.ncbi.nlm.nih.gov/31171887/
1016. Antonini, F, Crippa, S, Falconi, M, Macarri, G, Pezzilli, R, Pancreatic enzyme replacement therapy after gastric resection: An update., Dig Liver Dis, 2018. 50 (1)(1): p. 1-5., https://pubmed.ncbi.nlm.nih.gov/29170072/
1017. Barkin, JA, Westermann, A, Hoos, W, Moravek, C, Matrisian, L, Wang, H, et.al. Frequency of Appropriate Use of Pancreatic Enzyme Replacement Therapy and Symptomatic Response in Pancreatic Cancer Patients., Pancreas, 2019. 48 (6)(6): p. 780-786., https://pubmed.ncbi.nlm.nih.gov/31210656/
1018. Catarci, M, Berlanda, M, Grassi, GB, Masedu, F, Guadagni, S, Pancreatic enzyme supplementation after gastrectomy for gastric cancer: a randomized controlled trial., Gastric Cancer, 2018. 21 (3)(3): p. 542-551., https://pubmed.ncbi.nlm.nih.gov/28804801/
1019. Alawa, F., et al., Herausforderungen der Pankreasenzymersatztherapie aus Sicht von außerklinisch tätigen ErnährungstherapeutInnen, Aktuelle Ernährungsmedizin, 2023. 48(03): p. E1., https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0043-1768082
1020. DGE, Referenzwerte für die Nährstoffzufuhr (D-A-CH Referenzwerte der DGE, ÖGE, SGE/SVE) VitaminB12 (Cobalamine), 2024., http://www.dge.de/modules.php?name=Content&pa=showpage&pid=3&page=7
1021. Jun, JH, Yoo, JE, Lee, JA, Kim, YS, Sunwoo, S, Kim, BS, et.al. Anemia after gastrectomy in long-term survivors of gastric cancer: A retrospective cohort study., Int J Surg, 2016. 28 (): p. 162-8., https://pubmed.ncbi.nlm.nih.gov/26931339/
1022. Teixeira Farinha, H, Bouriez, D, Grimaud, T, Rotariu, AM, Collet, D, Mantziari, S, et.al. Gastro-Intestinal Disorders and Micronutrient Deficiencies following Oncologic Esophagectomy and Gastrectomy., Cancers (Basel), 2023. 15 (14)(14):, https://pubmed.ncbi.nlm.nih.gov/37509216/
1023. Lim, CH, Kim, SW, Kim, WC, Kim, JS, Cho, YK, Park, JM, et.al. Anemia after gastrectomy for early gastric cancer: long-term follow-up observational study., World J Gastroenterol, 2012. 18 (42)(42): p. 6114-9., https://pubmed.ncbi.nlm.nih.gov/23155340/
1024. Hastka, J., Metzgeroth, G., Gattermann, N., Onkopedia-Leitlinie: Eisenmangel und Eisenmangelanämie, 2022.
1025. Bundesministerium der Justiz und für Verbraucherschutz, Sozialgesetzbuch Neuntes Buch - Rehabilitation und Teilhabe von Menschen mit Behinderungen, (Neuntes Buch Sozialgesetzbuch - SGB IX) – Zuletzt geändert durch Art. 6 Abs. 3 G v. 28.11.2018 l 2016., 2018.
1026. Deutsche Rentenversicherung (DRV), Indikationskatalog für Anschlussrehabilitation (AHB), 2017.
1027. Bundesarbeitsgemeinschaft für Rehabilitation (BAR), Rahmenempfehlungen zur ambulanten onkologischen Rehabilitation, 2004.
1028. Deutsche Rentenversicherung (DRV), Strukturqualität von Reha-Einrichtungen - Anforderungen der Deutschen Rentenversicherung, 2. überarbeitete und erweiterte Auflage, 2014.
1029. Deutsche Rentenversicherung (DRV), Anforderungsprofil für eine stationäre Einrichtung zur onkologischen Rehabilitation Erwachsener, 2018.
1030. Deutsches Institut für Medizinische Dokumentation und Information (DIMDI), Internationale Klassifikation der Funktionsfähigkeit, Behinderung und Gesundheit (ICF), 2005.
1031. Rock, C. L., Doyle, C., Demark-Wahnefried, W., Meyerhardt, J., Courneya, K. S., Schwartz, A. L., et.al. Nutrition and physical activity guidelines for cancer survivors, CA Cancer J Clin, 2012. 62(4): p. 243-74., https://www.ncbi.nlm.nih.gov/pubmed/22539238
1032. Mishra, S. I., Scherer, R. W., Snyder, C., Geigle, P. M., Berlanstein, D. R., Topaloglu, O., Exercise interventions on health-related quality of life for people with cancer during active treatment, Cochrane Database Syst Rev, 2012. p. CD008465., https://www.ncbi.nlm.nih.gov/pubmed/22895974
1033. Bourke, L., Homer, K. E., Thaha, M. A., Steed, L., Rosario, D. J., Robb, K. A., et.al. Interventions to improve exercise behaviour in sedentary people living with and beyond cancer: a systematic review, Br J Cancer, 2014. 110(4): p. 831-41., https://www.ncbi.nlm.nih.gov/pubmed/24335923
1034. de Boer, A. G., Taskila, T. K., Tamminga, S. J., Feuerstein, M., Frings-Dresen, M. H., Verbeek, J. H., Interventions to enhance return-to-work for cancer patients, Cochrane Database Syst Rev, 2015. p. CD007569., https://www.ncbi.nlm.nih.gov/pubmed/26405010
1035. Hall, PS, Swinson, D, Cairns, DA, Waters, JS, Petty, R, Allmark, C, et.al. Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial., JAMA Oncol, 2021. 7 (6)(6): p. 869-877., https://pubmed.ncbi.nlm.nih.gov/33983395/
1036. Duregon, F, Vendramin, B, Bullo, V, Gobbo, S, Cugusi, L, Di Blasio, A, et.al. Effects of exercise on cancer patients suffering chemotherapy-induced peripheral neuropathy undergoing treatment: A systematic review., Crit Rev Oncol Hematol, 2018. 121 (): p. 90-100., https://pubmed.ncbi.nlm.nih.gov/29198853/
1037. Quinrui Z, Hui Q, Guorui S, Zhiqiang L, et al., Early postoperative tumor marker responses provide a robust prognostic indicator for Nr stage gastric cancer, Medicine, 2017. 96:, https://pubmed.ncbi.nlm.nih.gov/28796039/
1038. Fan W, Chunmei S, Riping W, Zhiginf H, et al., Peritoneal recurrence in gastric cancer following curative resection can be predicted by postoperative but preoperative biomarkers: a single-institution study of 320 cases, Oncotarget, 2017. 8: p. 78120-132.., https://pubmed.ncbi.nlm.nih.gov/29100454/
1039. Takahashi, Y., Takeuchi, T., Sakamoto, J., Touge, T., Mai, M., Ohkura, H., et.al. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study, Gastric Cancer, 2003. 6(3): p. 142-5., https://www.ncbi.nlm.nih.gov/pubmed/14520526
1040. Choi, S. R., Jang, J. S., Lee, J. H., Roh, M. H., Kim, M. C., Lee, W. S., et.al. Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy, Dig Dis Sci, 2006. 51(11): p. 2081-6., https://www.ncbi.nlm.nih.gov/pubmed/17009116
1041. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung, Langversion v2.2, AWMF-Registernummer: 128/001OL, 2020., https://www.leitlinienprogramm-onkologie.de/leitlinien/palliativmedizin/
1042. Chochinov, HM, Tataryn, D, Clinch, JJ, Dudgeon, D, Will to live in the terminally ill., Lancet, 1999. 354 (9181)(9181): p. 816-9., https://pubmed.ncbi.nlm.nih.gov/10485723/
1043. Dorman, S, Hayes, J, Pease, N, What do patients with brain metastases from non-small cell lung cancer want from their treatment?, Palliat Med, 2009. 23 (7)(7): p. 594-600., https://pubmed.ncbi.nlm.nih.gov/19443522/
1044. Matsuyama, R, Reddy, S, Smith, TJ, Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer., J Clin Oncol, 2006. 24 (21)(21): p. 3490-6., https://pubmed.ncbi.nlm.nih.gov/16849766/
1045. Ackroyd, R, Russon, L, Newell, R, Views of oncology patients, their relatives and oncologists on cardiopulmonary resuscitation (CPR): questionnaire-based study., Palliat Med, 2007. 21 (2)(2): p. 139-44., https://pubmed.ncbi.nlm.nih.gov/17344262/
1046. Chu, DT, Kim, SW, Hsu, HK, Cok, G, Roubec, J, Patil, S, et.al. Patient attitudes towards chemotherapy and survival: a prospective observational study in advanced non-small cell lung cancer., Lung Cancer, 2009. 66 (2)(2): p. 250-6., https://pubmed.ncbi.nlm.nih.gov/19264374/
1047. Slevin, ML, Stubbs, L, Plant, HJ, Wilson, P, Gregory, WM, Armes, PJ, et.al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public., BMJ, 1990. 300 (6737)(6737): p. 1458-60., https://pubmed.ncbi.nlm.nih.gov/2379006/
1048. Bruera, E, Sweeney, C, Calder, K, Palmer, L, Benisch-Tolley, S, Patient preferences versus physician perceptions of treatment decisions in cancer care., J Clin Oncol, 2001. 19 (11)(11): p. 2883-5., https://pubmed.ncbi.nlm.nih.gov/11387361/
1049. Voogt, E, van der Heide, A, Rietjens, JA, van Leeuwen, AF, Visser, AP, van der Rijt, CC, et.al. Attitudes of patients with incurable cancer toward medical treatment in the last phase of life., J Clin Oncol, 2005. 23 (9)(9): p. 2012-9., https://pubmed.ncbi.nlm.nih.gov/15774792/
1050. Bundesgerichtshof, BGH AZ XII ZB 2/03, N Jurist Wochenschr, 2003. 56: p. 1588 - 1594.
1051. Kettner, M., Wunscherfüllende Medizin. Ärztliche Behandlung im Dienst von Selbstverwirklichung und Lebensplanung, Reihe Kultur der Medizin, Campus Verlag, Frankfurt am Main, 2009.
1052. Sahm, S., Autonomie, ärztliche Indikation und Entscheidungsfindung, in Medizinische Indikation und Patientenwille, R. Charbonnier, K. Dörner, and S. Simon, Editors, 2008, Schattauer: Stuttgart. p. 121 - 131.
1053. Truog, RD, Is it always wrong to perform futile CPR?, N Engl J Med, 2010. 362 (6)(6): p. 477-9., https://pubmed.ncbi.nlm.nih.gov/20147712/
1054. Heußner, P., E.C. Winkler, Leitlinie zur Therapiebegrenzung der Medizinischen Klinik und Poliklinik III des Klinikums der Universität München, 2015.
1055. Lipp, V., Die medizinische Indikation – ein „Kernstück ärztlicher Legitimation“?, 2015. 33: p. 762 - 766.
1056. Bundesärztekammer (BÄK), Stellungnahme der Bundesärztekammer „Medizinische Indikationsstellung und Ökonomisierung, Deutsches Ärzteblatt, 2015. 15: p. A-836/B-708/C-684., https://www.aerzteblatt.de/archiv/169425/Stellungnahme-der-Bundesaerztekammer-Medizinische-Indikationsstellung-und-Oekonomisierung
1057. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatient*innen, Langversion 2.1, AWMF-Registernummer: 032-051OL, 2023., https://www.leitlinienprogramm-onkologie.de/leitlinien/psychoonkologie/
1058. Bee, PE, Barnes, P, Luker, KA, A systematic review of informal caregivers' needs in providing home-based end-of-life care to people with cancer., J Clin Nurs, 2009. 18 (10)(10): p. 1379-93., https://pubmed.ncbi.nlm.nih.gov/18624779/
1059. Docherty, A, Owens, A, Asadi-Lari, M, Petchey, R, Williams, J, Carter, YH, Knowledge and information needs of informal caregivers in palliative care: a qualitative systematic review., Palliat Med, 2008. 22 (2)(2): p. 153-71., https://pubmed.ncbi.nlm.nih.gov/18372380/
1060. Teunissen, SC, Wesker, W, Kruitwagen, C, de Haes, HC, Voest, EE, de Graeff, A, Symptom prevalence in patients with incurable cancer: a systematic review., J Pain Symptom Manage, 2007. 34 (1)(1): p. 94-104., https://pubmed.ncbi.nlm.nih.gov/17509812/
1061. Sanson-Fisher, R., Girgis, A., Boyes, A., Bonevski, B., Burton, L., Cook, P., The unmet supportive care needs of patients with cancer. Supportive Care Review Group, Cancer, 2000. 88(1): p. 226-37., https://www.ncbi.nlm.nih.gov/pubmed/10618627
1062. Kleeberg, U. R., Tews, J. T., Ruprecht, T., Hoing, M., Kuhlmann, A., Runge, C., Patient satisfaction and quality of life in cancer outpatients: results of the PASQOC study, Support Care Cancer, 2005. 13(5): p. 303-10., https://www.ncbi.nlm.nih.gov/pubmed/15729552
1063. Fallowfield, L., Jenkins, V., Communicating sad, bad, and difficult news in medicine, Lancet, 2004. 363(9405): p. 312-9., https://www.ncbi.nlm.nih.gov/pubmed/14751707
1064. Ong, L. M., Visser, M. R., Lammes, F. B., de Haes, J. C., Doctor-patient communication and cancer patients' quality of life and satisfaction, Patient Educ Couns, 2000. 41(2): p. 145-56., https://www.ncbi.nlm.nih.gov/pubmed/12024540
1065. de Haes, H., Teunissen, S., Communication in palliative care: a review of recent literature, Curr Opin Oncol, 2005. 17(4): p. 345-50., https://www.ncbi.nlm.nih.gov/pubmed/15933465
1066. Fukui, S., Ogawa, K., Ohtsuka, M., Fukui, N., A randomized study assessing the efficacy of communication skill training on patients' psychologic distress and coping: nurses' communication with patients just after being diagnosed with cancer, Cancer, 2008. 113(6): p. 1462-70., https://www.ncbi.nlm.nih.gov/pubmed/18661509
1067. Razavi, D., Merckaert, I., Marchal, S., Libert, Y., Conradt, S., Boniver, J., et.al. How to optimize physicians' communication skills in cancer care: results of a randomized study assessing the usefulness of posttraining consolidation workshops, J Clin Oncol, 2003. 21(16): p. 3141-9., https://www.ncbi.nlm.nih.gov/pubmed/12915605
1068. Lienard, A., Merckaert, I., Libert, Y., Delvaux, N., Marchal, S., Boniver, J., et.al. Factors that influence cancer patients' and relatives' anxiety following a three-person medical consultation: impact of a communication skills training program for physicians, Psychooncology, 2008. 17(5): p. 488-96., https://www.ncbi.nlm.nih.gov/pubmed/17879970
1069. Edwards, A., Elwyn, G., Inside the black box of shared decision making: distinguishing between the process of involvement and who makes the decision, Health Expect, 2006. 9(4): p. 307-20., https://www.ncbi.nlm.nih.gov/pubmed/17083558
1070. Butow, P., Juraskova, I., Chang, S., Lopez, A. L., Brown, R., Bernhard, J., Shared decision making coding systems: how do they compare in the oncology context?, Patient Educ Couns, 2010. 78(2): p. 261-8., https://www.ncbi.nlm.nih.gov/pubmed/19647966
1071. Stiefel, F., Favre, N., Despland, J. N., Communication skills training in oncology: it works!, Recent Results Cancer Res, 2006. 168: p. 113-9., https://www.ncbi.nlm.nih.gov/pubmed/17073197
1072. Stephens, M. R., Gaskell, A. L., Gent, C., Pellard, S., Day-Thompson, R., Blackshaw, G. R., et.al. Prospective randomised clinical trial of providing patients with audiotape recordings of their oesophagogastric cancer consultations, Patient Educ Couns, 2008. 72(2): p. 218-22., https://www.ncbi.nlm.nih.gov/pubmed/18513915
1073. Faller, H., Koch, G. F., Reusch, A., Pauli, P., Allgayer, H., Effectiveness of education for gastric cancer patients: a controlled prospective trial comparing interactive vs. lecture-based programs, Patient Educ Couns, 2009. 76(1): p. 91-8., https://www.ncbi.nlm.nih.gov/pubmed/19155155
1074. Weis, J., Domann, U., [Interventions in the rehabilitation of breast cancer patients--a critical literature review of the state of the art], Rehabilitation (Stuttg), 2006. 45(3): p. 129-45., https://www.ncbi.nlm.nih.gov/pubmed/16755432
1075. Edwards, Psychological interventions for women with metastatic breast cancer (Review), The Cochrane Library, 2009., https://pubmed.ncbi.nlm.nih.gov/23737397/
1076. Uitterhoeve, R. J., Vernooy, M., Litjens, M., Potting, K., Bensing, J., De Mulder, P., et.al. Psychosocial interventions for patients with advanced cancer - a systematic review of the literature, Br J Cancer, 2004. 91(6): p. 1050-62., https://www.ncbi.nlm.nih.gov/pubmed/15316564
1077. Jacobsen, P. B., Jim, H. S., Psychosocial interventions for anxiety and depression in adult cancer patients: achievements and challenges, CA Cancer J Clin, 2008. 58(4): p. 214-30., https://www.ncbi.nlm.nih.gov/pubmed/18558664
1078. Williams, S., Dale, J., The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review, Br J Cancer, 2006. 94(3): p. 372-90., https://www.ncbi.nlm.nih.gov/pubmed/16465173
1079. Kangas, M., Bovbjerg, D. H., Montgomery, G. H., Cancer-related fatigue: a systematic and meta-analytic review of non-pharmacological therapies for cancer patients, Psychol Bull, 2008. 134(5): p. 700-741., https://www.ncbi.nlm.nih.gov/pubmed/18729569
1080. Goedendorp, M. M., Gielissen, M. F., Verhagen, C. A., Bleijenberg, G., Psychosocial interventions for reducing fatigue during cancer treatment in adults, Cochrane Database Syst Rev, 2009. p. CD006953., https://www.ncbi.nlm.nih.gov/pubmed/19160308
1081. Soellner W, Keller M., Psychoonkologische Interventionen, Psychosomatische Medizin (Adler R, Herzog W, Joraschky P, Köhle K, Langewitz W, Söllner W, Wesiack W (Hrsg)), 2010, Munich.
1082. Osborn, R. L., Demoncada, A. C., Feuerstein, M., Psychosocial interventions for depression, anxiety, and quality of life in cancer survivors: meta-analyses, Int J Psychiatry Med, 2006. 36(1): p. 13-34., https://www.ncbi.nlm.nih.gov/pubmed/16927576
1083. Rehse, B., Pukrop, R., Effects of psychosocial interventions on quality of life in adult cancer patients: meta analysis of 37 published controlled outcome studies, Patient Educ Couns, 2003. 50(2): p. 179-86., https://www.ncbi.nlm.nih.gov/pubmed/12781933
1084. Luebbert, K., Dahme, B., Hasenbring, M., The effectiveness of relaxation training in reducing treatment-related symptoms and improving emotional adjustment in acute non-surgical cancer treatment: a meta-analytical review, Psychooncology, 2001. 10(6): p. 490-502., https://www.ncbi.nlm.nih.gov/pubmed/11747061
1085. Sheard, T., Maguire, P., The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses, Br J Cancer, 1999. 80(11): p. 1770-80., https://www.ncbi.nlm.nih.gov/pubmed/10468295
1086. Haun, MW, Estel, S, Rücker, G, Friederich, HC, Villalobos, M, Thomas, M, et.al. Early palliative care for adults with advanced cancer., Cochrane Database Syst Rev, 2017. 6 (6)(6): p. CD011129., https://pubmed.ncbi.nlm.nih.gov/28603881/
1087. Adler, K, Schlieper, D, Kindgen-Milles, D, Meier, S, Schwartz, J, van Caster, P, et.al. [Integration of palliative care into intensive care : Systematic review]., Anaesthesist, 2017. 66 (9)(9): p. 660-666., https://pubmed.ncbi.nlm.nih.gov/28589374/
1088. Dalgaard, KM, Bergenholtz, H, Nielsen, ME, Timm, H, Early integration of palliative care in hospitals: A systematic review on methods, barriers, and outcome., Palliat Support Care, 2014. 12 (6)(6): p. 495-513., https://pubmed.ncbi.nlm.nih.gov/24621947/
1089. Davis, MP, Temel, JS, Balboni, T, Glare, P, A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses., Ann Palliat Med, 2015. 4 (3)(3): p. 99-121., https://pubmed.ncbi.nlm.nih.gov/26231807/
1090. Gaertner, J, Siemens, W, Meerpohl, JJ, Antes, G, Meffert, C, Xander, C, et.al. Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis., BMJ, 2017. 357 (): p. j2925., https://pubmed.ncbi.nlm.nih.gov/28676557/
1091. Hui, D, Kim, YJ, Park, JC, Zhang, Y, Strasser, F, Cherny, N, et.al. Integration of oncology and palliative care: a systematic review., Oncologist, 2015. 20 (1)(1): p. 77-83., https://pubmed.ncbi.nlm.nih.gov/25480826/
1092. Hui, D, Meng, YC, Bruera, S, Geng, Y, Hutchins, R, Mori, M, et.al. Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review., Oncologist, 2016. 21 (7)(7): p. 895-901., https://pubmed.ncbi.nlm.nih.gov/27185614/
1093. Tassinari, D, Drudi, F, Monterubbianesi, MC, Stocchi, L, Ferioli, I, Marzaloni, A, et.al. Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature., Rev Recent Clin Trials, 2016. 11 (1)(1): p. 63-71., https://pubmed.ncbi.nlm.nih.gov/26464077/
1094. Radbruch, L., S. Payne, White Paper on standards and norms for hospice and palliative care in Europe: part 1, European Journal of Palliative Care, 2009. p. 278 - 289.
1095. Schneider, N, Mitchell, GK, Murray, SA, Palliative care in urgent need of recognition and development in general practice: the example of Germany., BMC Fam Pract, 2010. 11 (): p. 66., https://pubmed.ncbi.nlm.nih.gov/20843334/
1096. SACHVERSTÄNDIGENRAT zur Begutachtung der Entwicklung im Gesundheitswesen, Koordination und Integration − Gesundheitsversorgung in einer Gesellschaft des längeren Lebens. Sondergutachten, Bundestag-Drucksache 16/13770, 2009.
1097. Alt-Epping, B., F. Nauck, N. Schneider, Leben bis zuletzt. Hausärztliche und spezialisierte Palliativversorgung bei schwerstkranken Patienten, Der Hausarzt, 2012. Issue 11: p. 43 - 46., https://link.springer.com/journal/15200/volumes-and-issues/49-11
1098. Bruera, E, Hui, D, Dalal, S, Torres-Vigil, I, Trumble, J, Roosth, J, et.al. Parenteral hydration in patients with advanced cancer: a multicenter, double-blind, placebo-controlled randomized trial., J Clin Oncol, 2013. 31 (1)(1): p. 111-8., https://pubmed.ncbi.nlm.nih.gov/23169523/
1099. Nakajima, N, Hata, Y, Kusumuto, K, A clinical study on the influence of hydration volume on the signs of terminally ill cancer patients with abdominal malignancies., J Palliat Med, 2013. 16 (2)(2): p. 185-9., https://pubmed.ncbi.nlm.nih.gov/23327196/
1100. Raijmakers, NJH, van Zuylen, L, Costantini, M, Caraceni, A, Clark, J, Lundquist, G, et.al. Artificial nutrition and hydration in the last week of life in cancer patients. A systematic literature review of practices and effects., Ann Oncol, 2011. 22 (7)(7): p. 1478-1486., https://pubmed.ncbi.nlm.nih.gov/21199887/
1101. Bundesärztekammer (BÄK), Grundsätze der Bundesärztekammer zur ärztlichen Sterbebegleitung, Deutsches Ärzteblatt, 2011. p. A 346 - A348., https://www.aerzteblatt.de/archiv/80946/Grundsaetze-der-Bundesaerztekammer-zur-aerztlichen-Sterbebegleitung
1102. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Komplementärmedizin in der Behandlung von onkologischen PatientInnen, Langversion 2.01 Konsultationsfassung, AWMF-Registernummer: 032-055OL, 2023., https://www.leitlinienprogramm-onkologie.de/leitlinien/komplementaermedizin/
1103. Dobos, G. J., Voiss, P., Schwidde, I., Choi, K. E., Paul, A., Kirschbaum, B., et.al. Integrative oncology for breast cancer patients: introduction of an expert-based model, BMC Cancer, 2012. 12: p. 539., https://www.ncbi.nlm.nih.gov/pubmed/23170989
1104. Cheng, A. L., Kang, Y. K., Lin, D. Y., Park, J. W., Kudo, M., Qin, S., et.al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial, J Clin Oncol, 2013. 31(32): p. 4067-75., https://pubmed.ncbi.nlm.nih.gov/24081937/
1105. Horneber, M., Bueschel, G., Dennert, G., Less, D., Ritter, E., Zwahlen, M., How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis, Integr Cancer Ther, 2012. 11(3): p. 187-203., https://www.ncbi.nlm.nih.gov/pubmed/22019489
1106. Cheng, J. L., Bruno, M. J., Bergman, J. J., Rauws, E. A., Tytgat, G. N., Huibregtse, K., Endoscopic palliation of patients with biliary obstruction caused by nonresectable hilar cholangiocarcinoma: efficacy of self-expandable metallic Wallstents, Gastrointest Endosc, 2002. 56(1): p. 33-9., https://pubmed.ncbi.nlm.nih.gov/12085032/
1107. Ernst, Anke, Klein, Stefanie, Komplementäre und alternative Methoden bei Krebs einordnen und bewerten, Dtsch med Wochenschr, 2017. 142(12): p. 873-881., https://www.ncbi.nlm.nih.gov/pubmed/28637072
1108. Hubner, J., Muenstedt, K., Muecke, R., Micke, O., Stoll, C., Kleeberg, U. R., et.al. Counseling cancer patients on complementary and alternative medicine. Background, theory, and implementation of nationwide counseling facilities, Strahlenther Onkol, 2013. 189(8): p. 613-7., https://www.ncbi.nlm.nih.gov/pubmed/23824107
1109. Huebner, J., Rose, C., Geissler, J., Gleiter, C. H., Prott, F. J., Muenstedt, K., et.al. Integrating cancer patients' perspectives into treatment decisions and treatment evaluation using patient-reported outcomes--a concept paper, Eur J Cancer Care (Engl), 2014. 23(2): p. 173-9., https://www.ncbi.nlm.nih.gov/pubmed/23889081
1110. Frenkel, M., Cohen, L., Effective communication about the use of complementary and integrative medicine in cancer care, J Altern Complement Med, 2014. 20(1): p. 12-8., https://www.ncbi.nlm.nih.gov/pubmed/23863085
1111. Roter, D. L., Yost, K. J., O'Byrne, T., Branda, M., Leppin, A., Kimball, B., et.al. Communication predictors and consequences of Complementary and Alternative Medicine (CAM) discussions in oncology visits, Patient Educ Couns, 2016. 99(9): p. 1519-25., https://www.ncbi.nlm.nih.gov/pubmed/27296081
1112. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Manual Qualitätsindikatoren. Manual für Autoren., 2009.
1113. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft (DKG) e.V., Stiftung Deutsche Krebshilfe (DKH), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) e.V., Entwicklung von leitlinienbasierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie, Version 3.0., 2021., https://www.leitlinienprogramm-onkologie.de/methodik/grundlegende-informationen-zur-methodik
1114. Nakajima, T, Oda, I, Gotoda, T, Hamanaka, H, Eguchi, T, Yokoi, C, et.al. Metachronous gastric cancers after endoscopic resection: how effective is annual endoscopic surveillance?, Gastric Cancer, 2006. 9 (2)(2): p. 93-8., https://pubmed.ncbi.nlm.nih.gov/16767364/